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Laquinimod (LAQ), a new orally active immunomodulator, is currently under investigation 
for the treatment of multiple sclerosis (MS). In clinical trials LAQ considerably reduced the 
annualized relapse rate, disability progression and brain atrophy in MS patients, but its exact 
mechanism of action is not fully understood. Experimental data provide evidence for 
immunomodulatory effects of LAQ on antigen presenting cells and T cells, but the role of natural 
killer (NK) cells within the mechanism of action of LAQ has not been investigated yet.  
 The aim of the present study was to evaluate effects of LAQ on innate and adaptive 
immune cells in mice with experimental autoimmune encephalomyelitis (EAE), with a special 
focus on NK cells.  
First, a detailed analysis of immune cells was performed in MOG35-55-immunized animals 
preventively treated with 25mg/kg LAQ. Innate immune cells responded quickly to LAQ 
treatment, whereas major changes in the T cell compartment were detectable several days later. 
LAQ reduced the total number of splenic dendritic cells and the number of myeloid dendritic cells. 
In parallel, NK cells were activated by LAQ. As such LAQ increased the frequency of CD69+ NK cells 
and upregulated a number of activating NK cell receptors such as DNAM-1 and TACTILE. TIGIT, an 
inhibitory NK cell receptor, which shares the same ligand with DNAM-1 and TACTILE, was 
downregulated, suggesting that LAQ shifts the balance of inhibitory and activating NK cell 
receptors in favor of the latter. 
To test, whether the LAQ-induced NK cell activation improves classical NK cell effector 
functions, NK cells were sorted ex vivo from LAQ- or vehicle-treated animals. NK cells derived 
from LAQ-treated mice killed B16F10 melanoma cells in vitro more efficiently than NK cells 
derived from vehicle controls and produced more cytokines in response to IL-12 and IL-18 
stimulation. In a triple co-culture system with 2D2 T cells and bone marrow-derived dendritic 
cells, T cell proliferation in response to MOG35-55 was significantly better inhibited by NK cells 
derived from LAQ-treated mice in a cell contact-dependent manner. 
Finally, LAQ efficacy was analyzed in NK cell-depleted and competent EAE animals. Th/+ 
mice were depleted by administration of PK-136 antibodies, immunized with MOG35-55 and 
preventively treated with 25 mg/kg LAQ. Treatment with LAQ markedly attenuated EAE severity in 
NK cell-competent Th/+ mice. This beneficial LAQ effect was however only transient in Th/+ mice 
depleted of NK cells. While LAQ treatment prevented the death of animals in the presence of NK 
cells, a considerable number of animals depleted of NK cells died despite LAQ therapy. 
 
 Abstract IV 
 
In conclusion, this study identified NK cells as a novel direct cellular target of LAQ therapy 
with a central relevance for the therapeutic efficiency of the substance in EAE. These data indicate 
that the LAQ-mediated activation of NK cells is a crucial part of the immunomodulatory 
mechanism of LAQ in vivo. Most interestingly, LAQ specifically interfered with the DNAM-
1/TACTILE/TIGIT pairwise receptor family on NK cells, favoring a central role of this pathway 
within the mechanism of action of LAQ. It remains to be investigated whether similar effects of 
LAQ on human NK cells can be detected in patients with MS. Since published data reveal defective 
NK cell function as one pathogenic factor in MS, LAQ-induced restoration of NK cell functions 
could be a major component of its protective mechanisms in the treatment of MS patients.  
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 Introduction 1 
 
1. Introduction 
1.1 Multiple sclerosis 
Multiple sclerosis (MS), also known as encephalomyelitis disseminata, is a chronic 
inflammatory demyelinating disease of the central nervous system (CNS) with typically multifocal 
presentation. The disease course and symptoms show a broad range between individual patients 
and the etiology of MS is still not fully understood. MS is typically classified as an autoimmune 
disease and the destruction of CNS-intrinsic structures by auto-reactive immune cells appears to 
be one important mechanism leading to CNS injury. To date, ten medications have been approved 
for the long term disease-modifying treatment of MS, which display immunomodulatory or 
immunosuppressive properties and mainly target the autoimmune component of the disease. 
Additionally, several promising immunomodulatory drugs are currently under investigation for the 
treatment of MS. 
 
1.1.1 Clinical course and diagnostics 
MS is the most common non-traumatic neurological disease which leads to chronic 
disability in young adults. Generally two different forms can be distinguished based on the disease 
course at the beginning of the disease: relapsing remitting and primary progressive MS.  
Relapsing remitting MS (RRMS) is the most common form of MS in the early phase of 
disease, initially affecting 80 – 85% of MS patients. RRMS is characterized by the occurrence of 
relapses and an early onset of disease (mean 29 years). Typically, women display a two to three 
fold increased risk to develop RRMS compared to men and the most common initial symptoms 
are visual and sensory symptoms. A relapse is defined as an episode of neurological symptoms 
typical for an inflammatory demyelinating event in the CNS that lasts for at least 24 hours in the 
absence of fever and infection (Polman et al., 2011). After a relapse, patients typically show 
complete or partial recovery from the neurological symptoms. Up to now, ten medications have 
been approved for the long-term treatment of RRMS.  
At later disease stages about two thirds of RRMS patients develop a progressive disease 
course, referred to as secondary progressive MS (SPMS). Typically patients with SPMS do not 
experience episodes of acute symptoms with subsequent recovery anymore, but instead 
accumulate neurological deficits in a chronic process.  
10 – 15% of MS patients initially present with gradually increasing disability in the absence 
of relapses, a disease course known as primary progressive MS (PPMS). In contrast to RRMS, 
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PPMS equally affects men and women and is typically associated with a relatively late disease 
onset (mean 40 years). Characteristic neurological deficits are progressive spastic paresis and leg 
weakness, which are frequently caused by lesions in the spinal cord. Magnetic resonance imaging 
(MRI) typically reveals less distinct white matter lesions compared to RRMS patients. Currently, no 
efficient therapeutic strategy is available for the treatment of PPMS patients. 
There is a broad spectrum of neurological symptoms during a relapse, which depends on 
the affected CNS region. Typical symptoms caused by lesions within the optic nerve are visual 
symptoms such as blurred vision. Brain stem lesions can lead to double vision. Furthermore, 
sensory deficits, like paresthesia, pain and sensible ataxia, and motor symptoms, like para-, tetra- 
or hemiplegia, commonly occur. These symptoms can be associated with cerebral as well as spinal 
lesions, the latter typically leading to more severe neurological deficits. Bladder dysfunction is a 
frequent vegetative symptom. In addition, MS patients can experience cerebellar dysfunction 
such as dysmetria and ataxia. Affective disorders and fatigue are common, too. Cognitive deficits 
are observed very frequently in about 40% of the patients during the course of disease (Rao et al., 
1991).   
MS is classically diagnosed using the McDonalds criteria, which were implemented in 2000 
(McDonald et al., 2001) and revised in 2005 (Polman et al., 2005) and 2011 (Polman et al., 2011). 
The diagnosis is based on three factors: clinical symptoms, MRI data and cerebrospinal fluid (CSF) 
parameters. Concerning MRI data, lesions have to show dissemination in space (DIS) and time 
(DIT) to be considered predictive for MS. According to the current McDonalds criteria DIS is 
defined as at least one T2 lesion appearing in at least two of the four regions characteristic for 
MS: juxtacortical, periventricular, infratentorial and the spinal cord. The criterion of DIT is fulfilled 
when asymptomatic gadolinium-enhancing (GdE) and non-enhancing lesions are simultaneously 
present in one single MRI scan or when a new T2 or GdE lesion is detected on a follow up MRI. 
CSF markers are mainly used for the diagnosis of PPMS (Polman et al., 2011). Typical CSF 
parameters for MS include a slight mononuclear pleocytosis, elevated immunoglobulin G (IgG) 
concentrations and oligoclonal bands.  
 
1.1.2 Epidemiology and etiology 
MS is a common neurological disease affecting approximately 2.5 million patients 
worldwide (Milo and Kahana, 2010). MS displays an unequal geographic distribution, whereby the 
risk to develop MS appears to increase with the distance to the equator. High risk regions 
comprise Europe, Russia, Israel, Northern US, Canada and New Zealand (Kurtzke, 2000). In 
Germany, the prevalence of MS is relatively high with 127 patients per 100.000 inhabitants (Hein 
and Hopfenmuller, 2000). Besides geographic aspects, gender is a risk factor for RRMS. Within the 
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Caucasian population the risk to develop RRMS is two to three times higher in females than in 
males and this ratio is increasing over time (Kurtzke, 2000, Orton et al., 2010, Ahlgren et al., 2011, 
Wallin et al., 2012). This observation led to the concept that sex hormones could be implicated in 
the pathogenesis of MS and indeed female hormones seem to influence disease activity during 
pregnancy and estriol substitution attenuates MRI activity (Confavreux et al., 1998, Soldan et al., 
2003). 
It is widely accepted that MS is an autoimmune disorder. This assumption is based on 
genome wide association studies which demonstrated that the genetic variants, which are 
relevant for MS, belong to the function of the immune system. In addition, therapies which 
modulate or suppress the immune system are effective at least in RRMS. MS is most likely caused 
by a complex interplay between multiple predisposing genes and environmental factors. A genetic 
component of MS was indicated by twin studies, which revealed 25% concordance for 
homozygotic twins and 3 - 5% concordance for dizygotic twins and other first degree relatives 
(Mumford et al., 1994, Willer et al., 2003, Hansen et al., 2005). On the other hand, migration 
studies argue for the involvement of environmental factors (Dean and Kurtzke, 1971).  
In the 1970’s the first risk genes for MS, the human leukocyte antigen (HLA) genes, were 
described. Currently several HLA class II haplotypes are known to be associated with increased 
susceptibility for MS, like DRB1*15:01, DQA1*01:02 and DQB*06:02, with DRB1*15:01 showing 
the strongest association (Munoz-Culla et al., 2013). In an attempt to thoroughly investigate the 
risk genes for MS, a large international genome wide association (GWAS) study was performed by 
the International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control 
Consortium 2. The GWAS study identified 29 susceptibility genes, which include, besides the well 
known HLA genes, mainly risk genes playing a role in immunity and T cell differentiation, like 
genes associated with cytokine signaling (IL2RA, IL7R, IL12A), co-stimulation (CD40, CD80, CD86) 
and signal transduction (MALT1, STAT3). These findings consolidate the crucial role of the immune 
system in the pathogenesis of MS (Sawcer et al., 2011). 
Several environmental factors influence the risk to develop MS. Low vitamin D intake and 
serum levels are associated with an increased risk to develop MS and high vitamin D serum levels 
reduce the relapse risk (Munger et al., 2004, Munger et al., 2006, Simpson et al., 2010, Lucas et 
al., 2011). The critical role of vitamin D is further supported by data from the GWAS study, 
identifying CYP27B1 as a risk gene, which encodes a crucial enzyme for the conversion of vitamin 
D into its active form (Sawcer et al., 2011, Hewer et al., 2013). Furthermore, Epstein-Barr virus 
(EBV) infection has been discussed as potentially relevant environmental risk factor, but dissecting 
the role of EBV infection in the development of MS in adults is difficult, due to the high 
seroprevalence of EBV infection in more than 90% of the adult population (Ascherio and Munger, 
 
 Introduction 4 
 
2007, Almohmeed et al., 2013). Moreover, cigarette smoking is associated with an 1.5 fold 
increased risk to develop MS, clinical worsening and a faster transition from RRMS to SPMS 
(hazard ratio 2.5) (Hernan et al., 2001, Healy et al., 2009, Hedstrom et al., 2009).  
 
1.1.3 Pathogenesis 
MS is generally classified as chronic inflammatory autoimmune disease of the CNS. 
Especially during the early phase of MS, infiltration of auto-reactive immune cells is thought to be 
the primary cause of demyelination and CNS damage.  
The following sequence of events was described: Auto-reactive T cells become activated 
by an unknown trigger in the periphery. This leads to the upregulation of adhesion molecules on 
the surface of activated T cells and enables them to interact with endothelial cells, which 
promotes the adhesion and transmigration of activated T cells through the blood-brain barrier 
(BBB). Within the CNS, T cells become locally reactivated by antigen presenting cells and start to 
produce pro-inflammatory cytokines, especially interferon-gamma (IFNγ) and interleukin 17 (IL-
17). Pro-inflammatory cytokines and chemokines in turn activate resident microglia, increase the 
permeability of the BBB and recruit further inflammatory cells, subsequently causing 
demyelination and tissue damage (Sospedra and Martin, 2005, Buc, 2013).  
A dense infiltrate of T cells can be detected in active MS lesions, consisting of mainly 
CD8+, but also of CD4+ T cells. Evidence for an implication of these T cells in the pathogenesis of 
MS is mainly provided by studies, which reveal oligoclonal expansion of CD8+ and CD4+ T cells in 
CNS lesions and the CSF of MS patients. The robust oligoclonal expansion indicates that T cells 
locally react to CNS-intrinsic antigens (Hafler et al., 1988, Babbe et al., 2000, Jacobsen et al., 
2002). Interestingly, identical CD8+ T cell clones can be detected in different lesions within one 
patient and memory CD8+ T cell clones persist in the CSF for several years (Babbe et al., 2000, 
Skulina et al., 2004). 
Regulatory T cells appear also to be implicated in the pathogenesis of MS. In MS patients 
the suppressive function of regulatory T cells is profoundly compromised, which possibly might 
contribute to the pathogenic activation of T helper 1 (Th1) and T helper 17 (Th17) cells (Viglietta 
et al., 2004, Haas et al., 2005). 
Besides T cells, B cells have been appreciated to play a prominent role in the pathogenesis 
of MS. Local activity of plasma cells within the CNS leads to the appearance of immunoglobulins 
and oligoclonal bands in the CSF, which is an important diagnostic criterion for MS and is 
associated with disease activity (Walsh and Tourtellotte, 1986, Sharief and Thompson, 1991). As  
T cells, B cells clonally expand in the CSF of MS patients (Owens et al., 2003) and affinity 
maturation of B cells was detected within the CNS (von Budingen et al., 2012). The crucial role of 
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B cells within the pathogenesis was revealed by clinical trials showing that treatment with the  
B cell-depleting antibody rituximab was beneficial for RRMS patients (Hauser et al., 2008). 
The exact role of myelin-specific auto-reactive T and B cells is not fully understood. 
Increased numbers of high affinity myelin basic protein (MBP) specific Th1 and Th17 cells were 
reported in the peripheral blood of MS patients, but low numbers of these cells can also be 
detected in healthy donors (Olsson et al., 1992, Bielekova et al., 2004, Durelli et al., 2009). 
Furthermore, the oligoclonal B cell response is not targeted to MBP, proteolipid protein (PLP) or 
myelin oligodendrocyte glycoprotein (MOG) and the antigen-specificity of the clonally expanded  
T and B cells has not been identified yet (Owens et al., 2009). 
 In addition to adaptive immune cells, innate immune cells are also implicated in the 
pathogenesis of MS. Most prominent examples are dendritic cells, macrophages and microglia. 
Dendritic cells isolated from MS patients display an activated phenotype and predominantly 
induce Th1 and Th17 differentiation (Karni et al., 2006, Vaknin-Dembinsky et al., 2006). Activated 
macrophages and microglia, which are abundant in active MS lesions, mainly display the pro-
inflammatory M1 phenotype and contribute to inflammation through antigen-presentation and 
pro-inflammatory cytokine secretion (Gandhi et al., 2010, Vogel et al., 2013). 
 
1.1.4 Pathology 
MS patients typically present multifocal lesions within the CNS. These lesions can occur 
anywhere in the CNS, but are predominantly localized in characteristic predilection sites, including 
the optic nerve, periventricular and subcortical cerebral regions, the cerebellum, the brainstem 
and the spinal cord. Macroscopically, white matter lesions appear as rounded plaques with a 
brownish-gray color and compact consistency. The histopathological hallmarks of MS lesions are 
an inflammatory infiltrate, pronounced demyelination with variable efficiency of remyelination, 
axonal loss and reactive astrogliosis (Brück and Stadelmann, 2005). 
Demyelinating white matter lesions can be classified according to the grade of 
inflammation (van der Valk and De Groot, 2000). Traditionally, three types of lesions are 
distinguished according to the density and the localization of the inflammatory infiltrate: active 
lesions, characterized by a pronounced inflammatory infiltrate, chronic active lesions, displaying a 
hypocellular center and an inflammatory rim and chronic inactive lesions, defined as hypocellular. 
Alternatively, the staging system proposed by Brück and Lassmann differentiates between early 
active, late active and inactive lesions, which are mainly distinguished by differential macrophage 
markers and myelin degradation products. Early active lesions are characterized by macrophages, 
which express the marker myeloid-related protein 14 (MRP14) and contain myelin degradation 
products positive for MBP, PLP, myelin-associated glycoprotein, MOG and cyclic nucleotide 
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phosphodiesterase. In late active lesions macrophages only contain degradation products 
immunopositive for MBP and PLP. Inactive lesions still display varying numbers of macrophages, 
but these phagocytes do not contain any myelin proteins immunopositive for the markers 
mentioned above (Brück et al., 1995).  
Active demyelinating lesions were shown to be heterogeneous regarding the mechanism 
of oligodendrocyte damage. Three different patterns of lesions can be typically observed in living 
MS patients. Pattern I and pattern II lesions are both characterized by a massive infiltration of T 
cells and macrophages, but pattern II lesions additionally display considerable immunoglobulin 
and complement depositions. The typical feature of pattern III lesions is the pronounced 
apoptosis of oligodendrocytes in and around lesions. Interestingly, the lesion pattern may vary 
between different individuals, but within one patient it appears to remain stable over time 
(Lucchinetti et al., 2000).   
Beside white matter lesions, gray matter demyelination occurs in supra- and infratentorial 
as well as spinal areas. The extent of gray matter demyelination was shown to exceed the one of 
white matter demyelination in most CNS areas (Gilmore et al., 2009). Cortical demyelination plays 
a central role in the pathogenesis of MS. Cortical lesions contain less inflammatory cells compared 
to white matter lesions, but display substantial axonal transection, neuronal apoptosis and 
synaptic loss (Peterson et al., 2001, Wegner et al., 2006). Imaging studies indicate that gray matter 
atrophy occurs early during the course of disease (De Stefano et al., 2003, Fisher et al., 2008). 
One CNS-intrinsic repair mechanism is remyelination, an event that frequently occurs in 
the early phase of MS, but decreases during the chronic phase (Goldschmidt et al., 2009). The 
extent of remyelination varies greatly among individuals and remyelination often remains 
incomplete (Patrikios et al., 2006).  
Chronic disability in MS is mainly associated with neuroaxonal degeneration – particularly 
in the corticospinal tracts. Axonal injury is an early event during the disease course, which 
correlates with the degree of inflammation (Trapp et al., 1998, Bitsch et al., 2000). The extent of 
axonal loss was described to be associated with disease duration and progression (Schirmer et al., 
2011). Different mechanism are discussed which could contribute to neuroaxonal damage in MS, 
like direct damage of axons through reactive oxygen species and nitric oxide (Smith and 
Lassmann, 2002), Wallerian degeneration (Dziedzic et al., 2010), mitochondrial dysfunction (Dutta 
et al., 2006, Mahad et al., 2009, Campbell et al., 2011) and alterations in neurotransmission with 
increased excitotoxity (Pitt et al., 2003, Srinivasan et al., 2005, Dutta et al., 2006).  
In addition to the well defined white and gray matter lesions, MS patients also display 
diffuse abnormalities in the normal-appearing white matter (NAWM) and also in the normal-
appearing gray matter. NAWM changes comprise low grade T cell infiltration (Kutzelnigg et al., 
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2005, Androdias et al., 2010), microglia activation (Howell et al., 2010), the presence of microglial 
nodules (Singh et al., 2013), decreased axonal densities (Evangelou et al., 2000, Evangelou et al., 
2000) and increased axonal damage (Kutzelnigg et al., 2005) as well as increased numbers of 
oligodendrocytes (Hoftberger et al., 2010). This diffuse damage of the NAWM is associated with 
white matter atrophy and disease progression (Evangelou et al., 2000, Evangelou et al., 2000, 
Kutzelnigg et al., 2005). 
 
1.1.5 Treatment 
Two paradigms have to be distinguished in the treatment of RRMS patients: First, the 
intervention therapy during an acute relapse and second, long term disease-modifying 
treatments. 
The first line medication during an acute MS relapse is the intravenous application of high 
dose methylprednisolon. If glucocorticoid administration fails to control the exacerbation, plasma 
exchange is the second therapeutic option. 
Today ten different medications are approved for the long term treatment of RRMS in 
Europe, which are classified into first line, second line and third line therapy according to their 
safety profile. 
First line options are the different beta-interferons (IFNβ), glatiramer acetate (GA) and the 
recently approved orally active substance dimethyl fumarate. All these drugs have a highly 
favorable safety profile and exert moderate disease modifying activities. Teriflunomide and 
alemtuzumab are also approved as first line medications for RRMS, but both drugs display more 
severe side effects in comparison to the before mentioned first line treatments.  
Three different recombinant IFNβ compounds are available: Rebif® (Merck-Serono), 
Avonex® (Biogen-Idec) and Betaferon®/Extavia® (Bayer-Schering/Novartis). All medications have 
to be applied by subcutaneous or intramuscular injections. IFNβ has proven to be beneficial in 
RRMS patients (Jacobs et al., 2000, Filippi et al., 2004, Bagnato et al., 2005, Kappos et al., 2007, 
Trojano et al., 2007) and its protective effects seem to be based on the reduction of antigen 
presentation, T cell expansion, T cell trafficking into the CNS and pro-inflammatory cytokine 
secretion (Yong, 2002). 
GA (Copaxone®, Teva Pharmaceutical Industries) is a synthetic peptide of four amino acids 
resembling MBP. As IFNβ, GA is an injectable drug, which considerably attenuates RRMS (Johnson 
et al., 1995, Comi et al., 2001). The immunomodulatory effect of GA is thought to be due to the 
development of GA-specific suppressive T cells that mainly produce T helper 2 (Th2) cytokines 
(Aharoni et al., 1997, Neuhaus et al., 2000, Yong, 2002) and the increased secretion of brain-
derived neurotrophic factor (BDNF) by T cells (Ziemssen et al., 2002). 
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Dimethyl fumarate (Tecfidera®, Biogen-Idec) is an orally active compound approved for 
the treatment of psoriasis and, since 2013, RRMS. Dimethyl fumarate treatment was shown to be 
beneficial for RRMS patients (Fox et al., 2012, Gold et al., 2012), which is attributed to its 
neuroprotective antioxidative actions (Linker et al., 2011, Scannevin et al., 2012) and additional 
immunomodulatory properties (Ghoreschi et al., 2011). 
Teriflunomide (Aubagio®, Genzyme) and alemtuzumab (Lemtrada®, Genzyme) were also 
approved as first line medication for RRMS in 2013. Both drugs showed beneficial effects in phase 
III studies (O'Connor et al., 2006, Coles et al., 2008, O'Connor et al., 2011, Cohen et al., 2012), but 
treatment was associated with undesirable side effects. Teriflunomide mediates its effects mainly 
by blocking the de novo synthesis of pyrimidines and subsequent inhibition of cell proliferation. 
This mechanism affects activated T cells, but also other proliferating cells, leading to undesired 
effects such as teratogenicity (Cherwinski et al., 1995, Greene et al., 1995, Warnke et al., 2009). 
Alemtuzumab is a humanized antibody against CD52 and administration of this antibody induces 
pronounced and long-lasting depletion of T and B cells (Klotz et al., 2012). Side effects of 
alemtuzumab are slightly increased rates of infection and the development of antibody-mediated 
autoimmunity, such as idiopathic thrombocytopenic purpura and thyroid disorders (Coles et al., 
2008). Due to these adverse events, alemtuzumab is more likely to be chosen either as second 
line treatment or as first line therapy for patients with more aggressive MS in practice. 
Second line treatments are applied when first line treatments fail to efficiently control 
disease activity. Therapeutic options are natalizumab and fingolimod, which are characterized by 
their higher therapeutic efficacy, but also slightly reduced tolerability. 
Natalizumab (Tysabri®, Biogen Idec) is a humanized monoclonal antibody that binds to the 
α4 subunit of α4β1 and α4β7 integrins and thereby prevents lymphocyte adhesion to endothelial 
cells of the BBB and CNS infiltration (Yednock et al., 1992). Natalizumab efficiently reduces disease 
activity in RRMS patients (Polman et al., 2006), but rarely patients develop progressive multifocal 
leukoencephalopathy (PML) upon treatment (Rudick et al., 2006). The incidence of PML appears 
to be strongly associated with John Cunningham virus (JCV) infection and therefore patients 
should be tested for anti-JCV antibodies prior to treatment with natalizumab (Derfuss and Kappos, 
2013). 
Fingolimod (Gilenya®, Novartis) was the first orally active immunomodulator approved for 
the treatment of RRMS in 2011. Fingolimod is an unselective sphingosin-1-phosphat (S1P) 
receptor agonist, which exerts its beneficial effects in MS (Kappos et al., 2006, Kappos et al., 2010) 
mainly through the sequestration of lymphocytes within the lymph nodes (Brinkmann et al., 2002, 
Mandala et al., 2002).  
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Mitoxantrone is an immunosuppressive drug approved as third line treatment for RRMS. 
It intercalates into the deoxyribonucleic acid (DNA) double helix and reduces T and B cell 
activation and proliferation and the activation of macrophages (Hartung et al., 2002). 
Mitoxantrone very efficiently reduces disease activity in RRMS (Edan et al., 2011), but due to its 
cardiotoxicity, bone marrow depression and the development of secondary malignancies it is only 
rarely applied if all other therapeutic options fail. 
During the last ten years, several new drugs have been approved for the treatment of 
RRMS and additional promising substances like laquinimod, daclizumab and rituximab are 
currently under investigation to further ameliorate the therapy of RRMS patients. 
 
1.2 Experimental autoimmune encephalomyelitis 
1.2.1 EAE induction  
Experimental autoimmune encephalomyelitis (EAE) is the most common animal model to 
investigate autoimmune aspects of MS. EAE was first described by Koritschoner and Schweinburg 
in 1925 who immunized rabbits with human spinal cord homogenate (Koritschoner and 
Schweinburg, 1925).  
Typically EAE can be induced in susceptible animals by active immunization with distinct 
myelin peptides in complete Freund’s adjuvant (CFA) and administration of pertussis toxin 
(Stromnes and Goverman, 2006). EAE studies are most frequently performed in mice, but also in 
rats and marmosets. The specific peptide, used to initiate EAE, depends on the mouse strain: 
C57Bl/6 mice respond to MOG35-55 (Mendel et al., 1995), SJL/J mice to PLP139-151 (Tuohy et al., 
1992), Biozzi AB/H mice to MOG1-22 (Amor et al., 1994) and B10.PL mice to MBP1-9 (Ando et al., 
1989). MOG35-55-induced EAE in C57Bl/6 mice is one of the most frequently used EAE models, 
since genetically modified mice are mainly available on the C57Bl/6 background.  
As alternative to active immunization, adoptive transfer of activated myelin-specific T cells 
is a suitable approach to passively induce EAE in rodents (Ben-Nun et al., 1981, Zamvil et al., 1986, 
Stromnes and Goverman, 2006). 
The disease course of EAE is characterized by an ascending paralysis, which starts in the 
tail, typically ten to fourteen days after immunization, and subsequently affects the hind limbs, 
the abdominal muscles and the fore limbs. C57Bl/6 mice display a monophasic disease course 
with variable remission leading to chronic neurological impairment. In contrast, SJL/J and Biozzi 
mice develop a relapsing-remitting form of EAE (Gold et al., 2006). 
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During the last two decades the spectrum of EAE models was enriched by different 
genetically modified animals with spontaneous development of disease symptoms. Two examples 
are OSE and ODC-OVA/OT-1 mice. OSE (optico-spinal EAE) mice are double transgenic mice 
possessing MOG-specific T cell and B cell receptors. These animals are derived from 
crossbreedings of MOG-specific T cell receptor transgenic 2D2 (Bettelli et al., 2003) and MOG-
specific B cell receptor transgenic Th mice (Litzenburger et al., 1998) and spontaneously develop 
optico-spinal EAE with an incidence of approximately 50% (Krishnamoorthy et al., 2006). ODC-
OVA/OT-1 mice are double transgenic animals which express ovalbumin (OVA) specifically in 
oligodendrocytes (ODC) and contain CD8+ T cells carrying the OVA-specific T cell receptor OT-1. 
Up to 90% of these animals experience fulminant EAE starting 12 - 19 days after birth (Na et al., 
2008).    
 
1.2.2 Effector cells in MOG35-55-induced EAE 
The main effector cells in MOG35-55-induced EAE in C57Bl/6 mice are thought to be CD4+  
T cells. Encephalitogenic MOG35-55-specific T cell clones were shown to express Vβ1, Vβ6, Vβ8, 
Vβ14 and Vβ15 T cell receptors (TCR), with Vβ8 being the predominant form (40-43%) (Mendel et 
al., 1995). 
The first pathogenic effects of CD4+ T cells in EAE were described for IFNγ-producing Th1 
cells. Adoptive transfer of myelin-specific Th1 cells induces EAE (Baron et al., 1993), whereas 
genetical depletion of the lineage specific transcription factor T-bet renders animals resistant to 
EAE (Bettelli et al., 2004). IL-12 is a central cytokine for the differentiation of Th1 cells, but 
interestingly IL-12-deficient mice are still susceptible to EAE induction (Becher et al., 2002). In 
contrast, IL-23 was identified as crucial factor for autoimmune CNS inflammation (Cua et al., 
2003). 
The cytokine IL-23 promotes the development of IL-17-secreting CD4+ T cells (Th17 cells), 
which were subsequently recognized as the second central player for T cell-mediated 
autoimmunity in EAE. Th17 cells are highly encephalitogenic and promote EAE upon adoptive 
transfer (Langrish et al., 2005, Kroenke et al., 2008, Jäger et al., 2009). 
Both T cell subpopulations – Th1 and Th17 cells – induce EAE with a comparable severity 
in adoptive transfer experiments (Kroenke et al., 2008, Jäger et al., 2009), but the pathological 
mechanisms differ, since Th1 cells mainly recruit macrophages to the CNS, whereas Th17 cells 
secrete chemoattractants for neutrophils (Kroenke et al., 2008).  
Studies evaluating the impact of IFNγ and IL-17 in the pathogenesis of EAE revealed that 
each of these cytokines alone is not essential. IL-17 neutralization and genetic depletion of IL-17 
and its receptor attenuate disease severity, but IL-17-deficient as well as IFNγ-deficient animals 
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are still susceptible to EAE (Ferber et al., 1996, Hofstetter et al., 2005, Komiyama et al., 2006, 
Haak et al., 2009, Hu et al., 2010).  
Anti-inflammatory regulatory T cells represent the third important effector cell population 
in EAE. Regulatory T cells were shown to inhibit the activation of auto-reactive T cells and the 
adoptive transfer of these IL-10 producing regulatory cells protects the recipient animals from EAE 
(Kohm et al., 2002, Zhang et al., 2004, Liu et al., 2006). During the course of disease, regulatory  
T cells accumulate in the CNS and they appear to be essential for the recovery phase (McGeachy 
et al., 2005). 
The exact role of CD8+ T cells in EAE is still controversial. Several groups claim a regulatory 
effect of CD8+ T cells, since the depletion of CD8+ T cells enhances EAE and the transfer of CD8+ 
CD28- T cells suppresses EAE (Najafian et al., 2003, Montero et al., 2004). In contrast, other 
studies provide evidence for a pathogenic role. Myelin-specific CD8+ T cells accumulate within the 
CNS (Ford and Evavold, 2005) and induce EAE upon adoptive transfer (Huseby et al., 2001, Sun et 
al., 2001). Furthermore, the activation of myelin-specific CD8+ T cells by viral infections can break 
T cell tolerance and induces CNS autoimmunity (Ji et al., 2010). 
C57Bl/6 mice fail to produce pathogenic antibodies upon immunization with MOG35-55 
(Bourquin et al., 2003). Therefore, MOG35-55-induced EAE in C57Bl/6 mice is not a suitable 
approach to investigate the contribution of pathogenic demyelinating antibodies. Suitable models 
to study the role of pathogenic antibodies comprise peptide-induced EAE in SJL/J or Biozzi AB/H 
mice, MOG-induced EAE in dark Agouti and brown Norway rats (Krishnamoorthy and Wekerle, 
2009) and MOG-specific B cell receptor transgenic (Th) mice (Litzenburger et al., 1998).  
 
1.2.3 The value of EAE for the development of MS therapies 
Preclinical studies, which evaluate the efficiency, safety and tolerability of a substance, 
are a prerequisite for the development of new therapeutic approaches. EAE has proven to be a 
valuable tool to investigate novel drugs for the treatment of MS. Four out of the ten currently 
approved MS medications were chosen to be evaluated in clinical trials based on their beneficial 
effects reported in different EAE models. 
Glatiramer acetate (GA), a synthetic peptide of four amino acids, was developed in the 
1970’s and its immunomodulatory properties were first investigated in different EAE models. In 
these studies GA completely inhibited acute EAE in guinea pigs, rabbits and rhesus monkeys 
(Teitelbaum et al., 1971, Teitelbaum et al., 1972, Teitelbaum et al., 1973, Teitelbaum et al., 1974), 
reduced the relapse rate in a relapsing-remitting model of EAE (Keith et al., 1979) and prevented 
adoptive transfer EAE (Aharoni et al., 1993). Besides its clinical efficiency, EAE studies revealed 
different components of the mechanism of action of GA, including the inhibition of antigen-
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dependent T cell activation and the induction of Th2-biased suppressor T cells (Teitelbaum et al., 
1996, Aharoni et al., 1997). 
Mitoxantrone is a DNA-intercalating immunosuppressive agent approved as third line 
medication for RRMS. First beneficial effects of the drug were observed in EAE studies, 
demonstrating complete inhibition of acute EAE, attenuation of relapsing-remitting EAE and the 
reduction of established paralysis (Ridge et al., 1985, Levine and Saltzman, 1986, Lublin et al., 
1987). Furthermore, data from EAE studies revealed that the potential mechanisms of action 
include the inhibition of lymphocyte proliferation as well as the reduced macrophage-mediated 
myelin destruction (Watson et al., 1991).  
The humanized antibody natalizumab was developed on the basis of murine anti-α4 
integrin antibodies, which efficiently prevented EAE induction by blocking the influx of activated  
T cells into the CNS of experimental animals (Yednock et al., 1992, Brocke et al., 1999). Notably, 
administration of these antibodies was beneficial during the whole course of disease and 
achieved remission of established clinical signs (Kent et al., 1995, Keszthelyi et al., 1996).  
The first orally active compound approved for the treatment of RRMS was fingolimod. 
This unselective S1P receptor agonist was also first evaluated in EAE studies. Preventive treatment 
protected the animals from EAE induction and therapeutic treatment reduced EAE progression 
and relapse rates (Brinkmann et al., 2002, Kataoka et al., 2005). Furthermore, a dual mechanism 
of action was described in EAE studies. The immunomodulatory component is mediated by 
inhibiting the egress of lymphocytes from the lymph nodes, whereas CNS intrinsic effects appear 
to be triggered by the interaction with S1P1 receptors on the surface of astrocytes (Mandala et 
al., 2002, Choi et al., 2011). 
Additional substances for the treatment of MS, which are currently under investigation in 
clinical trials, were previously evaluated in EAE models, like the quinoline-3-carboxamide 
laquinimod (Brunmark et al., 2002, Runström et al., 2006, Wegner et al., 2010, Aharoni et al., 
2012, Mishra et al., 2012, Schulze-Topphoff et al., 2012, Thöne et al., 2012, Jolivel et al., 2013, 
Moore et al., 2013, Ruffini et al., 2013) and the humanized anti-CD25 antibody daclizumab 
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1.3 Natural killer cells 
1.3.1 NK cell biology 
Natural killer (NK) cells originally received their name based on their natural ability to 
exert cytotoxic activity towards target cells without prior immunization. NK cells develop in the 
bone marrow from the same common lymphoid progenitor cell as T and B cells, but despite their 
classification as lymphocytes, NK cells recognize their targets using germline encoded receptors 
and are thus considered as component of the innate immune system. 
The main effector functions of NK cells are the direct killing of target cells as well as the 
secretion of a variety of cytokines and chemokines. Thereby, NK cells considerably contribute to 
the defense against viral infections and play a major role in tumor surveillance (Cooper et al., 
2001, Vivier et al., 2011). 
NK cell effector functions need to be tightly controlled to assure efficient discrimination 
between self and foreign as well as healthy and diseased. The activation of NK cells is regulated by 
an array of activating and inhibitory receptors on their surface. Inhibitory receptors, such as killer 
cell immunoglobulin-like receptors (KIR) and leukocyte immunoglobulin-like receptors in humans, 
Ly49 family members in mice and CD94/NKG2A in both species, mainly recognize MHC class I 
family molecules and contain immunoreceptor tyrosine-based inhibitory (ITIM) motifs within their 
intracellular domain. Recruitment and activation of SH2 domain-containing tyrosine phosphatases 
(SHP1 and SHP2) mediate inhibitory signaling (de Andrade et al., 2013). Activating NK cell 
receptors, like natural cytotoxicity receptors (NKp30, NKp44, NKp46, NKp80), NKG2D and CD244, 
bind to molecules associated with cellular stress and damage and trigger the activation of NK 
cells. NK cell activation is mediated by the recruitment of immunoreceptor tyrosine-based 
activation (ITAM) motif-containing molecules and the subsequent activation of downstream 
signaling molecules, such as nuclear factor kappa B (NF-κB), phospholipase Cγ or protein kinase C. 
Another important receptor family binds to nectins and nectin-like proteins and includes the 
activating receptors DNAM-1 (DNAX Accessory Molecule-1) and TACTILE (T cell-activated 
increased late expression) as well as the inhibitory receptor TIGIT (T cell immunoreceptor with Ig 
and ITIM domains). Engagement of one single activating NK cell receptor is not sufficient to 
efficiently trigger NK cell activation, but a combination of different receptors is required to 
activate NK cells. One exception to this rule is CD16, which specifically recognizes the Fc region of 
immunoglobulins and mediates antibody dependent cellular cytotoxicity (ADCC) without 
bystander activation of any other receptor. Beside their regulation via activating and inhibitory 
receptors, NK cells do also react directly to different cytokines (Vivier et al., 2011, de Andrade et 
al., 2013, Long et al., 2013). 
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During the last two decades the concept of NK cells as crucial regulatory element within 
immunity has emerged. On the one hand, NK cells support dendritic cell maturation and promote 
the Th1 response by secreting pro-inflammatory cytokines or by direct cell contact (Gerosa et al., 
2002, Piccioli et al., 2002, Martin-Fontecha et al., 2004, Vitale et al., 2005). On the other hand, NK 
cells are able to kill immature dendritic cells in vitro (Wilson et al., 1999, Ferlazzo et al., 2002) and 
to inhibit T cell responses through the secretion of anti-inflammatory cytokines, p21-mediated cell 
cycle arrest and lysis of activated T cells (Cooper et al., 2001, Rabinovich et al., 2003, Trivedi et al., 
2005, Cerboni et al., 2007, Lu et al., 2007, Deniz et al., 2008). 
The overall pool of NK cells consists of different subpopulations. In humans, NK cells are 
classically subdivided into CD56dim CD16+ and CD56bright CD16- NK cells. The CD56dim subset is 
characterized by a low proliferation rate, high levels of inhibitory receptors and the expression of 
the adhesion molecules PEN-5 and LFA-1 and of the chemokine receptors CXCR1 and CX3CR1. In 
contrast, CD56bright NK cells have a high proliferative potential, display low levels of inhibitory 
receptors and express the adhesion molecule CD62L and the chemokine receptors CCR7 and 
CXCR3 (Cooper et al., 2001). Moreover, the two subsets differentially express the surface 
molecules CD27 and CD11b: CD11b+ NK cells are mainly found within the CD56dim subpopulation, 
whereas CD27 expression is dominant on the CD56bright subset (Fu et al., 2011). Additionally, the 
two subsets differ with regard to their anatomical localization. CD56dim NK cells are mainly found 
in the peripheral blood and the spleen, whereas CD56bright NK cells dominate in lymph nodes and 
tonsils (Vivier et al., 2008). 
The two subsets also display functional differences. CD56dim NK cells exhibit higher basal 
cytotoxicity and efficiently produce cytokines upon engagement of activating receptors, but are 
less responsive to cytokine stimulation. In contrast, lower basal cytotoxicity, but effective cytokine 
secretion in response to cytokine stimulation is ascribed to CD56bright NK cells (Cooper et al., 2001, 
Long et al., 2013).  
The human NK cell marker CD56 is not expressed in the murine system. In C57Bl/6 mice, 
NK cells are identified by the expression of the pan-NK cell markers NK1.1 and NKp46 on CD3-
negative cells and subpopulations can be classified according to the surface expression of CD27 
and CD11b: CD27+ CD11b- NK cells, CD27+ CD11b+ NK cells and CD27- CD11b+ NK cells 
(Chiossone et al., 2009). CD27+ CD11b- NK cells display a higher proliferative potential and 
express the chemokine receptor CXCR3. CD27- CD11b+ NK cells proliferate less vigorously and are 
characterized by high levels of inhibitory receptors (Kim et al., 2002, Hayakawa et al., 2006). All 
murine NK cell subsets are fully functional with regard to cytokine secretion and cytotoxicity, but 
in contrast to human NK cells, the predominant effector functions of individual subsets of murine 
NK cells are less well defined (Takeda et al., 2000, Kim et al., 2002, Hayakawa et al., 2006, Vahlne 
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et al., 2008, Chiossone et al., 2009). Regarding their tissue distribution, CD27+ CD11b- NK cells are 
mainly present in the bone marrow and the lymph nodes, while CD27- CD11b+ NK cells are more 
abundant in the peripheral blood and the spleen (Vivier et al., 2008).  
 
1.3.2 NK cells and autoimmunity 
NK cells appear to be implicated in different autoimmune diseases like type I diabetes 
(TID), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and MS, exerting either 
protective or destructive functions. 
The role of NK cells in TID is still very controversial. On the one hand, NK cells only 
represent a minor fraction of the inflammatory infiltrate in the pancreas (Willcox et al., 2008). 
Reduced numbers and functional impairment of NK cells were observed in the peripheral blood of 
TID patients, suggesting a rather protective effect of NK cells (Rodacki et al., 2007). On the other 
hand, patients with coxsackie B4 enterovirus infected β cells displayed considerable NK cell 
infiltration of the pancreas, leading to β cell destruction (Dotta et al., 2007). Animal studies 
highlight these controversial effects by revealing protective (Lee et al., 2004, Lee et al., 2008) as 
well as destructive (Poirot et al., 2004) effects of NK cells.  
Studies in RA patients point towards a dual role of NK cells. Activated CD56bright NK cells 
were shown to specifically accumulate in the inflamed synovial tissue. These cells appear to 
contribute to the maintenance of Th1 inflammation and auto-reactive T cell activation through 
the production of pro-inflammatory cytokines (Pridgeon et al., 2003, de Matos et al., 2007, Zhang 
et al., 2007). In contrast to the inflamed joints, NK cell numbers and activity are considerably 
diminished in the blood of RA patients, pointing towards a regulatory role of these cells in the 
periphery (Aramaki et al., 2009, Park et al., 2009). 
In SLE, NK cells seem to contribute to disease attenuation. Reduced NK cell numbers and 
impaired cytotoxicity are correlated with clinical manifestation of SLE and NK cells were reported 
to reduce the secretion of pathogenic auto-antibodies (Takeda and Dennert, 1993, Yabuhara et 
al., 1996, Park et al., 2009, Huang et al., 2011).  
The contribution of NK cells to the pathogenesis of MS is not fully elucidated yet, but a 
large body of evidence supports the concept of a beneficial role of NK cells in MS. Several studies 
associate MS with reduced circulating NK cell numbers (Vranes et al., 1989, Munschauer et al., 
1995, De Jager et al., 2008, Martinez-Rodriguez et al., 2010) and defective NK cell effector 
functions (Benczur et al., 1980, Hauser et al., 1981, Neighbour et al., 1982). Phases of particularly 
low NK cell activity precede disease exacerbation and the expansion of anti-inflammatory 
cytokine-secreting type II NK cells was observed during the remission phase (Takahashi et al., 
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2001, Kastrukoff et al., 2003). The beneficial role of NK cells in MS is further supported by several 
studies reporting NK cell expansion and activation upon treatment with different MS medications. 
 
1.3.3 NK cells in the treatment of multiple sclerosis 
NK cell numbers and function were shown to be an important target of different MS 
therapies, underpinning the notion of a primarily regulatory and beneficial function of NK cells in 
MS. 
MS patients treated with IFNβ display slightly decreased total numbers of circulating NK 
cells, but a robust expansion of the regulatory CD56bright subset in secondary lymphoid organs and 
the peripheral blood (Perini et al., 2000, Saraste et al., 2007, Vandenbark et al., 2009, Martinez-
Rodriguez et al., 2010), which was significantly related to the therapy response (Martinez-
Rodriguez et al., 2011).  
Glatiramer acetate (GA) reduces auto-antigen presentation by different mechanisms. 
Besides its direct binding to major histocompatibility complex (MHC) molecules (Fridkis-Hareli et 
al., 1994), GA considerably enhances the cytotoxicity of NK cells towards immature dendritic cells. 
Furthermore, the cytokine secretion of NK cells is altered upon GA treatment, but total numbers 
remain unaffected (Al-Falahi et al., 2009, Sand et al., 2009). 
Natalizumab treatment mainly interferes with the localization of NK cells, increasing 
circulating NK cells and reciprocally decreasing their numbers within the CNS, the lymph nodes 
and the spleen, suggesting that α4 integrin blockade alters the trafficking of NK cells (Putzki et al., 
2010, Skarica et al., 2011, Gan et al., 2012, Planas et al., 2012). 
Fingolimod treatment was reported to reduce the frequency of circulating CD56bright NK 
cells, without affecting their effector functions, which was attributed to an inhibition of NK cell 
egress from the lymph nodes, as evidenced for T and B cells (Mandala et al., 2002, Johnson et al., 
2011). Interestingly, another study could show increased NK cell frequencies in the CSF of 
fingolimod-treated MS patients, potentially indicating a protective role of NK cells within the CNS 
compartment (Kowarik et al., 2011). 
Most striking effects on NK cells were described for daclizumab, a humanized antibody 
recognizing the high affinity IL-2 receptor CD25, which is still under investigation for the 
treatment of MS. Daclizumab was originally designed to directly inhibit CD4+ T cell function, but in 
vivo studies only revealed a very mild effect on T cells. In contrast, daclizumab treatment induced 
a pronounced expansion of CD56bright NK cells, most likely mediated by the binding of IL-2 to the 
intermediate affinity receptor CD122, which is highly expressed on this subset (Bielekova et al., 
2006, Wynn et al., 2010). This expansion was observed in the peripheral blood and the CSF of MS 
patients and was significantly correlated with reduced contrast-enhancing MRI lesions and a 
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positive treatment response (Bielekova et al., 2006, Bielekova et al., 2011). Functionally, 
daclizumab-treated NK cells display increased proliferation rates and reduce the survival of 
activated T cells, which appears to be a central component of the mechanism of action in MS 
(Bielekova et al., 2006, Martin et al., 2010).   
 
1.4 The new immunomodulator laquinimod 
The new orally active immunomodulator laquinimod (LAQ) is currently under investigation 
for the treatment of MS. LAQ (5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-
dihydroquinoline-3-carboxamide) (FIGURE 1) has been developed in a structure-activity 
relationship program through modification of its precursor substance roquinimex, which was 
withdrawn from clinical studies due to severe cardiopulmonary toxicities (Noseworthy et al., 
2000, Jönsson et al., 2004). The substitution of the 5-H and the 12-N-methyl group of roquinimex 
by a 5-Cl and a 12-N-ethyl group defined a new substance, LAQ, with increased efficacy and 
tolerability (Jönsson et al., 2004). Despite its higher efficiency to inhibit EAE compared to 
roquinimex (Brunmark et al., 2002, Jönsson et al., 2004), LAQ is not immunosuppressive and 





FIGURE 1: Structural formula of laquinimod 






1.4.1 Clinical studies 
Several clinical trials evaluated the safety, tolerability and therapeutic efficiency of LAQ in 
MS patients. 
Phase II studies revealed a favorable safety profile and a significant reduction of 
gadolinium-enhancing (GdE) active MRI lesions, indicating decreased disease activity. (Polman et 
al., 2005, Comi et al., 2008, Comi et al., 2010). 
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Subsequently, two randomized, double-blind, phase III studies, the ALLEGRO (Comi et al., 
2012) and the BRAVO study (Vollmer et al., 2014) were performed and a third phase III trial, the 
CONCERTO study has recently been started. Data from the ALLEGRO trial indicated a moderate 
decrease of the annualized relapse rate by 23% in the LAQ group. Strikingly, LAQ exerted more 
dominant effects on the secondary endpoints “risk of disability progression” and “brain volume 
loss”, which were markedly reduced by 30% and 43%, respectively, indicating neuroprotective 
effects of LAQ treatment (Comi et al., 2012). Additional MRI measures further support the 
concept of a neuroprotective component within the mechanism of action of LAQ (Filippi et al., 
2013).  
Consequently, LAQ appears to have a dual mechanism of action, consisting of 
neuroprotective and immunomodulatory effects. The neuroprotective effect of LAQ could be 
partially due to an upregulation of brain-derived neurotrophic factor (BDNF) secretion in the 
periphery (Thöne et al., 2012). The immunomodulatory capacity of LAQ in MS patients was 
evidenced by considerably reduced frequencies of different dendritic cell populations in the 
peripheral blood after LAQ treatment and attenuated production of pro-inflammatory cytokines 
and chemokines by these dendritic cells upon stimulation ex vivo (Jolivel et al., 2013). 
Taken together, data from clinical trials indicate that LAQ treatment is beneficial for MS 
patients, which is most likely mediated by immunomodulatory as well as neuroprotective effects. 
Still, the exact mechanism of action of LAQ in MS is not clear and a large panel of experimental 
studies was performed to elucidate different aspects of this mechanism.  
 
1.4.2 Experimental studies 
The effects of laquinimod treatment were studied in EAE. Preventive LAQ treatment 
efficiently inhibits acute EAE in mice (Brunmark et al., 2002, Aharoni et al., 2012, Mishra et al., 
2012, Schulze-Topphoff et al., 2012, Thöne et al., 2012, Jolivel et al., 2013) and rats (Yang et al., 
2004) in a dose-dependent manner (Yang et al., 2004, Runström et al., 2006, Wegner et al., 2010, 
Moore et al., 2013, Ruffini et al., 2013). Therapeutic treatment attenuates EAE severity (Wegner 
et al., 2010, Aharoni et al., 2012, Moore et al., 2013) and reduces the incidence of relapses in 
relapsing EAE models (Brunmark et al., 2002, Schulze-Topphoff et al., 2012, Jolivel et al., 2013). 
Histological analysis of spinal cord sections from LAQ-treated EAE animals revealed 
decreased immune cell infiltration and microglia activation, which was associated with reduced 
demyelination, axonal damage and astrogliosis (Brunmark et al., 2002, Runström et al., 2006, 
Wegner et al., 2010, Mishra et al., 2012, Moore et al., 2013, Ruffini et al., 2013) and increased 
oligodendrocyte proliferation (Moore et al., 2013). 
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Clinical trials point towards a dual role of LAQ in the treatment of MS, exerting 
neuroprotective as well as immunomodulatory effects. This notion is underpinned by several 
experimental studies, which provide evidence for both components within its mechanisms of 
action. 
 
1.4.2.1 Effects of LAQ within the CNS 
The first prerequisite for a substance to exert CNS intrinsic effects is its availability within 
the CNS. 13% of the blood concentration of LAQ reaches the CNS in rodents with EAE and 7 - 8% 
in healthy animals (Brück and Wegner, 2011).  
LAQ has shown to be neuroprotective in different experimental studies. Within the CNS, 
LAQ directly targets different cell types. LAQ inhibits toxin-mediated demyelination in the 
cuprizone-model and reduces the production of pro-inflammatory cytokines in astrocytes (Brück 
et al., 2012) and microglia (Mishra et al., 2013). Astrocytes show reduced NF-κB activity upon LAQ 
exposure (Brück et al., 2012), whereas in microglia mainly c-Jun N-terminal kinase (JNK) and 
protein kinase B (AKT) signaling are affected (Mishra et al., 2013). Furthermore, LAQ directly 
interferes with the neurotransmission in EAE animals, by reducing glutamatergic transmission and 
excitotoxicity as well as by enhancing GABAergic transmission (Ruffini et al., 2013) and callosal 
conduction (Moore et al., 2013). One further factor for the protective effect of LAQ in EAE seems 
to be BDNF, since the therapeutic efficiency of LAQ is reduced in BDNF-deficient animals and wild-
type animals display increased BDNF mRNA levels in the spinal cord after LAQ treatment (Thöne et 
al., 2012).  
 
1.4.2.2 LAQ effects on immune cells 
Beside its CNS intrinsic effects, LAQ significantly modulates autoimmunity in EAE and 
recent studies indicate that antigen presenting cells are one of the direct targets of LAQ therapy.  
LAQ treatment profoundly alters antigen presentation, regarding quantity and quality. On 
the one hand, LAQ reduces the frequency of antigen-presenting cells, monocytes as well as 
dendritic cells (Schulze-Topphoff et al., 2012, Thöne et al., 2012, Jolivel et al., 2013). On the other 
hand, LAQ changes the phenotype of antigen-presenting cells, by inducing a type II cytokine 
profile with decreased levels of IL-6, IL-12 and TNF and increased levels of IL-10 (Schulze-Topphoff 
et al., 2012) and by upregulating the co-stimulatory molecule CD86 which is associated with Th2 
differentiation (Thöne et al., 2012, Jolivel et al., 2013). Adoptive transfer of LAQ-treated 
monocytes reduces EAE severity (Schulze-Topphoff et al., 2012) and this beneficial effect appears 
to be at least partially mediated by BDNF (Thöne et al., 2012). In vitro therapy approaches 
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identified monocytes and dendritic cells as direct targets of LAQ and different pro-inflammatory 
signaling pathways, including NF-κB, signal transducer and activator of transcription (STAT) and 
JNK, were found to be altered by LAQ (Mishra et al., 2012, Schulze-Topphoff et al., 2012, Jolivel et 
al., 2013).   
T cell differentiation is markedly biased towards anti-inflammatory subsets during LAQ 
therapy. LAQ considerably decreases the frequencies of pro-inflammatory Th1 and Th17 cells 
(Schulze-Topphoff et al., 2012, Jolivel et al., 2013) and their corresponding cytokines IFNγ and IL-
17 (Wegner et al., 2010, Moore et al., 2013). In turn, anti-inflammatory regulatory T cells are 
increased by LAQ (Schulze-Topphoff et al., 2012, Jolivel et al., 2013). Moreover, LAQ slightly 
attenuates T cell proliferation in vivo (Jolivel et al., 2013) and inhibits the VLA-4-dependent 
adhesion of T cells to VCAM-1 upon CCL21 stimulation (Wegner et al., 2010). 
The observed effects of LAQ on T cell differentiation are most likely indirect. Treatment 
with LAQ in vivo does not inhibit pro-inflammatory T cell differentiation in vitro (Schulze-Topphoff 
et al., 2012) and in vitro therapy of T cells does not influence their proliferation (Jolivel et al., 
2013). The alterations in T cell differentiation are thought to be mediated by LAQ-treated antigen 
presenting cells, as LAQ-treated monocytes can inhibit T cell differentiation and proliferation as 
well as pro-inflammatory cytokine production in vitro (Schulze-Topphoff et al., 2012, Thöne et al., 
2012, Jolivel et al., 2013).  
In brief, according to the current literature, LAQ exerts its immunomodulatory effects 
mainly through the reduction and alteration of antigen presentation, which subsequently leads to 
a shift in T cell differentiation and attenuates EAE severity. Still, the mechanism of action of LAQ is 
not fully elucidated and different important cell populations like B cells and NK cells have not 
been studied so far in detail. 
 
1.5 Aims 
The overall aim of the present study is to further elucidate the immunomodulatory 
mechanism of action of LAQ by investigating effects of the substance on innate and adaptive 
immune cells in animals with EAE. In detail, this work intends to evaluate LAQ-mediated 
alterations in three different immune cell populations: T cells, dendritic cells and most 
importantly NK cells. 
 
1. Effects of LAQ on T cells 
Pro-inflammatory T cell subsets are of central relevance for the pathogenesis of EAE and LAQ 
has been shown to efficiently inhibit EAE induction. Therefore, the present study aims to 
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analyze effects of LAQ on pro-inflammatory Th1 and Th17 cells and anti-inflammatory 
regulatory T cells in vivo. The question, whether LAQ directly acts on T cells, will also be 
addressed by in vitro therapy experiments. 
 
2. Effects of LAQ on dendritic cells 
Dendritic cells are potent antigen presenting cells and can profoundly influence the 
differentiation of T cells. Hence, this work aims to evaluate the effects of LAQ treatment on 
the frequencies of splenic dendritic cells and the expression of co-stimulatory molecules in 
vivo. 
 
3. Effects of LAQ on NK cells 
NK cells are involved in the pathogenesis of several autoimmune diseases and modulation of 
their phenotype and function appears to be associated with the beneficial effects of different 
MS treatments. NK cells may thus represent an interesting target for immunomodulatory 
therapies, however effects of LAQ treatment on NK cells have not been described before. 
Therefore, the central part of this project will assess the effects of LAQ on NK cell phenotype 
and function. Specific aims are to determine absolute NK cell numbers, NK cell frequency and 
NK cell subpopulations after LAQ administration. The impact of LAQ treatment on the 
activation state of NK cells will be assessed phenotypically, by analyzing surface activation 
markers and the NK cell receptor profile, and functionally by evaluating IFNγ production, 
cytotoxic activity and the potential to reduce T cell proliferation in vitro. Furthermore, time 
course experiments will examine the kinetics of LAQ-mediated alterations in NK cells and 
direct effects of LAQ on NK cells will be evaluated using an in vitro therapy approach. Finally, 
this work will address the question whether NK cells are of central relevance for the 
mechanism of action of LAQ. For this purpose, NK cell-competent and NK cell-depleted 
heterozygous MOG-specific B cell receptor transgenic mice (Th/+) mice will be immunized 
with MOG35-55 and treated with LAQ or vehicle. The efficiency of LAQ treatment in the 
presence and absence of NK cells will be assessed using the clinical EAE score and survival 
rates.   
 
The central aim of this study is to evaluate the effects of LAQ on NK cells and their 
importance within the mechanism of action of this new immunomodulatory drug. The results 
obtained in this work can lead to a better understanding of the mechanism of action of LAQ in 
EAE and might thereby contribute to optimize the future therapy of MS patients.  
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2. Materials and methods 
2.1 Materials 
2.1.1 Reagents 
TABLE 1: Reagents 
 
Reagent Source of supply 
Acetic acid, 100% Merck Millipore, Darmstadt, Germany 
Agarose StarLab GmbH, Hamburg, Germany 
Annexin V binding buffer, 10x eBioscience, San Diego, CA, USA 
BD FACS Shutdown Solution BD Biosciences, Franklin Lakes, NJ, USA 
BD FACSClean™ BD Biosciences, Franklin Lakes, NJ, USA 
BD FACSFlow™ BD Biosciences, Franklin Lakes, NJ, USA 
BD FACS™ Lysing Solution, 10x BD Biosciences, Franklin Lakes, NJ, USA 
BD Pharm Lyse™, 10x BD Biosciences, Franklin Lakes, NJ, USA 
Boric acid Merck Millipore, Darmstadt, Germany 
Crystal violet Sigma Aldrich, St. Louis, MO, USA 
Cytofix/Cytoperm™ BD Biosciences, Franklin Lakes, NJ, USA 
Cytofix™ BD Biosciences, Franklin Lakes, NJ, USA 
DMSO (dimethyl sulfoxide) Sigma Aldrich, St. Louis, MO, USA 
dNTP (desoxynucleoside triphosphate) mix Thermo Scientific, Waltham, Massachusetts, USA 
EDTA (ethylenediamine tetraacetic acid 
disodiumsalt dihydrate) 
Carl Roth, Karlsruhe, Germany 
Ethanol, 100% Merck Millipore, Darmstadt, Germany 
Ethidium bromide Sigma Aldrich, St. Louis, MO, USA 
FCS (fetal calf serum) Sigma Aldrich, St. Louis, MO, USA 
FoxP3 Fixation/Permeabilization Concentrate eBioscience, San Diego, CA, USA 
FoxP3 Fixation/Permeabilization Diluent eBioscience, San Diego, CA, USA 
FoxP3 Permeabilization buffer, 10x eBioscience, San Diego, CA, USA 
GeneRuler™, 100 base pairs (bp) DNA ladder Plus Thermo Scientific, Waltham, MA, USA 
Go-Taq® DNA polymerase buffer, 5x Promega, Madison, WI, USA 
HBSS (Hank‘s buffered salt solution) with Ca2+ and 
Mg2+ 
Sigma Aldrich, St. Louis, MO, USA 
HCl (hydrochloric acid) Merck Millipore, Darmstadt, Germany 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer, 1M 
Sigma Aldrich, St. Louis, MO, USA 
HL-1™ serum-free medium Lonza, Basel, Switzerland 
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Reagent Source of supply 
Ionomycin Sigma Aldrich, St. Louis, MO, USA 
Isopropyl alcohol Merck Millipore, Darmstadt, Germany 
Ketamine, 10% Medistar®, Ascheberg, Germany 
LAQ (laquinimod) Teva pharmaceutical industries Ltd., Netanya, Israel 
L-glutamine, 200 mM Sigma Aldrich, St. Louis, MO, USA 
LPS (lipopolysaccharide) Sigma Aldrich, St. Louis, MO, USA 
Mannide monooleate Sigma Aldrich, St. Louis, MO, USA 
MEM (minimum essential medium) non-essential 
amino-acids, 100x 
Sigma Aldrich, St. Louis, MO, USA 
NaCl (sodium chloride) Carl Roth, Karlsruhe, Germany 
NaCl (sodium chloride), 0.9% solution, sterile B. Braun Melsungen AG, Germany 
Paraffin oil Carl Roth, Karlsruhe, Germany 
PBS (phosphate buffered salt solution), sterile Sigma Aldrich, St. Louis, MO, USA 
Penicillin, 10,000 units / streptomycin, 10 mg/ml Sigma Aldrich, St. Louis, MO, USA 
Perm/Wash™ buffer, 10x BD Biosciences, Franklin Lakes, NJ, USA 
PMA (phorbol 12-myristate 13-acetate) Sigma Aldrich, St. Louis, MO, USA 
RPMI-1640 (Roswell Park Memorial Institute-1640) Sigma Aldrich, St. Louis, MO, USA 
SDS (sodium dodecyl sulfate) Sigma Aldrich, St. Louis, MO, USA 
Sodium pyruvate, 100 mM Sigma Aldrich, St. Louis, MO, USA 
TMB (3,3’,5,5’-tetramethylbenzidine) substrate 
solution 
eBioscience, San Diego, CA, USA 
Tris (tris(hydroxymethyl)aminomethane) Carl Roth, Karlsruhe, Germany 
Trypan blue Sigma Aldrich, St. Louis, MO, USA 
Xylazine solution, 20 mg/ml Ecuphar, Oostkamp, Belgium 
β-mercaptoethanol Sigma Aldrich, St. Louis, MO, USA 
 
Abbreviations 
Ca2+: calcium ion; DNA: deoxyribonucleic acid; FACS: fluorescence-activated cell sorting; FoxP3: forkhead 
box P3; MACS: magnetic-activated cell sorting; Mg2+: magnesium ion 
 
2.1.2 Solutions, buffers and cell culture media 
TABLE 2: Solutions, buffers and cell culture media 
 
Solution Composition 
Acetic acid, 33% Bidistilled water 
33% acetic acid, 100% 
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Solution Composition 
CFA (Complete Freund’s Adjuvant) Paraffin oil 
15% mannide monooleate 
6.7 mg/ml Mycobacterium tuberculosis H37RA  
 





Crystal violet staining solution 
 
Bidistilled water 
0.4 % crystal violet 
8% ethanol, 100% 
 






















1 mM sodium pyruvate 
1x non-essential amino acids 
13 mM HEPES buffer 
50 µM β-mercaptoethanol 
100 units penicillin 
0.1 mg/ml streptomycin 
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Solution Composition 
Tail lysis buffer Bidistilled water 
0.1 M Tris-HCl pH 8.5    
5 mM EDTA    
200 mM NaCl   
0.2% SDS  
pH 8.5  
 
TBE (Tris/borate/EDTA) buffer 
 
Bidistilled water 
90 mM Tris    
90 mM boric acid   
2 mM EDTA  
 
Abbreviations 
BSA: bovine serum albumin; EDTA: ethylenediamine tetraacetic acid disodiumsalt dehydrate; FCS: fetal 
calf serum; HCl: hydrochloric acid; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; NaCl: 
sodium chloride; PBS: phosphate buffered salt solution; RPMI-1640: Roswell Park Memorial Institute-
1640 medium; SDS: sodium dodecyl sulfate; Tris: tris(hydroxymethyl)aminomethane 
 
2.1.3 Cell lines and bacteria 
TABLE 3: Cell lines and bacteria 
 
Organism Source of supply 
B16F10 melanoma cell line Kindly provided by Prof. Evelyn Ullrich, Children’s 
Hospital, Department of Pediatric Hematology and 
Oncology, Goethe-University, Frankfurt, Germany 
 
Mycobacterium tuberculosis H37RA, non-viable 
 
DIFCO, Detroit, MI, USA 
 
2.1.4 Proteins, cytokines and dyes 
TABLE 4: Proteins, enzymes and inhibitors 
 
Proteins, enzymes, inhibitors  Source of supply 
BSA (bovine serum albumin) SERVA Electrophoresis GmbH, Heidelberg, Germany 
MOG35-55  Institute of Medical Immunology, University Medical      
Center Charité, Berlin, Germany 
PTX (pertussis toxin) List biological laboratories, Campbell, CA, USA 
Collagenase D Roche, Basel, Switzerland 
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Proteins, enzymes, inhibitors  Source of supply 
DNase I Roche, Basel, Switzerland 
Go-Taq® DNA polymerase Promega, Madison, WI, USA 
Proteinase K Sigma Aldrich, St. Louis, MO, USA 
Trypsin, 0.05% Gibco/Invitrogen, Carlsbad, CA, USA 
GolgiStop™ BD Biosciences, Franklin Lakes, NJ, USA 
 
Abbreviations 
DNA: deoxyribonucleic acid; MOG35-55: myelin oligodendrocyte glycoproteine amino acids 35 – 55 
 
 
TABLE 5: Monoclonal antibodies for flow cytometry 
 
Specificity Fluorochrome Clone Dilution Source of supply 
B220 PerCP RA3-6B2 1:200 BD  
CD11b APC M1/70 1:200 eB 
CD11b PE-Cy7 M1/70 1:200 eB 
CD11b  PerCP M1/70 1:200 BL 
CD11c PE N418 1:200 BL 
CD16/CD32 - 93 1:100 BL 
CD19 APC-Cy7 6D5 1:200 BL 
CD19 FITC eBio1D3 1:200 eB 
CD2 FITC RM2-5 1:200 eB 
CD205 PE-Cy7 NLDC-145 1:200 BL 
CD244.2 FITC m2B4 1:200 BL 
CD25  APC PC61.5 1:200 eB 
CD27 PE LG.3A10 1:200 BL 
CD3 FITC 145-2C11 1:200 BL 
CD3 PE-Cy7 145-2C11 1:200 eB 
CD3 APC-Cy7 145-2C11 1:200 BL 
CD4 PerCP RM4-5 1:200 BL 
CD44 APC IM7 1:200 eB 
CD45 APC-Cy 30-F11 1:200 BL 
CD62L PE MEL-14 1:200 eB 
CD69 PE H1.2F3 1:200 eB 
CD69 PE-Cy7 H1.2F3 1:200 BL 
CD8 PE-Cy7 53-6.7 1:200 eB 
CD8 APC-Cy7 53-6.7 1:200 BL 
CD80 APC 16-10A1 1:200 BL 
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Specificity Fluorochrome Clone Dilution Source of supply 
CD86  APC-Cy7 GL1 1:200 BL 
CXCR3 PerCP/Cy5.5 CXCR3-173 1:200 BL 
DNAM-1 PE 10 E5 1:200 BL 
FoxP3 PE FJK-16S 1:100 eB 
IFNγ PE XMG1.2 1:200 eB 
IFNγ APC XMG1.2 1:200 eB 
IL-17A PE-Cy7 eBio17B7 1:200 eB 
LFA-1 PE M17/4 1:200 eB 
Ly49A PE A1 1:200 eB 
Ly49C/I/F/H FITC 14B11 1:200 eB 
Ly49D PE 4 E5 1:200 BL 
Ly49G2 FITC eBio4D11 1:200 eB 
MHCII FITC M5/114.15.2 1:200 BL 
NK1.1 PE-Cy7 PK-136 1:200 BL 
NK1.1 APC PK-136 1:200 BL 
NKG2D APC CX5 1:200 BL 
NKp46 PerCP 29A1.4 1:200 BL 
NKp46 PE 29A1.4 1:200 BL 
TACTILE PE 3.3 1:200 BL 
TIGIT PE 1G9 1:200 BL 
γδ TCR APC eBioGL3 1:200 eB 
 
Abbreviations 
APC: allophycocyanin; BD: BD Biosciences, Franklin Lakes, NJ, USA; BL: BioLegend, San Diego, 
CA, USA; eB: eBioscience, San Diego, CA, USA; CD: cluster of differentiation; CXCR3: chemokine 
(C-X-C motif) receptor 3; Cy7: cyanine 7; DNAM-1: DNAX accessory molecule-1; FITC: 
fluorescein isothiocyanate; FoxP3: forkhead box P3; IFNγ: interferon gamma; IL-17A: interleukin 
17A; LFA-1: leukocyte function-associated antigen-1; MHCII: major histocompatibility complex 
class II molecule; NK: natural killer; NKG2D: natural killer group 2, member D; NKp46: natural 
killer cell p46-related protein; PE: phycoerythrin; PerCP: peridinin chlorophyll protein; TACTILE: 
T cell-activated increased late expression; TCR: T cell receptor; TIGIT: T cell immunoreceptor 
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TABLE 6: Monoclonal antibodies for antigen-independent activation 
of T cell proliferation in vitro 
 
Specificity Clone Source of supply 
CD3 145-2C11 Bio X Cell, West Lebanon, NH, USA 
CD28 PV-1 Bio X Cell, West Lebanon, NH, USA 
 
Abbreviations 
CD: cluster of differentiation 
 
 
TABLE 7: Monoclonal antibodies for NK cell depletion in vivo 
 
Specificity Clone Application Source of supply 
NK1.1 PK-136 In vivo depletion of NK cells Bio X Cell, West Lebanon, NH, USA 
unknown C1.18.4 Isotype control antibody Bio X Cell, West Lebanon, NH, USA 
 
Abbreviations 
NK: natural killer 
 
 
TABLE 8: Cytokines 
 
Cytokine  Source of supply 
GM-CSF, mouse, recombinant PeproTech, Rocky Hill, NJ, USA 
IL-12, mouse, recombinant PeproTech, Rocky Hill, NJ, USA 
IL-18, mouse, recombinant PeproTech, Rocky Hill, NJ, USA 
IL-2, human, recombinant Novartis, Nuremberg, Germany 
 
Abbreviations 
GM-CSF: granulocyte macrophage colony-stimulating factor; IL: interleukin 
 
 
TABLE 9: Fluorescent dyes 
 
Name Fluorochrome Dilution Source of supply 
Annexin V APC 1:20 eBioscience, San Diego, CA, USA 
7-AAD  - 1:40 eBioscience, San Diego, CA, USA 
 
Abbreviations 
7-AAD: 7-aminoactinomycin D; APC: allophycocyanin 
 
 Materials and methods 29 
 
2.1.5 Applied kits 
TABLE 10: Kits 
 
Kit Source of supply 
CD11c MicroBeads Miltenyi Biotec, Bergisch Gladbach, Germany 
CD4+ T cell isolation kit II, mouse Miltenyi Biotec, Bergisch Gladbach, Germany 
CellTrace™ CFSE Cell Proliferation Kit Life Technologies, Carlsbad, CA,USA 
Mouse IFNγ DuoSet® ELISA development system R&D Systems, Minneapolis, MN, USA 
Mouse IL-17 DuoSet® ELISA development system R&D Systems, Minneapolis, MN, USA 
NK cell isolation kit II, mouse Miltenyi Biotec, Bergisch Gladbach, Germany 
 
Abbreviations 
CD: cluster of differentiation; CFSE: carboxyfluorescein succinimidyl ester; ELISA: enzyme linked 
immunosorbent assay; IFNγ: interferon gamma; IL-17: interleukin 17; NK: natural killer 
 
2.1.6 Oligonucleotide primers 
TABLE 11: Oligonucleotide primers 
 
Name Sequence Function Used for genotyping of 
oIMR1746 5’-GAG GTT CCG CTA CGA CTC 
TG-3’ 







5’-TGG ATG TGG AAT GTG TGC 
GAG-3’  
 
Forward primer for the 

















5’-CCC GGG CAA GGC TCA GCC 
ATG CTC CTG-3’ 
 







5’-GCG GCC GCA ATT CCC AGA 
GAC ATC CCT CC-3’ 
 







5’-TGA GGA CTC TGC CGT CTA 
TTA CTG T- 3’ 
 







5’-GGA GAC TGT GAG AGT GGT 
GCC T-3’ 
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Name Sequence Function Used for genotyping of 
mIgH-sense 5’-ATT GGT CCC TGA CTC AAG 
AGA TG-3’ 
Forward primer for the 





5’-TGG TGC TCC GCT TAG TCA 
AA-3’ 
 
Reverse primer for the 




Source of supply 
All oligonucleotide primers were purchased from Eurofins MWG, Ebersberg, Germany 
Abbreviations 
2D2 mice: MOG-specific T cell receptor transgenic mice; mIgH: murine immunoglobulin heavy chain;  




TABLE 12: Consumables 
 
Consumable Source of supply 
Bottle top filter, 0.2 µm Sarstedt, Nuembrecht, Germany 
Cell culture dish, 60 x 15 mm Greiner bio-one, Kremsmuenster, Austria 
Cell culture flask, 75 cm2 Greiner bio-one, Kremsmuenster, Austria 
Cell culture plates, flat bottom (6 well, 24 well, 96 well) Greiner bio-one, Kremsmuenster, Austria 
Cell strainer (70 µm, 40 µm) BD Biosciences, Franklin Lakes, NJ, USA 
Cryogenic tubes Thermo Scientific, Waltham, MA, USA 
FACS tube, 5 ml BD Biosciences, Franklin Lakes, NJ, USA 
Filter units, 0.2 µm GE Healthcare, Chalfont St Giles, Great Britain 
GentleMACS™ C-tube Miltenyi Biotec, Bergisch Gladbach, Germany 
HTS Transwell®-96 Well Permeable Support Corning, Corning, NY, USA 
LS columns Miltenyi Biotec, Bergisch Gladbach, Germany 
Needles BD Biosciences, Franklin Lakes, NJ, USA 
Nunc™ MaxiSorp® 96 well ELISA plate Thermo Scientific, Waltham, MA, USA 
Nunc™ MicroWell™ Plates, 96 well round bottom Thermo Scientific, Waltham, MA, USA 
Pre-separation filters, 30 µm Miltenyi Biotec, Bergisch Gladbach, Germany 
Syringes BD Biosciences, Franklin Lakes, NJ, USA 
Tubes (50 ml, 15 ml, 2 ml, 1,5 ml, 0.2 ml) Sarstedt, Nuembrecht, Germany 
 
Abbreviations 
ELISA: enzyme linked immunosorbent assay; FACS: fluorescence-activated cell sorting; MACS: magnetic-
activated cell sorting; 
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2.1.8 Technical devices 
TABLE 13: Technical devices 
 
Device Source of supply 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
FACS Aria™ II BD Biosciences, Franklin Lakes, NJ, USA 
FACS Canto™ II BD Biosciences, Franklin Lakes, NJ, USA 
gentleMACS™ Dissociator Miltenyi Biotec, Bergisch Gladbach, Germany 
Hera cell 150 incubator Heraeus, Hanau, Germany 
iMark™ microplate reader Bio-Rad, Munich, Germany 
Neubauer chamber Superior Marienfeld, Lauda-Koenigshofen, Germany 
Power supply Bio-Rad, Munich, Germany 
QuadroMACS™ separator Miltenyi Biotec, Bergisch Gladbach, Germany 
Speed vacuum Concentrator 5301 Eppendorf, Hamburg, Germany 
T3 Thermocycler Biometra, Germany 
Thermo mixer comfort Eppendorf, Hamburg, Germany 
UV transluminator Vilber Lourmat, Eberhardzell, Germany  
Nalgene™ Cryo 1 C Freezing Container Thermo Scientific, Waltham, MA, USA 
 
Abbreviations 
FACS: fluorescence-activated cell sorting; MACS: magnetic-activated cell sorting; 
 
2.1.9 Software 
TABLE 14: Software 
 
Software Application Source of supply 
BD FACSDiva Software 6.1.2 Data acquisition flow cytometry BD Biosciences, Franklin Lakes, NJ, 
USA 
FlowJo 7.6.1 Data analysis flow cytometry Tree Star Inc., Ashland, OR, USA 
GraphPad Prism 5.01 Statistical analysis 
Graphs 
GraphPad software Inc., La Jolla, 
CA, USA 
PSRemote 1.6.5 Gel documentation Breeze systems limited, 
Camberley, UK 
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2.2 Animals 
2.2.1 Mouse strains 
The following mouse strains were used for in vivo experiments and/or cell isolations: 
 
C57Bl/6J mice 
Seven- to eight-weeks-old female C57Bl/6J mice were purchased from Charles River 
laboratories, Sulzfeld, Germany. 
 
Rag1-deficient mice 
Rag1-deficient (Rag1-/-) mice were developed and characterized by Mombaerts and 
colleagues in 1992 and subsequently backcrossed to C57BL/6J for more than 10 generations. They 
are characterized by a complete lack of mature B and T cells and are a valuable tool to investigate 
B and T cell-dependant and independent effects on the immune system (Mombaerts et al., 1992). 
 
2D2 mice 
2D2 mice were generated and characterized by Bettelli and colleagues in 2003. 90-95% of 
the CD4+ T cells in 2D2 animals express the MOG35-55-specific T cell receptor Vα3.2/ Vβ11 (Bettelli 
et al., 2003). A small percentage of 2D2 mice develops spontaneous EAE (2-5%) and around 40% 
of the 2D2 mice develop a spontaneous isolated neuritis of the optic nerves within 1 year. 2D2 
CD4+ T cells were used as reporter cells in a number of assays. 
 
Th mice 
Th mice, generated and characterized by Litzenburger and colleagues, are IgH chain knock 
in mice in which the VDJ region of the hybridoma 8.18-C5 is inserted into the regular location of 
the rearranged V genes of the Ig heavy chain. In these mice around 30% of the B cells are specific 
for MOG and demyelinating MOG-specific antibodies can be found in the serum. Th mice do not 
spontaneously develop EAE, but their disease course is accelerated and exacerbated upon 
immunization compared to wild-type littermates (Litzenburger et al., 1998). 
 
2.2.2 Breeding 
All genetically modified mice were derived from in house breeding colonies at the central 
animal facility of the University Medical Center Goettingen. 
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2.2.3 Housing 
All mice were housed in the central animal facility of the University Medical Center 
Goettingen under specific pathogen free (SPF) conditions. The animals had access to food and 
water ad libitum and were kept on a 12/12 hour light/dark cycle. Before each experiment, mice 
were allowed to adapt to the new environment for seven days. Animal experiments were 
performed in accordance with the European Communities Council Directive of 24 November 1986 




2.3.1 Genotyping of genetically modified mice 
Genotyping of genetically modified mice was performed by Ms. Katja Schulz (Department 
of Neuropathology, University Medical Center Goettingen).  
 
DNA extraction 
Genomic DNA was isolated from tail biopsies of Rag1-/-, 2D2 and Th mice. For this 
purpose, the tissue was digested in 350 µl lysis buffer with 20 µl of proteinase K over night  
(350 rpm, 56°C). Remaining tissue was removed by centrifugation (5 min, 13,200 rpm, RT). DNA in 
the supernatant was precipitated by adding 350 µl isopropyl alcohol. After a second 
centrifugation, the pellet was washed in 350 µl 70% ethanol. After a third centrifugation, the 
supernatant was discarded, the pellet was dried for 10 min in a speed vacuum concentrator and 
resuspended in 100 µl bidistilled water.   
 
Genotyping of Rag1-/- mice 
PCR reaction 
Each reaction contained 2 µl genomic DNA, 1 µl 10 mM dNTP Mix, 1 µl of each 
oligonucleotide primer (oIMR1746, oIMR3104, oIMR8162), 0.2 µl Go-Taq® DNA polymerase, 5 µl 
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PCR program 
PCR reactions were run in a T3 thermocycler at the following cycling conditions: 
 
Temperature Time  Step 
94°C   120 s  Pre-denaturation 




58°C   45 s Annealing 
72°C   45 s Elongation 
72°C 120 s  Final elongation 
4°C   ∞  Storage 
 
Agarose gel electrophoresis 
To analyze the PCR products, 10 µl of the sample were loaded on an agarose gel (2% in 
TBE buffer) containing 3 µl ethidium bromide. Electrophoresis was performed at 100 V for 60 min. 
PCR product length was evaluated in relation to a 100 bp DNA ladder. A band at 474 bp was 
characteristic for the wild-type allele, whereas a product with a length of 530 bp was detected in 
Rag1-deficient samples. Heterozygous animals displayed both bands.  
 
Genotyping of 2D2 mice 
PCR reaction 
Each reaction contained 5 µl genomic DNA, 0.4 µl 10 mM dNTP Mix, 0.5 µl of each 
oligonucleotide primer (oIMR6711, oIMR6712), 0.1 µl Go-Taq® DNA polymerase, 4 µl Go-Taq® 
DNA polymerase buffer (5x) and 9.5 µl bidistilled water.  
 
PCR program 
PCR reactions were run in a T3 thermocycler at the following cycling conditions: 
 
Temperature Time  Step 
94°C   120 s  Pre-denaturation 




58°C   60 s Annealing 
72°C   60 s Elongation 
72°C 10 min  Final elongation 
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Agarose gel electrophoresis 
To analyze the PCR products, 20 µl of the sample were loaded on an agarose gel (2% in 
TBE buffer) containing 3 µl ethidium bromide. Electrophoresis was performed at 120 V for 45 min. 
PCR product length was evaluated in relation to a 100 bp DNA ladder. Animals carrying the 
transgene displayed a band at 675 bp, whereas no band was detected in wild type animals. 
 
Genotyping of Th mice 
PCR reaction 
Each reaction contained 5 µl genomic DNA, 0.4 µl 10 mM dNTP Mix, 0.5 µl of each 
oligonucleotide primer (8.18C5-sense, 8.18C5-antisense, mIgH-sense, mIgH-antisense), 0.1 µl Go-
Taq® DNA polymerase, 4 µl Go-Taq® DNA polymerase buffer (5x) and 8.5 µl bidistilled water.  
 
PCR program 
PCR reactions were run in a T3 thermocycler at the following cycling conditions: 
 
Temperature Time  Step 
94°C   120 s  Pre-denaturation 




61°C   60 s Annealing 
72°C   60 s Elongation 
72°C 10 min  Final elongation 
4°C   ∞  Storage 
 
Agarose gel electrophoresis 
To analyze the PCR products, 20 µl of the sample were loaded on an agarose gel (2% in 
TBE buffer) containing 3 µl ethidium bromide. Electrophoresis was performed at 120 V for 45 min. 
PCR product length was evaluated in relation to a 100 bp DNA ladder. The wild type allele was 
characterized by a band at 150 bp, the transgenic allele by a band at 100 bp. Both bands were 
detected in heterozygous animals. 
 
2.3.2 Experimental autoimmune encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used 
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2.3.2.1 EAE induction 
In this thesis, EAE was induced in C57Bl/6J and heterozygous Th (Th/+) mice by active 
immunization with MOG35-55 emulgated in complete Freund’s adjuvant (CFA). Mice were 
anesthetized with 100 µl ketamine/xylazine anesthesia per 10 g body weight and subcutaneously 
immunized with 50 µl MOG35-55/CFA at the dorsal side of each limb. The amount of peptide per 
animal was 200 µg MOG35-55 for C57Bl/6J mice and 50 µg for Th/+ mice. On the day of 
immunization and at day 2 post immunization (p.i.) 400 ng pertussis toxin (PTX) in PBS were 
administered intraperitoneally to each mouse.  
 
2.3.2.2 Clinical EAE score 
To assess EAE severity, body weight and disease score were evaluated daily in each 
animal, starting at day seven after immunization until the end of the experiment. The criteria 
defining the clinical EAE score used in this study are summarized in TABLE 15. Animals reaching a 
disease score of 4 had to be sacrificed, due to ethical reasons. The final score of all sacrificed 
animals was carried forward until the end of the experiment, while animals which died of EAE 
were scored 5.  
 
TABLE 15: Clinical EAE score 
 
Score Clinical correlate 
0 Healthy; no clinical signs 
0.5 Partial paralysis of the tail 
1 Complete paralysis of the tail 
2 Beginning paralysis of the hind limbs; mouse can be turned on the back 
2.5 Strong paralysis of the hind limbs; no self-dependent turning  
3 Complete paralysis of hind limbs; beginning paralysis of abdominal muscles 
3.5 Complete paralysis of abdominal muscles, beginning weakness of fore limbs 
4 Pronounced weakness or complete paralysis of fore limbs 
5 Dead 
 
2.3.2.3 LAQ treatment 
LAQ was kindly provided by Teva Pharmaceutical Industries, Ltd., Netanya, Israel. Animals 
received daily treatment with 25 mg/kg LAQ by oral gavage. Body weight was determined daily 
and 100 µl LAQ (2.5 mg/ml in water) were administered per 10 g body weight. Control animals 
received the same volume of vehicle (water). 
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To analyze the therapeutic efficiency of LAQ in EAE, C57Bl/6J mice and Th/+ mice were 
treated with LAQ or vehicle from the day of immunization until day 28 after immunization. To 
investigate early LAQ-induced changes within different immune cell populations in immunized 
animals, C57Bl/6J mice received LAQ or vehicle for eleven days, starting at the day of 
immunization. To study the effects of LAQ in naïve animals, naïve C57Bl/6J mice and Rag1-/- mice 
were treated with LAQ or vehicle for 20 days. 
 
2.3.2.4 NK cell depletion in EAE 
NK cell depletion was performed in C57Bl/6J and Th/+ mice. In immunized C57Bl/6J 
animals the influence of NK cells on LAQ-mediated changes in dendritic cells was investigated.  
Experiments in Th/+ mice assessed the relevance of NK cells for the treatment effect of 
LAQ in EAE. This experimental setup compared four different groups of EAE animals: 
1. NK cell-competent Th/+ mice treated with vehicle. 
2. NK cell-depleted Th/+ mice treated with vehicle. 
3. NK cell-competent Th/+ mice treated with 25 mg/kg LAQ. 
4. NK cell-depleted Th/+ mice treated with 25 mg/kg LAQ. 
NK cells were depleted by the intraperitoneal administration of 300 µg anti-NK1.1 
antibody (clone PK-136) in PBS at day 2 and 1 before immunization and thereafter every other day 
until the end of the experiment. NK cell-competent animals received identical treatment with an 
isotype control antibody (clone C1.18.4). Successful NK cell depletion was controlled in the 
peripheral blood of all animals at the day of immunization and at the end of the experiment by 
flow cytometry. LAQ and vehicle were administered daily by oral gavage, starting at the day of 
immunization until the end of the experiment. The experimental setup is presented in FIGURE 31 
(see section 3.6). 
 
2.3.3 Analysis of immune cells ex vivo 
To investigate LAQ-induced changes in different cell populations of the innate and 
adaptive immune system, different organs and tissues were isolated from LAQ- and vehicle-
treated animals. Single cell suspensions were prepared and immune cells were analyzed ex vivo 
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2.3.3.1 Preparation of single cell suspensions 
Single cell suspensions were prepared from spleen, lymph node and blood for further 
analysis. All centrifugation steps were performed for 10 min at 300 x g and 4°C and cells were 
washed in 10 ml of RPMIcomplete, if not stated otherwise. 
 
2.3.3.1.1 Preparation of spleen leukocytes 
To investigate effects of LAQ on splenocytes, spleens were isolated from naïve and 
immunized animals, treated with LAQ or vehicle in vivo. 
To study effects of LAQ on T and NK cells in the spleen, single cell suspensions were 
obtained by mechanical dissociation. For this purpose, spleens were disrupted with a syringe 
plunger on a sterile 70 µm cell strainer. Cells were flushed through the cell strainer by adding  
10 ml of RPMIcomplete and collected in a 50 ml tube. After one washing step, splenocytes were 
further processed dependent on the following experiment.  
For direct flow cytometric analysis of T and NK cells, erythrocytes were lysed by 
resuspending the pellet in 1 ml of BD Pharm lyse™ solution (pre-diluted 1:10 in bidistilled water). 
Lysis was performed for 3 min at 37°C and stopped by adding 20 ml of RPMIcomplete. After one 
washing step, cells were resuspended in 10 ml of RPMIcomplete. 
For further purification of T and NK cells by magnetic-activated cell sorting (MACS) and 
fluorescence-activated cell sorting (FACS), no erythrocyte lysis was performed. Instead, cells were 
washed once and were then resuspended in 5 ml of MACS buffer.  
To evaluate effects of LAQ on dendritic cells, single cell suspensions were obtained by 
parallel enzymatic digestion and mechanical dissociation. Spleens, isolated from LAQ- and vehicle-
treated animals, were transferred into a gentleMACS™ C-tube with 2 ml of digestion solution 
(HBSS [with Ca2+, Mg2+] containing 2.5 mg/ml Collgenase D and 2 mg/ml DNaseI). Mechanical 
dissociation was performed using the gentleMACS™ Dissociator with the preprogrammed settings 
for murine spleen dissociation and the tissue was digested for 15 min at 37°C. The obtained cell 
suspension was transferred onto a sterile 70 µm cell strainer and single cells were flushed through 
by adding 10 ml of RPMIcomplete. Washing and erythrocyte lysis were performed as described 
above. 
Cell numbers were determined prior to further analyses (see 2.3.3.1.4). 
 
2.3.3.1.2 Preparation of leukocytes from the lymph nodes 
The effects of LAQ on the ability of lymph node cells to secrete IL-17 and IFNγ upon ex 
vivo stimulation were analyzed. To this end, axillary and inguinal lymph nodes were isolated from 
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animals, immunized with MOG35-55 and treated with LAQ or vehicle. Lymph nodes were 
transferred to a sterile 70 µm cell strainer and mechanically disrupted using a syringe plunger. 
Cells were flushed through the strainer by adding 10 ml of RPMIcomplete. After one washing step 
the pellet was resuspended in 3 ml of RPMIcomplete and cell numbers were determined in a 
Neubauer chamber (see 2.3.3.1.4). 
 
2.3.3.1.3 Preparation of peripheral blood leukocytes 
Peripheral blood leukocytes (PBMC) were isolated to confirm the efficiency of NK cell 
depletion in mice by flow cytometry. Blood samples were obtained by puncture of the Vena 
facialis. Several drops of blood were diluted in 300 µl of FACS buffer containing 1 mM EDTA and 
were transferred to a 5 ml FACS tube. 1 ml of FACS buffer with 1 mM EDTA was added and the 
tubes were centrifuged. Cells were resuspended in 1 ml of FACS buffer with 1 mM EDTA. 
 
2.3.3.1.4 Cell counting 
Cell numbers were determined in a Neubauer chamber. To exclude dead cells, the cell 
suspension was diluted 1:10 in trypan blue (pre-diluted 1:10 in PBS) prior to counting. Four 
squares with a surface of 1 mm2 and a volume 0.1 µl each were counted for every sample. The 
concentration of cells in the original sample was calculated using FORMULA 1. Total cell numbers 
were extrapolated to the sample volume. 
 






∗ 10 ∗ 104 
 
FORMULA 1 
Calculating the concentration of cells in a given sample after cell 
counting in a Neubauer chamber. 
 
2.3.3.2 Flow cytometry 
The effects of LAQ on different cell populations of the innate and adaptive immune 
system were analyzed by flow cytometry. Single cell suspensions were stained with different 
combinations of fluorochrome-labeled antibodies (see TABLE 5) and cell populations were 
analyzed using a FACS Canto™ II and the BD FACSDiva Software 6.1.2. If not stated otherwise, the 
staining procedure was performed in 96 well round bottom plates, plates were centrifuged for 5 
min at 300 x g and 4°C and cells were washed with 200 µl FACS buffer. 
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2.3.3.2.1 FACS staining procedure of splenocytes 
Splenocytes were counted using a Neubauer chamber (see 2.3.3.1.4) and up to 0.5*106 
cells were added per well. Cells were centrifuged and washed with FACS buffer. Cells were 
resuspended in 50 µl blocking buffer, consisting of anti-CD16/CD32 antibody diluted 1:100 in FACS 
buffer, and incubated for 15 min at 4°C. Up to six fluorochrome-labeled antibodies per staining 
were diluted 1:100 in FACS buffer, 50 µl of this master mix were added to each well (final dilution 
1:200) and samples were incubated for 20 min at 4°C. After the staining, wells were filled with 100 
µl FACS buffer and plates were centrifuged. Cells were washed and resuspended in 50 µl of the 
appropriate fixation buffer. Cells, receiving pure surface staining, were fixed in Cytofix™ pre-
diluted 1:5 in FACS buffer. Fixed cells were analyzed by flow cytometry.  
 
2.3.3.2.2 FACS staining procedure of peripheral blood leukocytes 
FACS tubes with peripheral blood cells (compare 2.3.3.1.3) were centrifuged for 8 min at 
300 x g and 4°C and the pellets were resuspended in 100 µl blocking buffer, consisting of anti-
CD16/CD32 antibody diluted 1:100 in FACS buffer with 1 mM EDTA. Cells were incubated for  
15 min at 4°C. Up to six fluorochrome-labeled antibodies per staining were diluted 1:100 in FACS 
buffer with 1 mM EDTA. 100 µl of this master mix were added to each tube (final dilution 1:200) 
and samples were incubated for 25 min at 4°C. 1 ml of FACS buffer with 1 mM EDTA was added to 
each reaction and tubes were centrifuged for 8 min at 300 x g and 4°C. Cells were washed in 1 ml 
of FACS buffer with 1 mM EDTA and centrifuged as mentioned before. Lysis of erythrocytes was 
performed by resuspending the pellet in 1 ml of BD FACS™ lysing solution (pre-diluted 1:10 in 
bidistilled water) and incubating the suspension for 4 min at RT. Lysis was stopped by adding 4 ml 
of FACS buffer. Cells were centrifuged as described before and washed in 1 ml of FACS buffer. 
After a final centrifugation step, cells were resuspended in 100 µl FACS buffer and analyzed by 
flow cytometry. 
 
2.3.3.2.3 Intracellular detection of FoxP3 
First, surface molecules were stained on splenocytes (see 2.3.3.2.1) and cells were fixed in 
FoxP3 fixation concentrate diluted 1:4 in dilution buffer for FoxP3 staining for at least one hour. 
For the intracellular FoxP3 staining, FoxP3 permeabilization buffer (10x) was diluted 1:10 in 
bidistilled water. Wells were filled with 150 µl of permeabilization buffer and plates were 
centrifuged. The anti-FoxP3 antibody was diluted 1:100 in permeabilization buffer and 100 µl of 
the staining solution were added to each well. Cells were incubated for 35 min at 4°C. Wells were 
filled with 150 µl of Perm/Wash™ buffer and plates were centrifuged. Cells were washed once 
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with 200 µl of Perm/Wash™ buffer and once with FACS buffer. After a final centrifugation step, 
cells were resuspended in 100 – 200 µl of FACS buffer and analyzed by flow cytometry. 
 
2.3.3.2.4 Intracellular detection of cytokines  
To analyze the percentage of IL-17- and IFNγ-producing CD4+ T cells by flow cytometry, up 
to 0.5*106 splenocytes from immunized animals, treated with LAQ or vehicle in vivo, were seeded 
per well of a 96 well round bottom plate. Cytokine production was stimulated by adding 200 µl of 
RPMIcomplete, supplemented with 25 ng/ml PMA and 1 µg/ml ionomycin. Cytokine secretion was 
blocked by adding GolgiStop™ at a dilution of 1:1000 to the medium. Cells were incubated for  
5 – 6 h at 37°C and 5% CO2. Thereafter, surface staining was performed as described in 2.3.3.2.1, 
using FACS buffer supplemented with GolgiStop™ (1:1000) to inhibit cytokine secretion during the 
staining procedure. Cells were fixed in Cytofix/Cytoperm™ for at least one hour. For the 
intracellular cytokine staining, Perm/Wash™ buffer (10x) was diluted 1:10 in bidistilled water. 
Wells were filled with 150 µl of Perm/Wash™ buffer and plates were centrifuged. Anti-IL-17 and 
anti-IFNγ antibodies were diluted 1:25 in Perm/Wash™ buffer and 50 µl of the staining solution 
were added to each well. Cells were incubated with the staining antibodies for 35 min at 4°C. 
Wells were filled with 150 µl of Perm/Wash™ buffer and plates were centrifuged. Cells were 
washed with FACS buffer, resuspended in 100 – 200 µl of FACS buffer and analyzed by flow 
cytometry. 
 
2.3.3.2.5 Classification T cells, dendritic cells and NK cells according to surface and 
intracellular markers 
The effects of LAQ on different subpopulations of T cells, dendritic cells and NK cells were 
analyzed using flow cytometry. The investigated cell populations were classified according to the 
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T cells  
 
TABLE 16: Classification of T cell subpopulations 
 
T cell population Specific surface and intracellular markers 
Naïve T cells CD19-  CD3+ CD4+ CD62L+ CD44low 
Effector memory T cells CD19-  CD3+ CD4+ CD62L- CD44high 
Regulatory T cells CD19-  CD3+ CD4+ FoxP3+  
Th1 cells CD19-  CD3+ CD4+ IFNγ+  
Th17 cells CD19-  CD3+ CD4+ IL-17+  
IL-17 producing γδ T cells CD19-  CD3+ γδ TCR+ IL-17+  
NKT cells CD19-  CD3int NK1.1int   
Activating receptors DNAM-1 TACTILE    
Inhibitory receptor TIGIT     
 
Abbreviations 
CD: cluster of differentiation; DNAM-1: DNAX accessory molecule-1; FoxP3: forkhead box P3; 
IFNγ: interferon gamma; IL-17: interleukin 17; NK: natural killer; TACTILE: T cell-activated 
increased late expression; TCR: T cell receptor; Th1: T helper 1; Th17: T helper 17; TIGIT: T cell 





TABLE 17: Classification of dendritic cell subpopulations  
 
Dendritic cell population Specific surface markers 
Dendritic cells MHCII+  CD11chigh  
Myeloid dendritic cells MHCII+  CD11chigh CD11b+ 
Plasmacytoid dendritic cells MHCII+  CD11chigh B220+ 
Co-stimulatory molecules on dendritic cells CD80 CD86  
 
Abbreviations 








TABLE 18: Classification of NK cell subpopulations 
 
NK cell population Specific surface and intracellular markers 
NK cells CD19-  CD3- NK1.1+ NKp46+    
CD27+ NK cells CD19-  CD3- NK1.1+ CD27+ CD11b-   
CD27+ CD11b+ NK cells CD19-  CD3- NK1.1+ CD27+ CD11b+   
CD11b+ NK cells CD19-  CD3- NK1.1+ CD27- CD11b+   
IFNγ producing NK cells CD19-  CD3- NK1.1+ IFNγ+    
Activation marker CD69        
Activating receptors CD2  CD244.2 DNAM-1 LFA-1+ Ly49D NKG2D TACTILE 
Inhibitory receptors Ly49A Ly49C Ly49F Ly49G2 Ly49I TIGIT  
 
Abbreviations 
CD: cluster of differentiation; DNAM-1: DNAX accessory molecule-1; IFNγ: interferon gamma; LFA-1: 
leukocyte function-associated antigen-1; NK: natural killer; NKG2D: natural killer group 2, member D; 
NKp46: natural killer cell p46-related protein; TACTILE: T cell-activated increased late expression 
 
 
2.3.4 Co-culture experiments 
To analyze effects of LAQ on NK cells in detail, experiments were performed to investigate 
NK cell effector functions in co-culture with tumor cells, T cells and dendritic cells. For this 
purpose, NK cells as well as CD4+ T cells and bone marrow-derived dendritic cells were purified 
and the B16F10 melanoma cell line was cultured. If not stated otherwise, cells were centrifuged 
for 10 min at 300 x g and 4°C and washed in a volume of 10 ml. 
 
2.3.4.1 Purification of NK cells 
NK cells were isolated from the spleens of LAQ- and vehicle-treated animals and 
sequentially purified by MACS and FACS sorting. In a first step, untouched NK cells were enriched 
by MACS and then sorted to a purity of above 99% with a cell sorter. The latter method allowed 
also to purify NK cell subpopulations.  
Splenocytes were isolated as described in 2.3.3.1.1 and resuspended in 5 ml of MACS 
buffer. The cell suspension was applied on a 40 µm cell strainer and cells were flushed through 
the cell strainer by adding 5 ml of MACS buffer. Cells were counted in a Neubauer chamber (see 
2.3.3.1.4). NK cells were then purified using the NK cell isolation kit II (mouse), LS columns and the 
QuadroMACS™ separator. MACS was performed following the manufacturer’s instructions. After 
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MACS, cells were resuspended in 200 µl of FACS buffer and transferred to a 96 well round bottom 
plate for the surface staining. The plate was centrifuged for 5 min at 300 x g and 4°C and washed 
once with 200 µl of FACS buffer. Per well, 200 µl of the staining solution were prepared, 
containing FACS buffer, Fc-blocking anti-CD16/CD32 antibody (1:100) and fluorochrome-labeled 
antibodies (1:200). After centrifugation, cells were resuspended in 200 µl of the staining solution 
and incubated for 15 min at 4°C. Cells were washed once with 200 µl FACS buffer and 
resuspended in 300 – 400 µl FACS buffer for cell sorting.  
Total NK1.1+ CD3- NK cells or CD27+ CD11b- NK cells and CD27- CD11b+ NK cells were 
purified using a BD FACSAria™ II and the BD FACSDiva Software 6.1.2. After FACS sorting, NK cells 
were washed in RPMIcomplete, counted in a Neubauer chamber (see 2.3.3.1.4) and the appropriate 
number of cells was put into culture (see 2.3.4.5, 2.3.4.6, 2.3.4.8, 2.3.4.9, 2.3.4.10, 2.3.5.2, 2.3.6.4 
and 2.3.6.5). 
 
2.3.4.2 Purification of CD4+ T cells 
CD4+ T cells were purified from the spleens of naïve C57Bl/6J and 2D2 mice using MACS. 
Splenocytes were isolated as described in 2.3.3.1.1 and resuspended in 5 ml of MACS buffer. The 
cell suspension was applied on a 40 µm cell strainer and cells were flushed through the cell 
strainer by adding 5 ml of MACS buffer. Cells were counted in a Neubauer chamber (see 
2.3.3.1.4). CD4+ T cells were then purified using the CD4+ T cell isolation kit II (mouse), LS columns 
and the QuadroMACS™ separator. MACS was performed following the manufacturer’s 
instructions. After purification, cells were washed in RPMIcomplete and counted in a Neubauer 
chamber (see 2.3.3.1.4). The appropriate cell number was either directly put into culture (see 
2.3.4.9) or T cells were stained with CFSE (see 2.3.4.11) for assessment of in vitro proliferation 
(see 2.3.4.8, 2.3.4.9 and 2.3.4.10). The purity of CD4+ T cells was controlled by flow cytometry. 
 
2.3.4.3 Generation of bone marrow-derived dendritic cells  
Bone marrow was isolated from naïve C57Bl/6J mice for the subsequent in vitro 
differentiation of bone marrow-derived dendritic cells. Therefore, hind limbs were isolated and 
muscle, cartilage and sinews were completely removed from bones. Femur and tibia were washed 
in a petri dish with RPMIcomplete. Bones were opened at both ends and bone marrow was flushed 
out using a syringe filled with 5 ml of RPMIcomplete. Bone marrow was collected in a fresh petri dish 
and a single cell suspension was obtained by pipetting the cell suspension up and down with a 1 
ml pipette. The single cell suspension was then transferred onto a sterile 70 µm cell strainer and 
cells were flushed through by adding 10 ml of RPMIcomplete. Thereafter, cells were centrifuged and 
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washed twice. Finally, the pellet was resuspended in 10 ml of RPMIcomplete per donor mouse and 
the cell number was determined in a Neubauer chamber (see 2.3.3.1.4).  
For the in vitro differentiation of dendritic cells, bone marrow cells were diluted to a 
concentration of 106 cells per ml in RPMIcomplete containing 25 ng/ml GM-CSF. 4.5 ml of the cell 
suspension were added per well of a 6 well plate. Cells were cultured in this differentiation 
medium for 7 days (37°C, 5% CO2). At day 3 and day 5 of the culture, 2.5 ml medium per well 
were replaced by fresh RPMIcomplete containing 25 ng/ml GM-CSF. After 7 days of differentiation, 
the cells were harvested, washed in MACS buffer and counted in a Neubauer chamber (see 
2.3.3.1.4). Bone marrow-derived dendritic cells were then purified using CD11c MicroBeads 
(mouse), LS columns and the QuadroMACS™ separator. MACS was performed following the 
manufacturer’s instructions. After purification, dendritic cells were washed in RPMIcomplete and 
counted in a Neubauer chamber (see 2.3.3.1.4). The appropriate number of cells was seeded in a 
96 well flat bottom plate and dendritic cells were allowed to adhere over night. For experiments 
with LPS exposure, dendritic cell maturation was induced by supplementing the medium with 50 
ng/ml LPS during this overnight culture. 
The purity of bone marrow-derived dendritic cells was controlled by flow cytometry.  
 
2.3.4.4 Culture of B16F10 cells 
Cryo-stocks of the melanoma cell line B16F10 (Fidler, 1973, Fidler, 1975) were kindly 
provided by Prof. Evelyn Ullrich (Children’s Hospital, Department of Pediatric Hematology and 
Oncology, Goethe-University, Frankfurt, Germany). Cells were thawed at 37°C and transferred 
into 10 ml of RPMIcomplete. After one washing step in RPMIcomplete, cells were resuspended in 15 ml 
of RPMIcomplete, seeded in a 75 cm2 cell culture flask and incubated at 37°C and 5% CO2. 
Passaging of the melanoma cells was first performed when cells reached confluency and 
then every second or third day. Adherent cells were washed once with 10 ml of PBS. Cell adhesion 
was disrupted by adding 1.5 ml of 0.01% trypsin in PBS for 2 – 5 min at room temperature and 
cells were loosened by gently tapping on the flask. Trypsinization was stopped by adding 8.5 ml of 
RPMIcomplete to the cell culture flask. 1 ml of the cell suspension was transferred to a new flask and 
filled up with 14 ml of RPMIcomplete (split ration 1:10). 
Cryo-stocks of B16F10 melanoma cells were prepared as follows. Cells were harvested as 
described above, washed in RPMIcomplete and counted in a Neubauer chamber (see 2.3.3.1.4). 
5*106 cells were dissolved in 1 ml of RPMIcomplete with 10% DMSO and transferred to a cryogenic 
tube. Cells were frozen in a freezing container at -80°C over night. For optimal cryopreservation, 
cryogenic tubes were stored in liquid nitrogen. 
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2.3.4.5 Co-culture of NK cells with B16F10 cells 
The effects of LAQ were investigated on the killing efficiency of NK cells towards NK cell-
sensitive tumor cells in vitro. B16F10 melanoma cells (target) were harvested (see 2.3.4.4), 
washed in RPMIcomplete, counted in a Neubauer chamber (see 2.3.3.1.4) and 5,000 cells were 
seeded per well of a 96 well flat bottom plate. Splenocytes were isolated (see 2.3.3.1.1) from 
mice, immunized with MOG35-55 and treated with LAQ or vehicle in vivo. Total NK cells, CD27+ NK 
cells and CD11b+ NK cells (effector) were purified (see 2.3.4.1) and added to the tumor cells at 
different effector/target ratios, ranging from 5:1 to 0.5:1 as described in the literature (Chan et 
al., 2010, Mizutani et al., 2012, Cui et al., 2013). NK and tumor cells were co-cultured in 
RPMIcomplete, supplemented with IL-2 (5,000 U/ml), for 48 h (37°C, 5% CO2). To generate baseline 
values for tumor cell survival, 5,000 tumor cells were cultured without NK cells. Samples were run 
in triplicates. The survival of tumor cells was assessed by crystal violet staining (see 2.3.4.7). 
 
2.3.4.6 Co-culture of NK cells with bone marrow-derived dendritic cells 
To evaluate whether NK cells directly killed bone marrow-derived dendritic cells in vitro, 
splenic NK cells were purified (see 2.3.3.1.1 and 2.3.4.1) from mice, immunized with MOG35-55 and 
treated with LAQ or vehicle for eleven days in vivo. Bone marrow-derived dendritic cells were 
generated as described above (see 2.3.4.3), 50,000 dendritic cells were seeded per well of a  
96 well flat bottom plate and 50% of the wells were treated with 50 ng/ml LPS over night. 
Dendritic cells were washed with RPMIcomplete and 50,000 NK cells in RPMIcomplete, supplemented 
with IL-2 (5,000 U/ml) were added per well. To generate baseline values for dendritic cell survival, 
50,000 dendritic cells were cultured without NK cells. Samples were run in triplicates. NK cells and 
bone marrow-derived dendritic cells were co-cultured for 48 h (37°C, 5% CO2) and dendritic cell 
survival was assessed by crystal violet staining (see 2.3.4.7). 
 
2.3.4.7 Assessment of NK cell mediated lysis of B16F10 cells and dendritic cells by crystal 
violet staining 
The cytotoxicity of NK cells towards tumor cells and bone marrow-derived dendritic cells 
in vitro was assessed using the crystal violet assay (Bonnotte et al., 2001). 
For this purpose, NK cells were co-cultured with the respective target cells as described above 
(see 2.3.4.5 and 2.3.4.6). After 48 h of co-culture, tumor cells were washed with 200 µl 0.9% NaCl 
solution, bone marrow-derived dendritic cells with 200 µl RPMIcomplete, to remove dead and non-
adherent cells. Wells were emptied by tapping the plate firmly against paper towels. Cells were 
fixed in 200 µl of 100% ethanol for 10 min at RT. Wells were emptied by tapping the plate firmly 
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against paper towels. Cells were stained with 50 µl of crystal violet solution for 5 min at RT. Wells 
were gently washed with water to remove excess crystal violet solution and were emptied by 
tapping the plate firmly against paper towels. Cells were lysed in 100 µl of 33% acetic acid and the 
optical density (OD) was determined at 540 nm using the iMark™ microplate reader. The 
proportion of viable cells was calculated using FORMULA 2, the proportion of specific lysis was 
calculated using FORMULA 3.   
 
 





𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 [%] = �1 −
𝑂𝐷𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡
𝑂𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
� ∗ 100 
 
FORMULA 2 
Calculating the percentage of viable cells 
remaining after the incubation with NK cells. 
  
FORMULA 3 
Calculating the percentage of specific lysis induced by 
NK cells upon co-culture with target cells. 
 
2.3.4.8 Co-culture of NK cells with CD4+ T cells 
The effect of NK cells (treated with LAQ or vehicle in vivo) on antigen-independent T cell 
proliferation was analyzed in vitro. Splenic NK cells were purified (see 2.3.3.1.1 and 2.3.4.1) from 
mice, immunized with MOG35-55 and treated with LAQ or vehicle for eleven days in vivo. Splenic  
T cells were purified (see 2.3.3.1.1 and 2.3.4.2) from naïve C57Bl/6J mice and were labeled with 
CFSE (see 2.3.4.11). 50,000 NK cells and 100,000 CFSE-labeled T cells were seeded in 200 µl 
RPMIcomplete per well of a 96 well round bottom plate. T cell proliferation was induced by agonistic 
anti-CD3 antibody (4 µg/ml, pre-coated) and anti-CD28 antibody (1 µg/ml, soluble) and cells were 
cultured for 72 h (37°C, 5% CO2). Finally, cells were stained for T cell and NK cell markers (see 
2.3.3.2.1) and the CFSE profile was measured by flow cytometry. 
 
2.3.4.9 Co-culture of NK cells with bone marrow-derived dendritic cells and CD4+ T cells 
The triple co-culture system of NK cells, T cells and bone marrow-derived dendritic cells 
was used to evaluate effects of NK cells, pre-treated with LAQ or vehicle in vivo, on antigen-
dependent T cell proliferation and T and dendritic cell survival. 
Bone marrow-derived dendritic cells were generated as described above (see 2.3.4.3), 
50,000 cells were seeded per well of a 96 well flat bottom plate and maturation was induced by 
incubating the dendritic cells in RPMIcomplete, supplemented with LPS (50 ng/ml), over night (37°C, 
5% CO2). Splenic NK cells were purified (see 2.3.3.1.1 and 2.3.4.1) from mice, immunized with 
MOG35-55 and treated with LAQ or vehicle for eleven days in vivo. 50,000 NK cells per well were 
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added to the bone marrow-derived dendritic cells. Splenic CD4+ T cells were purified (see 
2.3.3.1.1 and 2.3.4.2) from naïve 2D2 mice. To assess NK cell effects on T cell proliferation, 2D2  
T cells were labeled with CFSE (see 2.3.4.11). To analyze NK cell-mediated killing of T cells and 
dendritic cells, 2D2 T cells remained unlabeled. 100,000 T cells were added to the wells, 
containing 50,000 NK cells and 50,000 bone marrow-derived dendritic cells. To induce T cell 
proliferation, the culture medium (RPMIcomplete) was supplemented with MOG35-55 (20 µg/ml). 
Samples were run in triplicates. Baseline values for proliferation and cell death were measured in 
stimulated samples without NK cells. Spontaneous proliferation was controlled in samples 
without stimulation. NK cell dependent cell death of T cells and dendritic cells was evaluated after 
18 h of co-culture by Annexin V and 7-AAD staining (see 2.3.4.12). NK cell effects were assessed 
on the T cell proliferation after 72 h of co-culture by analyzing the CFSE profile (see 2.3.4.11). 
 
2.3.4.10 Transwell experiments 
To analyze whether the inhibition of T cell proliferation by NK cells was cell contact-
dependent, the triple co-culture experiments were repeated in 96 well transwell plates. In these 
plates, each well consisted of two compartments, separated by a polyester membrane with 1 µm 
pore size, allowing diffusion of soluble factors, but inhibiting cell contact. 
Bone marrow-derived dendritic cells were generated as described above (see 2.3.4.3), 
20,000 cells per well were seeded on the transwell membrane of a 96 well transwell plate and 
maturation was induced by incubating the dendritic cells in RPMIcomplete, supplemented with LPS 
(50 ng/ml), over night (37°C, 5% CO2). Splenic T cells were purified (see 2.3.3.1.1 and 2.3.4.2) from 
naïve 2D2 mice and were labeled with CFSE (see 2.3.4.11). 40,000 CFSE-labeled 2D2 T cells were 
added to each well of the transwell insert. Splenic NK cells were purified (see 2.3.3.1.1 and 
2.3.4.1) from mice, immunized with MOG35-55 and treated with LAQ or vehicle for eleven days in 
vivo. 20,000 NK cells per well were added either to the lower compartment (inhibiting direct 
contact) or to the transwell insert (allowing direct contact). To induce T cell proliferation, the 
culture medium (RPMIcomplete) was supplemented with MOG35-55 (20 µg/ml). Samples were run in 
triplicates. Baseline proliferation was measured in stimulated samples without NK cells. 
Spontaneous proliferation was controlled in samples without stimulation. The NK cell effects on 
the T cell proliferation were assessed after 72 h of co-culture by analyzing the CFSE profile using 




 Materials and methods 49 
 
2.3.4.11 Analysis of T cell proliferation by CFSE dilution 
The effect of LAQ-treated NK cells on T cell proliferation in vitro was assessed by CFSE-
staining of CD4+ T cells and subsequent flow cytometric analysis of CFSE dilution. CFSE penetrates 
the intact cell membrane and becomes irreversibly captured within the cell through a stable cross 
linking to intracellular proteins. Upon proliferation, the fluorescence intensity is halved at each 
cell division, since the cytoplasm is shared between the two daughter cells. The CFSE profile of 
dividing cells can be analyzed by flow cytometry (Parish, 1999). CD4+ T cells were isolated from 
the spleen of naïve C57Bl/6J or 2D2 mice (see 2.3.3.1.1) and purified by MACS separation (see 
2.3.4.2). CD4+ T cells were counted in a Neubauer chamber (see 2.3.3.1.4) and cells were 
resuspended in CFSE buffer at a concentration of 106 cells/ml. The CFSE stock solution (5 mM) was 
diluted 1:1,000 to a final concentration of 5 µM in the cell suspension. Cells were then incubated 
with CFSE for 10 min at 37°C in the dark. The staining reaction was stopped with the 4-fold 
amount of cold RPMIcomplete and the cells were incubated for 5 min on ice. The cells were 
centrifuged for 10 min at 300 x g and 4°C, the supernatant was discarded and the cells were 
washed in 10 ml of RPMIcomplete. This washing procedure was repeated twice, for a total of three 
washes. Finally, cells were resuspended in RPMIcomplete and counted in a Neubauer chamber (see 
2.3.3.1.4). The appropriate number of CFSE-labeled CD4+ T cells was then used in cultures for 
different proliferation experiments (see 2.3.4.8, 2.3.4.9 and 2.3.4.10). T cell proliferation was 
analyzed by measuring the CFSE dilution using flow cytometry. 
 
2.3.4.12 Detection of apoptosis via Annexin V and 7-AAD staining 
To analyze whether NK cells isolated from LAQ-treated and control animals triggered cell 
death of activated T cells and bone marrow-derived dendritic cells in a triple co-culture system 
(see 2.3.4.9), Annexin V and 7-AAD staining was performed. Annexin V binds to 
phosphatidylserine and is a marker for early and late apoptotic/dead cells. 7-AAD is an 
intercalating substance that binds to GC regions of the DNA and strongly labels late 
apoptotic/dead cells. Both molecules do not permeate viable cells (Vermes et al., 1995, Philpott et 
al., 1996, Zhang et al., 1997).  
To detect cell death in CD4+ T cells and bone marrow-derived dendritic cells from the 
triple co-culture, cells were resuspended and transferred to a 96 well round bottom plate. Wells 
of the original plate were flushed with ice cold 0.9% NaCl solution to detach bone marrow-derived 
dendritic cells, which were then also transferred to the new plate. Annexin V binding buffer (10x) 
was diluted 1:10 in bidistilled water. The plate was centrifuged and cells were washed once in PBS 
and once in Annexin V binding buffer. The staining solution was prepared as follows: Annexin V 
 
 Materials and methods 50 
 
binding buffer with anti-CD16/CD32 antibody (1:100), fluorochrome-labeled antibodies against 
CD3, NK1.1, CD11c and MHCII (1:200) and APC-conjugated Annexin V (1:20). Per well, 100 µl of 
the staining solution were added and cells were incubated for 15 min at RT protected from light. 
After the staining, cells were washed once in 200 µl Annexin V binding buffer and were finally 
resuspended in 100 µl Annexin V binding buffer. The plate was set on ice, 2.5 µl of 7-AAD solution 
were added per well and after 10 – 15 min Annexin V and 7-AAD staining was analyzed by flow 
cytometry.   
 
2.3.5 In vitro stimulation of cytokine secretion 
To analyze the effects of LAQ on cytokines in T cells and NK cells, splenocytes and purified 
NK cells were stimulated ex vivo and cytokine production was measured. 
 
2.3.5.1 Stimulation of T cells 
To investigate effects of LAQ on the production of pro-inflammatory cytokines in T cells, 
lymph node cells were isolated (see 2.3.3.1.2) from animals, immunized with MOG35-55 and 
treated with LAQ or vehicle for eleven days in vivo.  
To evaluate cytokine secretion over time, lymph node cells were resuspended at a 
concentration of 2*106 cells per ml in HL-1™ serum-free medium. 1 ml of the cell suspension was 
transferred to each well of a 24 well plate and cytokine secretion was stimulated by adding  
10 µg/ml of MOG35-55. Lymph node cells were incubated with MOG35-55 for 72 h at 37°C and  
5% CO2. IL-17 and IFNγ concentrations in the supernatant of the culture were measured by ELISA 
(see 2.3.5.3).  
The baseline of cytokine production was assessed in unstimulated samples. 
 
2.3.5.2 Stimulation of NK cells 
Flow cytometry and ELISA were applied to assess effects of LAQ on the capacity of NK cells 
to produce IFNγ. For this purpose, splenocytes (see 2.3.3.1.1) were isolated from mice, immunized 
with MOG35-55 and treated with LAQ or vehicle for eleven days in vivo. NK cells were purified as 
described in 2.3.4.1. 50,000 cells were seeded per well of a 96 well round bottom plate. To 
stimulate cytokine production, cells were cultured in RPMIcomplete, supplemented with IL-12  
(1 ng/ml) and IL-18 (25 ng/ml), over night (37°C, 5% CO2). After overnight culture, plates were 
centrifuged for 5 min at 300 x g and 4°C. The supernatant was removed and IFNγ concentrations 
were determined by ELISA (see 2.3.5.3). NK cells were resuspended in RPMIcomplete, supplemented 
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with IL-12 (1 ng/ml), IL-18 (25 ng/ml) and GolgiStop™ (1/1,000) and incubated for 5 – 6 h (37°C, 
5% CO2). NK cell surface staining (see 2.3.3.2.1) and intracellular IFNγ staining (see 2.3.3.2.4) were 
performed and the frequency of IFNγ+ NK cells was analyzed by flow cytometry. The baseline of 
the cytokine production was assessed in unstimulated samples. 
 
2.3.5.3 Detection of cytokines using ELISA 
T cells and NK cells are potent producers of a variety of cytokines. LAQ-effects on this 
effector function were assessed by measuring cytokine concentrations in the supernatant of 
stimulated lymph node cells and purified NK cells using ELISA.  
Lymph node cells were stimulated as described in 2.3.5.1 and IL-17 and IFNγ secretion was 
analyzed. Purified NK cells were stimulated as described in 2.3.5.2 and IFNγ production was 
evaluated. 
ELISA was performed using the suitable DuoSet® ELISA Development System and 
following the manufacturer’s instructions. The OD was determined at 450 nm with 540 nm 
wavelength correction using the iMark™ microplate reader. 
 
2.3.6 In vitro LAQ treatment 
T cells, bone marrow-derived dendritic cells and NK cells were treated with LAQ in vitro to 
differentiate between direct and indirect effects of LAQ on these cells. 
 
2.3.6.1 In vitro LAQ treatment of T cells 
To investigate whether T cells were directly modulated by LAQ, T cells were treated with 
LAQ in vitro. For this purpose, splenocytes (see 2.3.3.1.1) were isolated from C57Bl/6J mice 
immunized with MOG35-55. Splenocytes were seeded in a 96 well round bottom plate and 
resuspended in 200 µl of RPMIcomplete. LAQ was added at a concentration of 0 or 5 µM to the 
culture and splenocytes were incubated for 72 h (37°C, 5% CO2). Thereafter, the frequencies of 
Th1 and Th17 cells were assessed upon PMA and ionomycin stimulation.  
 
2.3.6.2 Intracellular detection of pro-inflammatory cytokines in T cells after in vitro LAQ 
treatment 
The frequencies of Th1 and Th17 cells were used as readout for the efficiency of in vitro 
LAQ treatment to reduce pro-inflammatory T cell subsets. Therefore, after the 72 h incubation 
period with LAQ (see 2.3.6.1) splenocytes were stimulated with PMA and ionomycin and the 
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frequencies of Th1 and Th17 cells were analyzed by flow cytometry after intracellular cytokine 
staining (see 2.3.3.2.4). 
 
2.3.6.3 In vitro LAQ treatment of bone marrow-derived dendritic cells 
To analyze whether LAQ-treated bone marrow-derived dendritic cells could induce NK cell 
activation upon co-culture, bone marrow-derived dendritic cells were generated in the presence 
of LAQ. For this purpose the differentiation medium was supplemented with LAQ at a 
concentration of 10 µM and fresh LAQ was added with each medium exchange. Apart from the 
addition of LAQ to the culture, bone marrow-derived dendritic cells were generated and purified 
as described above (see 2.3.4.3). 50,000 dendritic cells were seeded per well of a 96 well flat 
bottom plate and were allowed to adhere over night. No LPS was added to these cultures. LAQ-
treated bone marrow-derived dendritic cells were subsequently co-cultured with NK cells (see 
2.3.6.5). 
 
2.3.6.4 In vitro LAQ treatment of NK cells 
To investigate whether NK cells were a direct target of LAQ therapy, purified NK cells were 
treated with LAQ in vitro. For this purpose, splenocytes (see 2.3.3.1.1) were isolated from naïve 
C57Bl/6J mice and NK cells were purified (see 2.3.4.1). 50,000 NK cells were seeded per well of a 
96 well round bottom plate and resuspended in 200 µl of RPMIcomplete, supplemented with IL-2 
(1000 U/ml). LAQ was added at a concentration of 0 or 10 µM to the culture and NK cells were 
incubated for 48 h (37°C, 5% CO2). Direct effects of LAQ on NK cells were determined by analyzing 
the upregulation of the activation marker CD69.  
 
2.3.6.5 Co-culture of LAQ pre-treated bone marrow-derived dendritic cells with NK cells 
NK cells were co-cultured with LAQ-treated bone marrow-derived dendritic cells, to assess 
whether pre-treatment of bone marrow-derived dendritic cells with LAQ and subsequent co-
culture with NK cells could mimic direct effects of LAQ on NK cells. Splenic NK cells were purified 
(see 2.3.3.1.1 and 2.3.4.1) from naïve C57Bl/6J animals and 50,000 NK cells in RPMIcomplete, 
supplemented with IL-2 (1,000 U/ml), were added per well. NK cells were cultured alone or co-
cultured with 50,000 bone marrow-derived dendritic cells either pre-treated with 10 µM LAQ (see 
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2.3.6.6 Assessment of NK cell activation by CD69 staining 
The effect of direct in vitro LAQ treatment on NK cells, as well as the effect of co-culture 
with pre-treated bone marrow-derived dendritic cells on NK cells was assessed by measuring NK 
cell activation. Therefore, the surface marker CD69 was stained on NK cells derived from the 
cultures described in 2.3.6.4 and 2.3.6.5 and its expression was analyzed by flow cytometry (see 
2.3.3.2.1).  
 
2.3.7 Data analysis and statistics 
The software FlowJo 7.6.1 was used to analyze all flow cytometric data.  
Statistics were calculated using the software GraphPad Prism 5.01. Data were tested for 
normal distribution with the help of the Kolmogorov-Smirnov test with Dallal-Wilkinson-Lilliefor p-
value. To compare two experimental groups, unpaired t-tests were used for parametric data and 
Mann-Whitney U tests for non-parametric data. To compare three or more groups, one way 
ANOVA with Bonferroni post test was performed for parametric data and the Kruskal-Wallis test 
with Dunn’s post test was applied for non-parametric data. Survival analysis was calculated with 
the log-rank test. 
All the statistical analyses of EAE scores after NK cell depletion in vivo (compare 3.6.2) 
were performed in SAS 9.3 by Mr. Markus Harden (Department for Medical Statistics, University 
Medical Center Goettingen, Germany) using non-parametric rank-based ANOVA-type statistics. 
Statistical significance was defined as p<0.05. Data in text and figures are presented as  





 Results 54 
 
3. Results 
3.1 Preventive LAQ treatment blocked EAE induction and the 
development of auto-reactive T cells in vivo  
The new immunomodulatory substance LAQ is under development for the treatment of 
multiple sclerosis. The present work aimed to analyze the effects of this new compound on innate 
and adaptive immunity in mice with experimental autoimmune encephalomyelitis, the most 
common animal model, to study different autoimmune components of multiple sclerosis.  
To first approach LAQ-mediated alterations of adaptive immunity, the initial set of 
experiments tested the efficiency of LAQ to inhibit acute EAE in C57Bl/6J mice and evaluated the 
effects of LAQ on pro- and anti-inflammatory T cell subpopulations. In detail, the effects of LAQ on 
T cells were assessed by analyzing the proportion of naïve and effector memory T cells as well as 
the balance between anti-inflammatory regulatory T cells and pro-inflammatory Th1 and Th17 
cells. 
 
3.1.1 Preventive LAQ treatment completely inhibited acute EAE in C57Bl/6J mice 
To investigate the effect of preventive LAQ treatment on EAE, C57Bl/6J mice were 
immunized with MOG35-55 and received daily oral treatment with either 25 mg/kg LAQ or vehicle 
for 28 days, starting at the day of immunization. 
Control animals developed first clinical signs at day nine and clinical symptoms reached 
the peak of disease around days 15 – 20. In contrast all LAQ-treated animals remained healthy 
and did not develop any EAE symptoms (FIGURE 2). 
 
 
FIGURE 2: LAQ treatment protects 
C57Bl/6J mice from MOG35-55-induced 
EAE 
Clinical disease scores of acute EAE in 
C57Bl/6J mice, immunized with  
MOG35-55 and treated with 25 mg/kg 
LAQ (blue) or vehicle (gray) from day 0 
until day 28 after immunization. LAQ completely inhibits EAE symptoms in all treated animals (n=8), 
whereas control animals (n=8) develop first clinical signs at day nine after immunization, whereby clinical 
symptoms peak around day 15 – 20 after immunization. Data are presented as mean ± SEM. 
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3.1.2 LAQ treatment increased naïve and decreased effector memory T cells 
LAQ-induced changes in the frequencies of naïve and effector memory T cells were 
analyzed using splenocytes from MOG35-55-immunized mice treated with 25 mg/kg LAQ or vehicle 
for eleven days. Naïve and effector memory T cells were distinguished in the flow cytometric 
analysis by their expression levels of the surface markers CD62L and CD44. Naïve T cells were 
characterized as CD62L+ CD44low T cells, whereas effector memory T cells were defined as CD62L- 
CD44high T cells (FIGURE 3A). 
The frequency of naïve T cells was markedly increased in LAQ-treated animals (mean 
66.3% ± 1.2%) compared to control animals (mean 55.7% ± 3.7%, p<0.05) (FIGURE 3B). In contrast, 
LAQ-treated animals (mean 20.6% ± 0.8%) displayed a significantly lower frequency of effector 




FIGURE 3: LAQ augments naïve and reduces effector memory T cells 
The frequencies of CD62L+ CD44low naïve T cells and CD62L- CD44high effector memory T cells were 
evaluated by flow cytometry (A). Splenocytes were isolated from animals immunized with MOG35-55 and 
treated with 25 mg/kg LAQ (blue) or vehicle (gray) for eleven days. In vivo LAQ treatment significantly 
increases the frequency of naïve T cells compared to controls (n=6 per group, * p<0.05, unpaired t-test) (B). 
In contrast, the frequency of effector memory T cells is decreased in LAQ-treated animals compared to 
vehicle-treated controls (n=6 per group, ** p<0.01, Mann-Whitney U test) (C). Data are presented as  
mean ± SEM.  
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3.1.3 LAQ treatment decreased pro-inflammatory T cell subsets 
To evaluate the effects of LAQ treatment on pro-inflammatory T cell subsets, the 
production of the pro-inflammatory cytokines IL-17 and IFNγ was measured upon ex vivo 
stimulation of cells isolated from MOG35-55-immunized mice pre-treated with 25 mg/kg LAQ or 
vehicle for eleven days in vivo.  
 
3.1.3.1 LAQ reduced IL-17-producing CD4+ and γδ T cells 
To assess effects of LAQ on the frequency of IL-17-producing CD4+ T cells (Th17 cells) and 
IL-17-producing γδ T cells, splenocytes from LAQ-treated or control animals were stimulated with 
PMA and ionomycin ex vivo. Cytokine secretion was blocked and intracellular IL-17 staining was 
analyzed by flow cytometry (FIGURE 4A&C).  
Flow cytometry revealed a significant decrease in the frequency of Th17 cells in LAQ-
treated animals (mean 0.3% ± 0.05%) compared to control animals (mean 3.7% ± 1%, p<0.05) 
(FIGURE 4B). Similarly, the frequency of IL17+ γδ T cells declined. LAQ treatment reduced the 
proportion of IL-17+ γδ T cells from a mean of 16.6% ± 2.7% in controls to a mean of 5.5% ± 1.0% 
(p<0.01) (FIGURE 4D).  
The next step further investigated effects of LAQ on IL-17 production by measuring IL-17 
secretion over time in a recall assay. For this purpose, lymph node cells from LAQ- or vehicle-
treated immunized mice were re-stimulated with MOG35-55 ex vivo. IL-17 concentrations in the 
supernatant were determined by ELISA. 
The supernatant of lymph node cells, derived from vehicle-treated mice contained IL-17 at 
a mean concentration of 1437 pg/ml ± 429 pg/ml, whereas IL-17 was below the detection limit in 
the supernatant of all lymph node samples, isolated from LAQ-treated mice. This difference 
between LAQ and control group was highly significant with a p-value <0.001 (FIGURE 4E).  
 
3.1.3.2 LAQ reduced IFNγ-producing CD4+ T cells 
Effects of LAQ on the frequency of IFNγ-producing CD4+ T cells (Th1 cells) were 
investigated by ex vivo stimulation of splenocytes isolated from LAQ-treated and control animals 
with PMA and ionomycin. Cytokine secretion was blocked and intracellular IFNγ staining was 
analyzed by flow cytometry (FIGURE 5A).  
LAQ significantly reduced the frequency of Th1 cells upon ex vivo stimulation from a mean 
of 2.6% ± 0.9% in controls to a mean of 0.7% ± 0.1% in LAQ-treated samples (p<0.05) (FIGURE 5B).  
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FIGURE 4: In vivo LAQ treatment reduces Th17 cells and IL-17-producing γδ T cells 
IL-17 production was analyzed in splenocytes and lymph node cells isolated from animals with 
prior MOG35-55-immunization and treatment with 25 mg/kg LAQ (blue) or vehicle (gray) for eleven 
days. The frequencies of IL-17+ CD4+ T cells (A, B) and IL-17+ γδ T cells (C, D) upon ex vivo PMA 
and ionomycin stimulation were analyzed by flow cytometry. LAQ treatment significantly reduces 
the frequency of Th17 cells in the spleen (n=6 per group, * p<0.05, unpaired t-test) (B). The 
frequency of IL-17-producing γδ T cells in the spleen is also reduced by LAQ therapy (n=6 per 
group, ** p<0.01, unpaired t-test) (D). Lymph node cells were restimulated with MOG35-55 ex vivo 
and cytokine secretion was assessed by ELISA. IL-17 levels are undetectable in the supernatants of 
in vivo LAQ-treated lymph node cells, whereas considerable amounts of IL-17 are measured in 
samples derived from vehicle-treated control animals (Ctrl: n=11, LAQ: n=9, *** p<0.001, Mann-
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Furthermore, IFNγ secretion was determined in a recall assay. After re-stimulation of 
lymph node cells derived from LAQ- and vehicle-treated immunized animals with MOG35-55 ex 
vivo, IFNγ concentrations were measured in the supernatants by ELISA. No IFNγ was detected in 
the supernatant of any sample with in vivo LAQ treatment. In contrast, control samples produced 
a mean IFNγ concentration of 836.6 pg/ml ± 337.5 pg/ml. This difference between LAQ and 
control group was highly significant with a p-value <0.001 (FIGURE 5C). 
 
 
FIGURE 5: LAQ therapy reduces 
Th1 cells 
IFNγ production was evaluated in 
splenocytes and lymph node cells 
isolated from animals with prior 
MOG35-55-immunization and treat-
ment with 25 mg/kg LAQ (blue) or 
vehicle (gray) for eleven days. 
Flow cytometry was used to 
analyze the frequency of IFNγ+ 
CD4+ T cells in the spleen upon ex 
vivo PMA and ionomycin 
stimulation (A, B). Flow cyto-
metric data show a significant 
reduction of Th1 frequency after 
LAQ treatment (n=6 per group,  
* p<0.05, Mann-Whitney U test) (B). IFNγ secretion in lymph node cells was analyzed by ELISA after in vitro 
restimulation with MOG35-55. Quantitative data reveal a significantly lower IFNγ secretion in lymph node 
cells from LAQ-treated animals compared to controls. IFNγ concentrations in the supernatant of LAQ-
treated samples are under the detection limit of the assay, whereas control samples produce considerable 
amounts of IFNγ (Ctrl: n=11, LAQ: n=9, *** p<0.001, Mann-Whitney U test) (C). Data are presented as  
mean ± SEM. 
   
 
3.1.4 LAQ treatment increased the frequency of FoxP3+ regulatory T cells 
To analyze the effect of LAQ on anti-inflammatory T cells, the frequency of regulatory  
T cells among splenic CD4+ T cells was determined in naïve C57Bl/6J mice or MOG35-55-immunized 
mice treated with either 25 mg/kg LAQ or vehicle for 20 (naïve) or eleven days (immunized). 
Regulatory T cells are characterized by the expression of the lineage specific transcription factor 
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FoxP3 (Hori et al., 2003). Thus, intracellular staining of FoxP3 was performed and analyzed by flow 
cytometry (FIGURE 6A). 
Data analysis revealed a LAQ-induced increase in the frequency of regulatory T cells 
compared to controls. Furthermore, this effect was independent of a prior immunization with 
MOG35-55. In immunized mice, LAQ led to a significant rise of regulatory T cells from a mean 
frequency of 9.3 % ± 1.1% in controls to 14.7% ± 0.8% in treated animals (p<0.01) (FIGURE 6B). In 
naïve mice, LAQ treatment induced a similar increase of the mean frequency of regulatory T cells 




FIGURE 6: Regulatory T cells are increased in naïve and immunized mice after LAQ treatment 
The frequency of FoxP3+ regulatory T cells was analyzed in splenocytes from MOG35-55-immunized and 
naïve animals which had received treatment with 25 mg/kg LAQ (blue) or vehicle (gray) for eleven 
(immunized) or 20 days (naïve) by flow cytometry (A). LAQ treatment significantly augments the frequency 
of FoxP3+ regulatory T cells in immunized (n=6 per group, ** p<0.01, Mann-Whitney U test) (B) and in naïve 
mice (n=5 per group, *** p<0.001, unpaired t-test) (C). Data are presented as mean ± SEM.  
 
 
3.1.5 LAQ had no direct effect on IL-17+ and IFNγ+ CD4+ T cells in vitro 
To investigate whether T cells are a direct target of LAQ therapy, splenocytes were 
isolated from animals immunized with MOG35-55 which had not received prior LAQ treatment in 
vivo and were incubated in vitro with 0 or 5 µM LAQ for 72 h. The cells were subsequently 
stimulated with PMA and ionomycin and the frequency of IL-17+ and IFNγ+ CD4+ T cells was 
analyzed by flow cytometry (FIGURE 7A&C). 
In vitro treatment with 5 µM LAQ did not significantly alter the frequencies of Th17 and 
Th1 cells. The mean frequency of Th17 cells after a 72 h incubation period was very low in the 
control group (mean 1.1% ± 1%) as well as in the LAQ-treated group (mean 0.6% ± 0.1%, p>0.05) 
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(FIGURE 7B). The frequency of Th1 cells after 72 h of incubation was similar to the frequency 
obtained after direct ex vivo stimulation (compare 3.1.3.2 and FIGURE 5B), but no difference was 
detected between the control (mean 3.8% ± 0.5%) and the LAQ-treated group (mean 3.7% ± 0.6%, 




FIGURE 7: LAQ has no direct effect 
on Th17 and Th1 cells in vitro 
In vitro effects of LAQ treatment 
on pro-inflammatory T cell sub-
sets, isolated from the spleen of 
immunized mice, were investi-
gated using flow cytometry. 
Frequencies of IL-17+ (A, B) and 
IFNγ+ (C, D) CD4+ T cells were 
measured after in vitro treatment 
with 0 (gray) or 5 µM LAQ (blue) 
for 72 h and subsequent PMA and 
ionomycin stimulation for 5 h. LAQ 
does not significantly alter the 
frequencies of Th17 (B) and Th1 
(D) cells in vitro (n=6 per group, 
p>0.05, Mann-Whitney U test). 
Data are presented as  




3.2 Preventive LAQ treatment decreased total dendritic cells and 
myeloid dendritic cells in vivo 
To investigate the effects of LAQ treatment on antigen presenting cells, LAQ-induced 
changes were evaluated in splenic dendritic cells. The frequencies of total dendritic cells and 
myeloid dendritic cells in the spleen served as readouts for the therapeutic effects of LAQ.   
Naïve C57Bl/6J mice or MOG35-55-immunized mice received daily oral treatment with 
either 25 mg/kg LAQ or vehicle for 20 (naïve) or eleven days (immunized). Splenocytes were 
isolated and analyzed ex vivo by flow cytometry. 
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3.2.1 LAQ treatment reduced the frequency of dendritic cells 
The effect of LAQ on splenic dendritic cells was first evaluated by analyzing the frequency 
of total dendritic cells in the spleen of immunized or naïve animals, which had received either 25 
mg/kg LAQ or vehicle. Dendritic cells were defined as MHCII+ CD11chigh cells in the flow cytometric 
analysis (FIGURE 8A). 
The frequencies of splenic dendritic cells were considerably reduced after LAQ treatment 
and this effect was independent of the immunization with MOG35-55 – as evidenced by parallel 
investigations in naïve mice. In immunized mice, the mean frequency of dendritic cells decreased 
from 1.6% ± 0.2% in control animals to 0.6% ± 0.3% in LAQ-treated animals (p<0.01) (FIGURE 8B). 
In naïve mice, the frequency of dendritic cells in the spleen was slightly lower, but still a significant 
reduction was detected when comparing control animals (mean 0.8% ± 0.1%) to LAQ-treated 




FIGURE 8: LAQ decreases the frequency of dendritic cells in the spleen 
Splenocytes were isolated from MOG35-55-immunized and naïve animals which had received treatment with 
25 mg/kg LAQ (blue) or vehicle (gray) for eleven (immunized) or 20 days (naïve) in vivo. Dendritic cell 
frequencies were investigated by flow cytometry (A). LAQ treatment significantly decreases dendritic cell 
frequencies independently of a prior immunization. LAQ approximately halves the proportion of dendritic 
cells compared to controls in immunized (n=6 per group, ** p<0.01, unpaired t-test) (B) and naïve animals 
(Ctrl: n=7, LAQ: n=6, * p<0.05, unpaired t-test) (C). Data are presented as mean ± SEM.  
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3.2.2 LAQ treatment decreased myeloid dendritic cells 
Effects of LAQ on dendritic cells were further characterized by assessing the frequency of 
myeloid dendritic cells in the spleen of naïve and immunized mice with or without prior LAQ 
treatment (25 mg/kg). Myeloid dendritic cells are characterized by the expression of the surface 
marker CD11b. The frequency of CD11b+ myeloid dendritic cells among total dendritic cells was 
analyzed using flow cytometry (FIGURE 9A). 
LAQ treatment significantly decreased the frequency of CD11b+ myeloid dendritic cells in 
the spleen of immunized as well as naïve mice. In immunized animals, LAQ diminished the mean 
frequency of myeloid dendritic cells of about 5%, from 80.5% ± 1.8% in controls to 75.6% ± 0.6% 
in treated animals (p<0.05) (FIGURE 9B). In naïve mice, the LAQ-induced decrease in the mean 
frequency of myeloid dendritic cells was even more pronounced. LAQ treatment reduced the 
mean frequency of about 21%, from 74.2% ± 2.3% in controls to 53.1% ± 1.8% in treated animals 




FIGURE 9: LAQ reduces myeloid dendritic cells in the spleen 
Myeloid dendritic cells were investigated in spleens from MOG35-55-immunized and naïve animals which had 
received treatment with 25 mg/kg LAQ (blue) or vehicle (gray) for eleven (immunized) or 20 days (naïve) in 
vivo. The proportion of CD11b+ myeloid dendritic cells among all dendritic cells was analyzed ex vivo by 
flow cytometry (A). LAQ treatment significantly reduces the frequencies of CD11b+ myeloid dendritic cells 
in immunized as well as in naïve mice. In immunized mice myeloid dendritic cells are decreased by about 5% 
after LAQ treatment (n=6 per group, * p<0.05, unpaired t-test) (B). In naïve mice LAQ leads to a reduction of 
21% (Ctrl: n=7, LAQ: n=6, *** p<0.001, unpaired t-test) (C). Data are presented as mean ± SEM.  
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3.3 Preventive LAQ treatment led to the activation of natural killer cells 
in vivo 
To further study effects of LAQ on innate immunity, the next set of experiment 
investigated LAQ-induced alterations in NK cell numbers, subpopulations, activation state and 
effector functions. Therefore, naïve and MOG35-55-immunized mice received daily oral treatment 
with either 25 mg/kg LAQ or vehicle for 20 (naïve) or eleven days (immunized). Splenocytes were 
isolated from these mice and analyzed ex vivo.  
 
3.3.1 LAQ treatment reduced absolute NK cell numbers, but did not alter NK cell 
frequencies 
To analyze absolute NK cell numbers and NK cell frequency by flow cytometry, the NK cell 
specific surface marker NK1.1 was used (FIGURE 10D). NK1.1 is expressed on virtually all NK cells 
in C57Bl/6J mice and can be used as pan-NK cell marker. Besides NK cells a small subset of CD3+  
T cells presents NK1.1 at the cell surface. These cells, denominated NKT cells, respond to lipid-
antigens and display immunoregulatory properties (Godfrey et al., 2010). The current study 
excluded NKT cells from the analysis by pre-gating on CD19- CD3- cells. 
The impact of LAQ treatment on NK cell numbers was assessed by extrapolating NK cell 
counts from flow cytometric samples to total splenocyte numbers determined in a Neubauer 
chamber. Analysis of total splenocyte numbers revealed a 50% decrease in immunized LAQ-
treated mice (mean 40.8*106 ± 6.9*106) compared to controls (mean 84.8*106 ± 12.1*106, 
p<0.01) (FIGURE 10A). Absolute NK cell numbers were also reduced by approximately 50% in 
immunized LAQ-treated mice (mean 0.7*106 ± 0.2*106) compared to controls (mean  
1.7*106 ± 0.4*106, p=0.07) (FIGURE 10B). The Spearman correlation analysis of the total numbers 
of splenocytes and the absolute NK cell numbers revealed a very significant correlation (p<0.01; 
rs=0.84) (FIGURE 10C).  
NK cell frequency was calculated from flow cytometric data as percent NK1.1+ cells of all 
CD19- CD3- splenocytes (FIGURE 10D). The analysis of NK cell frequencies in the spleen of 
immunized mice showed a similar proportion of NK cells in LAQ-treated (mean 5.8% ± 0.7%) and 
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FIGURE 10: LAQ reduces absolute NK cell numbers, but does not alter NK cell frequencies 
Total splenocyte numbers, absolute NK cell numbers and NK cell frequencies were assessed in mice, 
immunized with MOG35-55 and treated with LAQ (25 mg/kg) (blue) or vehicle (gray) for eleven days in vivo. 
The total numbers of splenocytes were counted using a Neubauer chamber. Frequencies of NK1.1+ NK cells 
were analyzed by flow cytometry (D, E) and absolute NK cell numbers were extrapolated from these data. 
LAQ treatment halves the total number of splenocytes (n=6 per group, ** p<0.01, unpaired t-test) (A). A 
similar LAQ-induced decrease is observed for absolute NK cell numbers (n=6 per group, p=0.07, unpaired t-
test) (B). Spearman correlation analysis reveals a significant correlation between total splenocyte and 
absolute NK cell numbers (** p<0.01, rs=0.84) (C). NK cell frequencies among all CD19- CD3- cells are not 
significantly altered upon LAQ treatment (n=6 per group, p>0.05, unpaired t test) (E). Data are presented as 




 Results 65 
 
3.3.2 LAQ increased activation markers on the surface of NK cells 
Effects of LAQ on the phenotype of NK cells were evaluated by investigating NK cell 
molecules which reflect their subpopulations and activation state. 
 
3.3.2.1 LAQ treatment shifted NK cell subsets towards more CD27+ NK cells 
The different subpopulations of murine NK cells are characterized by a distinct expression 
pattern of the surface molecules CD27 and CD11b. Using flow cytometry, CD27+ CD11b- NK cells 
can be distinguished from CD27+ CD11b+ NK cells and CD27- CD11b+ NK cells (Chiossone et al., 
2009). CD27+ CD11b- and CD27- CD11b+ NK cells will be further referred to as CD27+ and CD11b+ 
NK cells, respectively, in this work.  
To investigate effects of LAQ on NK cell subpopulations, the proportions of CD27+, CD27+ 
CD11b+ and CD11b+ NK cells were analyzed within the population of NK1.1+ CD3- cells by flow 
cytometry using the classification mentioned above (FIGURE 11A). 
LAQ treatment profoundly altered NK cell subpopulations in naïve as well as in immunized 
mice. LAQ induced a shift towards more CD27+ and fewer CD11b+ NK cells, whereas the double 
positive cells remained constant. In immunized mice, CD27+ NK cells were increased by about 
18% in LAQ-treated animals (mean 36.8% ± 2.3%) compared to controls (mean 18.8% ± 3.9%, 
p<0.01). CD11b+ NK cells were decreased by about 20% in treated animals (mean 34.0% ± 2.4%) 
compared to controls (mean 55.9% ± 3.6%, p<0.001). Double positive NK cells showed similar 
frequencies in LAQ-treated (mean 22.7% ± 1.2%) and control animals (mean 19.3% ± 1.7%, 
p>0.05) (FIGURE 11B).  
Data from naïve mice revealed a similar LAQ effect on NK cell subpopulations, but in 
general these animals displayed a higher frequency of CD11b+ and a lower frequency of CD27+ 
NK cells in both treatment groups compared to immunized mice. LAQ treatment increased the 
mean proportion of CD27+ NK cells from 8.6% ± 1.7% in control animals to 22.4% ± 3.6% in 
treated animals (p<0.01). CD11b+ NK cells were decreased upon LAQ therapy from 70.4% ± 1.8% 
in controls to 57.5% ± 4.2% in treated animals (p<0.05). As in immunized animals, LAQ did not 
influence the frequency of double positive NK cells in naïve mice (Ctrl: mean 18.4% ± 1.0%; LAQ: 
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FIGURE 11: LAQ interferes with 
the relative frequency of NK 
cell subpopulations 
NK cell subpopulations 
were investigated in the spleen 
of MOG35-55-immunized and 
naïve animals which had re-
ceived treatment with 25 
mg/kg LAQ (blue) or vehicle 
(gray) for eleven (immunized) 
or 20 days (naïve) in vivo. The 
expression of CD27 and CD11b 
on the surface of NK1.1+ cells 
was analyzed by flow cytometry 
(A). Subsets of NK cells are 
classified as follows: CD27+ 
CD11b- (CD27+), CD27+ 
CD11b+ (double positive) and 
CD27- CD11b+ (CD11b+). LAQ 
treatment induces a shift in NK 
cell subpopulations towards 
more CD27+ and fewer CD11b+ 
cells. In immunized animals 
LAQ increases CD27+ NK cells of 
about 20% (Ctrl: n=8, LAQ: n=9, ** p<0.01, Mann-Whitney U test) and reciprocally decreases CD11b+ NK 
cells (*** p<0.01, unpaired t-test) (B). LAQ exerts similar effects in naïve mice, where an increase of about 
14% is observed for CD27+ NK cells (n=7 per group, ** p<0.01, unpaired t-test) and a decrease of 13% for 
CD11b+ NK cells (* p<0.05, unpaired t-test) (C). The proportion of CD27+ CD11b+ NK cells remains stable 
under LAQ treatment in immunized (Ctrl: n=8, LAQ: n=9, p>0.05, unpaired t-test) (B) and naïve mice (n=7 
per group, p>0.05, unpaired t-test) (C). Data are presented as mean ± SEM.  
 
 
3.3.2.2 LAQ treatment enhanced NK cell activation 
To evaluate the impact of LAQ on the activation state of NK cells, the next set of 
experiments investigated the expression of the early activation antigen CD69 as well as a panel of 
activating and inhibitory NK cell receptors.   
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3.3.2.2.1 LAQ increased the frequency of CD69+ NK cells 
The surface molecule CD69 is expressed on T cells and NK cells shortly after activation 
(Lanier et al., 1988, Werfel et al., 1997). Therefore, CD69 is widely used as an activation marker 
for these cells.  
To analyze the effect of LAQ on NK cell activation, the frequency of CD69+ NK cells among 
all NK1.1+ CD3- cells was measured by flow cytometry (FIGURE 12A). Splenocytes were isolated 
from naïve and immunized mice with or without prior LAQ treatment (25 mg/kg) in vivo. 
LAQ treatment markedly increased the frequency of CD69+ NK cells among all NK1.1+ 
CD3- cells in naïve and immunized mice. Immunized control animals displayed a mean frequency 
of CD69+ NK cells of 40.4% ± 5.7%, which was nearly doubled in LAQ-treated mice to 76.0% ± 
3.0% (p<0.001) (FIGURE 12B). In naïve mice, LAQ increased the mean frequency of CD69+ NK cells 
from 54.6% ± 4.8% in controls to 80.5% ± 3.5% in treated animals (p<0.001), which corresponds to 
a relative increase of approximately 50% (FIGURE 12C). 
Further analyses investigated whether the LAQ-induced increase in CD69 expression was 
restricted to a distinct subpopulation of NK cells. For this purpose, CD69 expression was evaluated 
on CD27+ NK cells and CD11b+ NK cells from spleens of immunized mice with and without prior 
LAQ treatment (25 mg/kg). 
 Both subpopulations responded to in vivo LAQ treatment with considerable upregulation 
of CD69. In the subpopulation of CD27+ NK cells LAQ approximately doubled the mean frequency 
of CD69+ NK cells from 29.4% ± 4.2% in controls to 67.3% ± 5.5% in treated animals (p<0.001) 
(FIGURE 12D). In the subpopulation of CD11b+ NK cells LAQ induced a 3.9 fold increase of CD69+ 
cells from 3.6% ± 0.4% in controls to 13.9% ± 0.9% in treated animals (p<0.001) (FIGURE 12E). In 
summary the relative increase of CD69+ cells after LAQ treatment was more pronounced in 
CD11b+ NK cells, but the absolute frequency of activated cells was higher in CD27+ NK cells. Thus, 
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FIGURE 12: LAQ augments the proportion of 
CD69+ NK cells 
To investigate the effects of LAQ on the activation 
of NK cells, splenocytes were isolated from  
MOG35-55-immunized and naïve animals which had 
received treatment with 25 mg/kg LAQ (blue) or 
vehicle (gray) for eleven (immunized) or 20 days 
(naïve) in vivo. The proportion of CD69+ cells 
among all NK1.1+ NK cells, CD27+ NK cells and 
CD11b+ NK cells was analyzed by flow cytometry 
(A). LAQ treatment nearly doubles the frequency of 
CD69+ NK cells in immunized animals (n=11 per 
group, *** p<0.001, unpaired t-test) (B). In naïve 
animals, LAQ also induces a 50% increase of CD69+ 
NK cells relative to controls (n=9 per group,  
*** p<0.001, Mann-Whitney U test) (C). LAQ raises 
the proportion of CD69+ NK cells among CD27+ NK 
cells (n=10 per group, *** p<0.001, unpaired t-test) 
(D) as well as CD11b+ NK cells (n=10 per group,  
*** p<0.001, unpaired t-test) (E). Data are 
presented as mean ± SEM. 
  
 
3.3.2.2.2 LAQ upregulated activating NK cell receptors  
The interplay of different activating and inhibitory receptors controls the activation of NK 
cell effector functions (Long et al., 2013). 
To further characterize LAQ-mediated changes on the activation state of NK cells, this 
thesis investigated the expression of different activating NK cell receptors by flow cytometry. 
Splenocytes were derived from MOG35-55-immunized animals which had received 25 mg/kg LAQ 
or vehicle for eleven days in vivo. The data were analyzed as percentage of positive cells among 
NK1.1+ CD3- cells (FIGURE 13A, C, E & G). The following activating NK cell receptors were 
investigated: TACTILE, DNAM-1, NKG2D, CD2, Ly49D, CD244.2 and LFA-1. 
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LAQ treatment significantly increased the mean frequencies of TACTILE+, DNAM-1+ and 
NKG2D+ NK cells. The mean frequency of TACTILE+ NK cells was elevated from 71.5% ± 1.5% in 
controls to 90.3% ± 0.7% in treated animals (p<0.001) (FIGURE 13B). DNAM-1+ NK cells showed an 
increase of about 10% upon LAQ treatment (Ctrl: mean 59.4% ± 2.5%; LAQ: mean 70.9% ± 2.4%; 
p<0.01) (FIGURE 13D). The mean frequency of NKG2D+ NK cells was slightly, but significantly 
higher in LAQ-treated animals (mean 96.5% ± 0.3%) compared to controls (mean 92.6% ± 0.9%, 
p<0.001) (FIGURE 13F).  
The only activating NK cell receptor of this panel that showed a decreased frequency after 
LAQ treatment was CD2. The mean frequency of CD2+ NK cells was reduced from 99.4% ± 0.2% in 
controls to 95.0% ± 0.5% in treated animals (p<0.001) (FIGURE 13H). LAQ had no influence on the 
frequencies of Ly49D+, CD244.2+ and LFA-1+ NK cells. 
Additional analyses examined if the upregulated expression of TACTILE and DNAM-1 by 
LAQ was restricted to NK cells. Since T cells can express TACTILE and DNAM-1, their receptor 
expression was analyzed on CD3+ T cells (FIGURE 14A & C). In contrast to NK cells, LAQ treatment 
did not lead to an upregulation of TACTILE and DNAM-1 on T cells. The proportion of TACTILE+  
T cells was similar in animals with (mean 60.4% ± 1.4%) and without LAQ treatment (mean  
62.5% ± 1.8%, p>0.05) (FIGURE 14B). DNAM-1 was clearly down-regulated on T cells after LAQ 
treatment (Ctrl: mean 49.1% ± 1.6%; LAQ: mean 44.3% ± 0.8%; p<0.05) (FIGURE 14C). 
 
3.3.2.2.3 LAQ downregulated inhibitory NK cell receptors 
Inhibitory NK cell receptors act in an antagonistic way to activating NK cell receptors in 
the regulation of NK cell effector functions and therefore play an important role in blocking or 
reducing NK cell activation (Long et al., 2013). 
To investigate effects of LAQ on inhibitory NK cell receptors, splenocytes from mice 
immunized with MOG35-55, which had received prior treatment with either 25 mg/kg LAQ or 
vehicle in vivo, were analyzed for the expression of several inhibitory receptors on the surface of 
NK cells by flow cytometry. The data were analyzed as percentage of positive cells among NK1.1+ 
CD3- cells (FIGURE 15A & C). The following inhibitory NK cell receptors were investigated: TIGIT, 
Ly49C/I/F/H, Ly49G2 and Ly49A. 
LAQ treatment significantly reduced the frequencies of TIGIT+ and Ly49C/I/F/H+ NK cells. 
The mean frequency of TIGIT+ NK cells was decreased from 10.1% ± 1.3% in controls to 3.9% ± 
0.6% in LAQ-treated animals (p<0.001) (FIGURE 15B). Mean frequencies of Ly49C/I/F/H+ NK cells 
were diminished from 69.9% ± 1.0% in controls to 64.0% ± 1.3% in LAQ-treated animals (p<0.01) 
(FIGURE 15D). The frequencies of Ly49G2+ and Ly49A+ NK cells were similar in LAQ- and vehicle-
treated animals. 
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FIGURE 13: LAQ increases the 
expression of activating NK 
cell receptors 
The effects of LAQ on 
activating NK cell receptors 
were assessed ex vivo in 
splenocytes from mice immu-
nized with MOG35-55 and 
treated with LAQ (25 mg/kg) 
(blue) or vehicle (gray) for 
eleven days in vivo. The surface 
expression of TACTILE (A, B), 
DNAM-1 (C, D), NKG2D (E, F) 
and CD2 (G, H) was analyzed by 
flow cytometry. LAQ treatment 
significantly raises the propor-
tion of TACTILE+ NK cells (n=10 
per group, *** p<0.001, 
unpaired t-test) (B), DNAM-1+ 
NK cells (n=10 per group,  
** p<0.01, unpaired t-test) (D) 
and NKG2D+ NK cells (n=10 per 
group, *** p<0.001, Mann-
Whitney U test) (F). The 
frequency of CD2+ NK cells is 
slightly reduced upon LAQ 
treatment (n=10 per group, 
*** p<0.001, Mann-Whitney U 
test) (H). Data are presented as 
mean ± SEM. 
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FIGURE 14: Effects of LAQ on the expression of TACTILE and DNAM-1 on T cells 
The effects of LAQ on the expression of TACTILE and DNAM-1 on T cells were evaluated ex vivo in the 
spleens of mice immunized with MOG35-55 and treated with LAQ (25 mg/kg) (blue) or vehicle (gray) for 
eleven days in vivo. The surface expression of TACTILE (A, B) and DNAM-1 (C, D) was analyzed by flow 
cytometry. The frequency of TACTILE+ T cells remains unaltered upon LAQ treatment (n=10 per group, 
p>0.05, unpaired t-test) (B). DNAM-1+ T cells are downregulated by LAQ (n=10 per group, * p<0.05, 
unpaired t-test) (D). Data are presented as mean ± SEM. 
 
  
Moreover, this set of experiments investigated effects of LAQ on the expression of TIGIT 
on CD3+ T cells (FIGURE 16A). Other than NK cells, T cells did not downregulate TIGIT in response 
to LAQ. The frequency of TIGIT+ T cells was comparable in LAQ-treated (mean 2.7% ± 0.2%) and 
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FIGURE 15: LAQ reduces the expression of inhibitory NK cell receptors 
The effects of LAQ on inhibitory NK cell receptors were studied ex vivo in the spleens of mice immunized 
with MOG35-55 and treated with LAQ (25 mg/kg) (blue) or vehicle (gray) for eleven days in vivo. The surface 
expression of TIGIT (A, B) and Ly49C/I/F/H (C, D) was analyzed by flow cytometry. LAQ treatment 
significantly decreases the proportion of TIGIT+ NK cells (n=10 per group, *** p<0.001, unpaired t-test) (B) 
and Ly49C/I/F/H+ NK cells (n=10 per group, ** p<0.01, unpaired t-test) (D). Data are presented as  
mean ± SEM. 
 
 
FIGURE 16: LAQ does not 
regulate TIGIT on T cells 
Treatment effects on the ex-
pression of TIGIT on T cells 
were investigated ex vivo in 
the spleens of mice immunized 
with MOG35-55 and treated 
with LAQ (25 mg/kg) (blue) or 
vehicle (gray) for eleven days 
in vivo. The surface expression of TIGIT (A) was analyzed by flow cytometry. The proportion of TIGIT+  
T cells remains constant upon LAQ treatment (n=10 per group, p>0.05, unpaired t-test) (B). Data are 
presented as mean ± SEM. 
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Taken together, LAQ treatment led to the upregulation of activating receptors and the 
downregulation of inhibitory receptors on NK cells. In detail, LAQ specifically altered the receptor 
status of NK cells for the recognition of CD155. The surface molecule CD155, which is expressed 
on endothelial cells, different leukocytes and a variety of tumor cells, regulates NK cell activation 
by interacting with the activating receptors DNAM-1 and TACTILE and the inhibitory receptor 
TIGIT (Bottino et al., 2003, Tahara-Hanaoka et al., 2004, Maier et al., 2007, Yu et al., 2009). 
DNAM-1 and TACTILE showed an increased expression on NK cells upon LAQ treatment, whereas 
TIGIT was diminished. This LAQ-induced alteration was specific for NK cells, as LAQ showed 
different effects on these three receptors on T cells. 
  
3.3.3 In vivo LAQ treatment increased NK cell effector functions ex vivo 
To investigate whether the LAQ-induced changes on NK cell subpopulations and activation 
state were paralleled by alterations in NK cell function, NK cell effector functions were tested ex 
vivo. Splenocytes were isolated from MOG35-55-immunized animals pre-treated with either  
25 mg/kg LAQ or vehicle for eleven days in vivo. NK cells were purified by MACS and FACS sorting 
and subsequently LAQ-induced alterations in NK cell cytotoxicity and IFNγ production were 
assessed in vitro.  
 
3.3.3.1 LAQ enhanced the killing efficiency of NK cells towards tumor cells in vitro 
One important function of NK cells is the recognition and the direct killing of tumor cells 
(Zamai et al., 2007, Vivier et al., 2011). This effector function can be tested in vitro by co-culturing 
NK cells with NK cell-sensitive tumor cells. The efficiency of NK cell-mediated tumor lysis is one 
characteristic functional feature depending on the subpopulation of NK cells. It has been 
described for human NK cells that CD11b+ NK cells are more effective in killing tumor cells in vitro 
compared to CD27+ NK cells (Fu et al., 2011).  
To assess LAQ-mediated changes in the killing efficiency of NK cells towards the B16F10 
melanoma cell line in vitro, CD27+ and CD11b+ NK cells (effector cells) isolated from LAQ- or 
vehicle-treated mice were co-cultures with B16F10 cells (target cells) at different effector/target 
ratios, ranging from 5:1 to 0.5:1. Killing of tumor cells was analyzed using a crystal violet staining. 
The results are presented as percentage of the B16F10 tumor cells which were lysed by NK cells 
during the co-culture (percent specific lysis). 
The overall comparison of CD27+ and CD11b+ NK cells, irrespective of a prior LAQ 
treatment, revealed that CD11b+ NK cells displayed a significantly higher capacity to lyse B16F10 
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tumor cells in vitro than CD27+ NK cells at all effector/target ratios investigated (FIGURE 17A). 
TABLE 19 summarizes sample size, mean specific tumor cell lysis ± SEM and p-values for the two 
NK cell subpopulations at all effector/target ratios. 
 
 
TABLE 19: CD11b+ NK cells display higher cytotoxicity towards B16F10 cells in vitro than CD27+ NK cells at 
all effector/target ratios 
 
Effector/target ratio 
Specific tumor cell lysis [%] 
p-value 
CD27+ NK cells 
n=13 
CD11b+ NK cells 
n=14 
5:1 68.7% ± 2.1% 74.2% ± 1.6% p<0.05 
2.5:1 54.2% ± 2.2% 66.8% ± 2.3% p<0.001 
1:1 29.3% ± 3.4% 51.8% ± 2.8% p<0.001 
0.5:1 15.3% ± 2.5% 30.4% ± 2.6% p<0.001 
 
Data are presented as mean ± SEM. 
  
 
To investigate LAQ-induced alterations in the ability of NK cells to lyse B16F10 melanoma 
cells, each NK cell subpopulation was analyzed separately. LAQ treatment significantly increased 
the specific lysis of CD27+ as well as CD11b+ NK cells at the highest effector/target ratio (5:1). For 
CD27+ NK cells LAQ rose the mean specific tumor cell lysis from 62.8% ± 2.5% in controls to 73.7% 
± 1.7% in treated animals (p<0.05) (FIGURE 17B). The mean specific tumor cell lysis by CD11b+ NK 
cells was augmented from 70.7% ± 1.9% in controls to 78.8% ± 1.4% in treated animals (p<0.01) 
(FIGURE 17C). At the lower effector/target ratios LAQ treatment also seemed to enhance tumor 
cell lysis by both NK cell subsets, but this effect did not reach statistical significance (FIGURE 17B 
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 FIGURE 17: LAQ increases the NK 
cell-mediated killing of tumor cells in 
vitro 
The killing efficiency of NK cells 
towards the B16F10 melanoma cell 
line in vitro was investigated using the 
crystal violet assay. NK cells were 
purified from the spleen of animals 
immunized with MOG35-55 and 
treated with LAQ (25 mg/kg) (blue) or 
vehicle (gray) for eleven days in vivo. 
NK cells (effector) were co-cultured 
with B16F10 melanoma cells (target) 
at different effector/target ratios for  
48 h. Surviving tumor cells were 
stained with crystal violet and the 
specific lysis of tumor cells [%] was 
calculated. The overall comparison of 
CD27+ and CD11b+ NK cells reveals a 
significantly higher killing efficiency of 
CD11b+ NK cells at all effector/target 
ratios investigated (CD27+ NK cells: 
n=13, CD11b+ NK cells: n=14,  
* p<0.05, *** p<0.001, unpaired t-
test) (A). At the highest 
effector/target ratio LAQ-treated NK cells show a significantly increased killing efficiency compared to 
control NK cells. This effect is observed for CD27+ NK cells (Ctrl: n=6, LAQ: n=7, ** p<0.01, unpaired t-test) 
(B) and CD11b+ NK cells (Ctrl: n=6, LAQ: n=7, ** p<0.01, Mann Whitney U test) (C). Data are presented as 
mean ± SEM. 
 
 
3.3.3.2 LAQ increased IFNγ-producing NK cells upon stimulation ex vivo 
The second key effector function of NK cells is the production and secretion of different 
cytokines upon stimulation. One prototypical marker cytokine of NK cells is IFNγ (Vivier et al., 
2011). 
To study effects of LAQ on the production of IFNγ in NK cells, NK cells were purified from 
MOG35-55-immunized animals with and without LAQ treatment (25 mg/kg) in vivo. Ex vivo, NK cells 
 
 Results 76 
 
were stimulated with IL-12 and IL-18. After stimulation IFNγ levels were measured in the 
supernatant by ELISA and the frequency of IFNγ+ NK cells was assessed by flow cytometry 
(FIGURE 18A). 
The mean frequency of IFNγ+ NK cells was significantly higher in LAQ-treated animals 
(mean 74.2% ± 2.2%) compared to controls (mean 67.0% ± 1.5%, p<0.05, unpaired T test) upon 
stimulation ex vivo (FIGURE 18B). 
The quantification of IFNγ levels in the supernatants of these stimulated NK cells revealed 
an increased IFNγ secretion in LAQ-treated animals. Supernatants of LAQ-treated samples (mean 
43.2 ng/ml ± 2.5 ng/ml) contained a 1.7 fold higher IFNγ concentration than control samples 




FIGURE 18: LAQ increases IFNγ+ NK cells 
NK cells were purified from the spleens of animals immunized with MOG35-55 and pre-treated with LAQ (25 
mg/kg) (blue) or vehicle (gray) for eleven days in vivo. After in vitro stimulation with IL-12 and IL-18 the 
proportion of IFNγ+ NK cells was assessed by intracellular cytokine staining and flow cytometry (A, B) and 
the IFNγ concentration was measured by ELISA in the supernatant (C). Flow cytometric data reveal a LAQ-
dependent rise of IFNγ+ NK cells of about 7% (Ctrl: n=8, LAQ: n=6, * p<0.05, unpaired t-test) (B). 
Furthermore, LAQ treatment nearly doubles the IFNγ secretion upon stimulation ex vivo (Ctrl: n=8, LAQ: 
n=6, *** p<0.001, Mann-Whitney U test) (C). Data are presented as mean ± SEM.  
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3.4 In vivo LAQ-treated NK cells inhibited antigen-dependent T cell 
proliferation in vitro in a contact dependent manner  
NK cells are part of a functional network and interact with T cells and dendritic cells. 
Within this network the different cell types influence each other in terms of activation, 
proliferation and survival. These interactions can be mediated either by direct cell-cell contact or 
by secretion of pro- and anti-inflammatory cytokines (Vivier et al., 2008, Vivier et al., 2011). 
To investigate whether LAQ treatment in vivo could alter the functional properties of NK 
cells within their network in vitro, NK cells were isolated from mice which were immunized with 
MOG35-55 and treated with either 25 mg/kg LAQ or vehicle for eleven days in vivo. The purified NK 
cells were tested in different co-culture systems to analyze the NK cell effects on T cell 
proliferation and cell death. Triple co-culture experiments with NK cells, 2D2 T cells and bone 
marrow-derived dendritic cells were performed to study the effect of LAQ-treated NK cells on 
antigen-dependent T cell proliferation and on cell death of T cells and bone marrow-derived 
dendritic cells. Further experiments used the triple co-culture setup in a transwell assay to 
determine, whether NK cell effects on antigen-dependent T cell proliferation were mediated by 
direct cell contact. Simple co-culture experiments of NK cells with T cells analyzed the effect of 
LAQ-treated NK cells on antigen-independent T cell proliferation. Simple co-culture setups of NK 
cells with bone marrow-derived dendritic cells examined the ability of LAQ-treated NK cells to 
induce cell death in bone marrow-derived dendritic cells.    
 
3.4.1 In vivo LAQ-treated NK cells reduced antigen-dependent T cell proliferation in a 
triple co-culture system of NK cells, T cells and bone marrow-derived dendritic 
cells by direct cell contact 
The effect of in vivo LAQ treatment on NK cell function in vitro was studied in a triple co-
culture system of NK cells, T cells and bone marrow-derived dendritic cells. In this co-culture, the 
proliferation of MOG35-55-specific 2D2 T cells was activated in an antigen-dependent manner using 
MOG35-55 as antigen and bone marrow-derived dendritic cells as antigen presenting cells. NK cells 
derived from LAQ- or vehicle-treated animals were added to investigate the effect of these cells 
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3.4.1.1 LAQ-treated NK cells reduced MOG35-55-induced T cell proliferation 
To study T cell proliferation in vitro, 2D2 CD4+ T cells were labeled with the fluorescent 
dye CFSE prior to antigen-dependent stimulation. CFSE stably crosslinks to proteins within the 
cytoplasm of T cells. With each cell division, the CFSE fluorescence intensity is then halved in the 
proliferated cells. By measuring the CFSE profile of 2D2 CD4+ T cells by flow cytometry after 72 h 
of stimulation, the maximal number of cell divisions and the proportion of cells in each division 
state can be analyzed (Parish, 1999). 
NK cell- and treatment-related effects on antigen-dependent T cell proliferation were 
assessed by analyzing the percentage of non-proliferating CD4+ T cells among all CD4+ T cells. 
Non-proliferating CD4+ T cells were defined as the percentage of CD4+ T cells that displayed 
maximal CFSE fluorescence intensity (FIGURE 19A).  
LAQ-treated NK cells significantly inhibited T cell proliferation compared to the baseline 
proliferation without NK cells (p<0.05). Moreover, LAQ-treated NK cells inhibited T cell 
proliferation to a significantly higher extent than control NK cells (p<0.05). Control NK cells also 
inhibited T cell proliferation to a certain extent, when compared to the baseline proliferation. 
However, this effect did not reach statistical significance (FIGURE 19B). TABLE 20 gives a summary 
of sample size, mean percentage of non-proliferating T cells and SEM. 
 
 
TABLE 20: NK cells from LAQ-treated animals inhibit antigen-
dependent T cell proliferation in vitro 
 
  Treatment Percentage of non-proliferating 
CD4+ T cells 
No NK cells (n=3) 6.3% ± 1.9% 
NK cells Ctrl (n=11) 10.2% ± 1.1% 
NK cells LAQ (n=12) 19.1% ± 1.8% 
 
Statistical significances:  
No NK cells vs. NK cells LAQ (* p<0.05) 
NK cells Ctrl vs. NK cells LAQ (* p<0.05)  
Data are presented as mean ± SEM. 
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FIGURE 19: LAQ-treated NK cells inhibit  
T cell proliferation 
NK cells were purified from the spleens of 
animals immunized with MOG35-55 and 
pre-treated with LAQ (25 mg/kg) (blue) or 
vehicle (gray) for eleven days in vivo. In 
vitro, these NK cells were co-cultured with 
bone marrow-derived dendritic cells and 
CFSE-labeled 2D2 T cells. T cell prolifera-
tion was induced by adding 20 µg/ml 
MOG35-55 to the culture. The proliferation 
was analyzed by flow cytometry in the 
absence of NK cells and in the presence of 
either LAQ-treated or control NK cells (A). 
LAQ-treated NK cells (n=12) significantly 
increase the proportion of non-prolifera-
ting CD4+ T cells compared to samples 
without NK cells (n=3, * p<0.05, Kruskal-
Wallis test with Dunn’s post test) and 
control NK cells (n=11, * p<0.05, Kruskal-
Wallis test with Dunn’s post test) (B). Data 
are presented as mean ± SEM.  
 
 
3.4.1.2 The NK cell-mediated inhibition of MOG35-55-induced T cell proliferation was 
dependent on direct cell contact  
NK cell-dependent inhibition of T cell proliferation can be mediated by different 
mechanisms, either involving direct cell-cell contact or cytokine secretion. 
To investigate whether the NK cell-mediated inhibition of T cell proliferation shown in 
3.4.1.1 was dependent on direct cell contact, the triple co-culture experiment was repeated in 
transwell plates. In these plates, each well consisted of two different compartments separated by 
a membrane, which allowed diffusion of soluble factors like cytokines, but prevented cell 
migration. NK cells, purified from mice immunized with MOG35-55, were either added to the same 
compartment as T cells and dendritic cells, allowing interactions by direct cell contact and 
cytokine secretion or they were added to the transwell compartment, inhibiting direct cell 
contact, but enabling the communication via soluble factors.  
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Contact-dependent versus contact-independent effects of NK cells on antigen-dependent 
T cell proliferation were again assessed by analyzing the percentage of non-proliferating CD4+  
T cells among all CD4+ T cells (FIGURE 20A).  
NK cell-mediated inhibition of T cell proliferation was dependent on direct cell contact. NK 
cells did not inhibit T cell proliferation when separated from T cells and dendritic cells by the 
transwell membrane. Only co-culture with NK cells in the same compartment together with 
activated T cells and dendritic cells led to a significant increase in the frequency of non-
proliferating CD4+ T cells compared to the baseline value where no NK cells were added to the 
culture (p<0.05) and compared to samples where NK cells were separated by the transwell 
membrane (p<0.001) (FIGURE 20B). TABLE 21 summarizes sample size, mean percentage of non-
proliferating CD4+ T cells and SEM.  
 
 
FIGURE 20: NK cell-mediated inhibition of 
T cell proliferation is contact-dependent 
NK cells were purified from the spleens of 
animals immunized with MOG35-55. In 
vitro, these NK cells were co-cultured with 
bone marrow-derived dendritic cells and 
CFSE-labeled 2D2 T cells either in direct 
contact or separated by a transwell 
membrane. T cell proliferation was in-
duced by adding 20 µg/ml MOG35-55 to the 
culture. Proli-feration was analyzed in 
samples without NK cells, with NK cells in 
direct contact and with NK cells separated 
from T cells and dendritic cells by a 
membrane using flow cytometry (A). NK 
cells which are separated from T cells and 
dendritic cells by the transwell membrane 
(n=24) do not inhibit T cell proliferation, 
whereas NK cells in direct contact with T 
cells and dendritic cells (n=24) significantly increase the proportion of non-proliferating CD4+ T cells 
compared to samples without NK cells (n=4, * p<0.05, one way ANOVA with Bonferroni post test) and to NK 
cells in the transwell (*** p<0.001, one way ANOVA with Bonferroni post test) (B). Data are presented as 
mean ± SEM. 
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TABLE 21: NK cells inhibit MOG35-55-induced T cell proliferation in a 
contact-dependent way 
 
Culture condition Percentage of non-proliferating 
CD4+ T cells 
No NK cells (n=4) 2.9% ± 0.6% 
NK cells transwell (n=24) 3.3% ± 0.3% 
NK cells direct contact (n=24) 6.8% ± 0.7% 
 
Statistical significances:  
No NK cells vs. NK cells direct contact (* p<0.05) 
NK cells transwell vs. NK cells direct contact (*** p<0.001) 
Data are presented as mean ± SEM. 
 
 
3.4.1.3 NK cells induced cell death in T cells and bone marrow-derived dendritic cells 
irrespective of in vivo LAQ treatment 
One mechanism by which NK cells could inhibit T cell proliferation in a contact-dependent 
manner is the induction of cell death in T cells and/or dendritic cells. 
To investigate whether NK cells induced cell death of activated T cells and dendritic cells 
in the triple co-culture and if this effect was LAQ-dependent, cells were stained with Annexin V 
and 7-aminoactinomycin D (7-AAD) after 18 h of co-culture.  
Annexin V, which binds to the phospholipid component phosphatidylserine, is a marker 
for early and late apoptotic/dead cells. 7-AAD, an intercalating substance that binds to GC regions 
of the DNA, strongly labels late apoptotic/dead cells. Both molecules are generally excluded from 
viable cells by an intact plasma membrane. 
In viable cells, phosphatidylserine is located at the cytosolic side of the lipid bilayer of the 
cell membrane. As an early event during apoptosis phosphatidylserine is moved from the inner 
leaflet of the plasma membrane to the outer leaflet, but the plasma membrane remains mostly 
intact. At this early stage of apoptosis, Annexin V is able to bind to phosphatidylserine at the cell 
surface, but only low amounts of 7-AAD enter the cell. During late stages of apoptosis or during 
necrotic cell death, the plasma membrane becomes permeable. Then Annexin V and 7-AAD can 
enter the cell efficiently and bind to their targets (Vermes et al., 1995, Philpott et al., 1996, Zhang 
et al., 1997).  
Annexin V and 7-AAD staining of CD3+ T cells (FIGURE 21A) and MHCII+ CD11chigh dendritic 
cells (FIGURE 22A) was analyzed by flow cytometry. Annexin V- 7-AAD- cells were classified as 
viable and Annexin V+ 7-AAD- cells as early apoptotic. Cells that were either Annexin V+ 7AAD+ or 
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Annexin V- 7-AAD+ were both classified as late apoptotic/dead. Data were analyzed as percentage 
of apoptotic and percentage of late apoptotic/dead cells among all CD3+ T cells and MHCII+ 
CD11chigh dendritic cells. 
NK cells did not increase the proportion of apoptotic T cells (FIGURE 21B) and dendritic 
cells (FIGURE 22B) irrespective of any treatment with LAQ in vivo at the time point analyzed.  
In contrast, the addition of NK cells to the culture considerably increased the frequency of 
late apoptotic/dead T cells from about 10% without NK cells to nearly 20%. Similar induction rates 
of cell death were observed in co-cultures with LAQ-treated NK cells (p<0.001) and control NK 
cells (p<0.001) (FIGURE 21C). 
In dendritic cells, the frequency of late apoptotic/dead cells was also markedly increased 
upon co-culture with NK cells from 16% to about 27%. LAQ-treated NK cells (p<0.001) and control 
NK cells (p<0.001) triggered cell death to a comparable degree (FIGURE 22C). TABLE 22 
summarizes sample sizes, mean percentages of apoptotic T cells, late apoptotic/dead T cells, 
apoptotic dendritic cells and late apoptotic/dead dendritic cells with the corresponding SEM.  
 
 
TABLE 22: NK cells trigger cell death in T cells and bone marrow-derived dendritic cells independent of 
LAQ treatment in vivo  
 
 Treatment 
 No NK cells 
(n=4) 
NK cells Ctrl 
(n=8) 
NK cells LAQ 
(n=8) 
Percentage of apoptotic T cells 5.7% ± 0.5% 6.4% ± 0.3% 6.3% ± 0.2% 
Percentage of late apoptotic/dead T cells 9.9% ± 0.6% 19.3% ± 0.6% 19.4% ± 0.3% 
Percentage of apoptotic dendritic cells 35.1% ± 2.6% 32.7% ± 1.2% 30.1% ± 0.8% 
Percentage of late apoptotic/dead dendritic cells 16.2% ± 0.5% 28.1% ± 1.0% 26.8% ± 0.5% 
 
Statistical significances:  
Late apoptotic/dead T cells: 
No NK cells vs. NK cells Ctrl (*** p<0.001), No NK cells vs. NK cells LAQ (*** p<0.001) 
Late apoptotic/dead dendritic cells: 
No NK cells vs. NK cells Ctrl (*** p<0.001), No NK cells vs. NK cells LAQ (*** p<0.001) 
 
Data are presented as mean ± SEM. 
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FIGURE 21: NK cells induce cell death in T cells in the triple co-culture system 
NK cells were purified from the spleens of animals immunized with MOG35-55 and pre-treated with LAQ  
(25 mg/kg) (blue) or vehicle (gray) for eleven days in vivo. In vitro, these NK cells were co-cultured with 
bone marrow-derived dendritic cells and 2D2 T cell. T cell proliferation was activated by adding MOG35-55 to 
the culture. Flow cytometry for Annexin V and 7-AAD staining was used to analyze the induction of cell 
death in the absence of NK cells and in the presence of either LAQ-treated or control NK cells (A). The 
addition of NK cells, LAQ-treated (n=8) or vehicle-treated (n=8), does not increase the proportion of early 
apoptotic T cells (p<0.05, one way ANOVA with Bonferroni post test) (B). In contrast, the proportion of late 
apoptotic/dead T cells is significantly augmented upon co-culture with NK cells. LAQ-treated (*** p<0.001, 
one way ANOVA with Bonferroni post test) and control NK cells (*** p<0.001, one way ANOVA with 
Bonferroni post test) lead to similar cell death rates of T cells (C). Data are presented as mean ± SEM. 
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FIGURE 22: NK cells induce cell death in dendritic cells in the triple co-culture system 
NK cells were purified from the spleens of animals immunized with MOG35-55 and pre-treated with LAQ  
(25 mg/kg) (blue) or vehicle (gray) for eleven days in vivo. In vitro, these NK cells were co-cultured with 
bone marrow-derived dendritic cells and 2D2 T cell. T cell proliferation was activated by adding MOG35-55 to 
the culture. Flow cytometry for Annexin V and 7-AAD staining was used to analyze the induction of cell 
death in the absence of NK cells and in the presence of either LAQ-treated or control NK cells (A). Dendritic 
cells in the early phase of apoptosis are not increased after adding LAQ-treated (n=8) or vehicle-treated 
(n=8) NK cells (p<0.05, one way ANOVA with Bonferroni post test) (B). As observed for T cells (compare 
FIGURE 21), the population of late apoptotic/dead dendritic cells is profoundly enlarged upon co-culture 
with NK cells. LAQ-treated (*** p<0.001, one way ANOVA with Bonferroni post test) and control NK cells 
(*** p<0.001, one way ANOVA with Bonferroni post test) lead to similar cell death rates in dendritic cells 
(C). Data are presented as mean ± SEM. 
 
 
3.4.2 NK cells did not affect antigen-independent T cell proliferation in a co-culture 
system with T cells 
LAQ-treated NK cells caused a significant inhibition of T cell proliferation in the triple co-
culture system with 2D2 T cells and bone marrow-derived dendritic cells (compare 3.4.1.1 and 
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FIGURE 19). To investigate whether this effect was dependent on the presence of bone marrow-
derived dendritic cells, the next set of experiments induced T cell proliferation in an antigen-
independent manner in a culture without dendritic cells. The proliferation of CFSE-labeled CD4+  
T cells, isolated from naïve C57Bl/6J mice, was stimulated via agonistic anti-CD3 and anti-CD28 
antibodies, whereby either no NK cells, LAQ-treated NK cells or control NK cells were added to the 
culture. The CFSE profile was measured after 72 h using flow cytometry. Results are shown as the 
percentage of CD4+ T cells with low proliferation rate versus the percentage of CD4+ T cells with 
high proliferation rate. Low proliferation rate was defined as no, one, two and three cell divisions 
and high proliferation rate as four cell divisions or more (FIGURE 23A). 
Neither control NK cells nor LAQ-treated NK cells reduced CD4+ T cell proliferation after 
antigen-independent stimulation. The frequencies of CD4+ T cells with low proliferation rate were 
similar in samples without NK cells (mean 64.2% ± 4.4%), samples with control NK cells (mean 
57.6% ± 5.2, p>0.05) and samples with LAQ-treated NK cells (mean 54.8% ± 5.5%, p>0.05) (FIGURE 
23B). The comparison of the frequencies of CD4+ T cells with high proliferation rate did not reveal 
any significant differences between samples without NK cells (mean 35.8% ± 4.4%), with control 
NK cells (mean 41.7% ± 5.1, p>0.05) and with LAQ-treated NK cells (mean 44.5% ± 5.3%, p>0.05) 
either (FIGURE 23C).  
 
3.4.3 NK cells did not kill bone marrow-derived dendritic cells in a co-culture system 
NK cells induced cell death in T cells and bone marrow-derived dendritic cells in the triple 
co-culture system (compare 3.4.1.3 and FIGURE 21 and FIGURE 22). To assess whether LAQ-
treated NK cells would directly kill bone marrow-derived dendritic cells in the absence of 
activated T cells, bone marrow-derived dendritic cells (target) with or without preceding LPS pre-
activation were co-cultured with LAQ-treated or control NK cells (effector) at an effector/target 
ratio of 1:1. The killing rates of dendritic cells were then analyzed using a crystal violet staining 
and data were presented as percentage of viable dendritic cells. 
Data analysis revealed no significant killing of bone marrow-derived dendritic cells by NK 
cells, irrespective of prior LPS and LAQ treatment. Dendritic cells without LPS treatment showed a 
viability of 100% ± 2.7% when co-cultured with control NK cells and 95.5% ± 2.3% with LAQ-
treated NK cells (p>0.05) (FIGURE 24A). Similar survival rates of LPS-activated dendritic cells were 
observed in co-culture with control NK cells (100% ± 2.7%) compared to LAQ-treated NK cells 
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FIGURE 23: NK cells do not interfere with T cell proliferation, when co-cultured with T cells alone 
NK cells were purified from the spleens of animals immunized with MOG35-55 and pre-treated with LAQ  
(25 mg/kg) (blue) or vehicle (gray) for eleven days in vivo. In vitro, these NK cells were co-cultured with 
CFSE-labeled CD4+ T cells. T cell proliferation was induced by agonistic anti-CD3 and anti-CD28 antibodies. 
Proliferation was analyzed by flow cytometry in the absence of NK cells and in the presence of either LAQ-
treated or control NK cells (A). Addition of NK cells to the culture does not significantly alter T cell 
proliferation. The proportion of CD4+ T cells with a low proliferation rate is similar in samples without NK 
cells (n=3), with LAQ-treated NK cells (n=7) and with control NK cells (n=8, p>0.05, Kruskal-Wallis test with 
Dunn’s post test) (B). Similarly, neither control NK cells (n=8) nor LAQ-treated NK cells influence the 
frequency of CD4+ T cells with a high proliferation rate (p>0.05, Kruskal-Wallis test with Dunn’s post test) 
(C). Data are presented as mean ± SEM.  
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FIGURE 24: NK cells do not kill dendritic cells when co-cultured with dendritic cells alone 
NK cells were purified from the spleens of animals immunized with MOG35-55 and pre-
treated with LAQ (25 mg/kg) (blue) or vehicle (gray) for eleven days in vivo. In vitro, these NK 
cells were co-cultured with bone marrow-derived dendritic cells. Viable dendritic cells were 
stained with crystal violet. In the absence of activated T cells, NK cells do not induce cell 
death in bone marrow-derived dendritic cells. Neither LAQ-treated (n=3) nor control NK cells 
(n=8) kill dendritic cells in this experimental setting. This is shown for both co-culture 
experiments of NK cells with naïve (A) and LPS-activated dendritic cells (B) (p>0.05, Mann-
Whitney U test). 
  
 
In summary, NK cells, treated with 25 mg/kg LAQ for eleven days in vivo, markedly 
reduced antigen-dependent T cell proliferation (see 3.4.1.1 and FIGURE 19) in a contact-mediated 
fashion (see 3.4.1.2 and FIGURE 20), when cultured with CD4+ T cells and bone marrow-derived 
dendritic cells in a triple co-culture system. In vivo LAQ treatment did not increase NK cell-
mediated killing of T cells and bone marrow-derived dendritic cells in this triple co-culture setting 
(see 3.4.1.3 and FIGURES 21 and 22). In contrast to the observed inhibitory effect of LAQ-treated 
NK cells on antigen-dependent T cell proliferation in the triple co-culture, NK cells did not 
interfere with antigen-independent T cell proliferation in a co-culture with CD4+ T cells alone (see 
3.4.2 and FIGURE 23). Furthermore, NK cells - irrespective of prior LAQ treatment - did not induce 
cell death in bone marrow-derived dendritic cells, when co-cultured with dendritic cells alone in 
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3.5 LAQ-mediated effects on NK cells were independent of dendritic cells 
and vice versa 
LAQ-mediated effects were demonstrated for different innate immune cells in vivo, 
namely dendritic cells (compare 3.2) and NK cells (compare 3.3). These two cell types interact in 
vivo and can influence each other by modulating activation, proliferation and survival.  
The following set of experiments investigated whether NK cells and dendritic cells were 
independent targets of LAQ treatment in vivo or if one effect was secondary to the other. First, 
time course experiments evaluated the kinetics of LAQ-induced changes in NK cells, dendritic cells 
and T cells. Moreover, effects of LAQ on dendritic cells were analyzed in NK cell-competent and 
NK cell-depleted animals, to investigate whether NK cell were essential or dispensable for LAQ 
action on dendritic cells. Finally, in vitro treatment experiments of naïve NK cells in the absence of 
any other cell type evaluated a direct LAQ effect on NK cell activation. 
 
3.5.1 NK cell and dendritic cell responses to LAQ treatment preceded changes in the T 
cell compartment 
To investigate the kinetics of LAQ-induced changes in NK cells, dendritic cells and T cells, 
time course experiments were performed.  
For this purpose, splenocytes were isolated from MOG35-55-immunized mice, which 
received 25 mg/kg LAQ or vehicle for one, two, three or four days. Treatment was started directly 
before the immunization and was then applied daily. Cells were analyzed using flow cytometry. 
Treatment of immunized C57Bl/6J mice with 25 mg/kg LAQ for eleven days in vivo 
considerably increased the frequencies of CD69+, TACTILE+ and NKG2D+ NK cells, as described 
previously in this work (compare 3.3.2.2.1 and 3.3.2.2.2 and FIGURES 12 and 13). Therefore, early 
LAQ-dependent modulation of NK cells was assessed by analyzing the frequencies of CD69+ 
(FIGURE 25A), TACTILE+ (FIGURE 25C) and NKG2D+ (FIGURE 25E) NK cells among all NK1.1+ CD3- 
cells. 
Data analysis revealed very early effects of LAQ treatment on NK cells. The mean 
frequency of TACTILE+ NK cells was already increased after one day of LAQ treatment compared 
to controls (p<0.01). A significant difference between LAQ treatment and control was further 
observed after two days (p<0.01) and a similar trend after three days of treatment (p=0.096) 
(FIGURE 25D). CD69+ as well as NKG2D+ NK cells showed a higher frequency in the LAQ-treated 
group compared to controls after two days of treatment. The proportion of CD69+ NK cells was 
markedly increased in the LAQ group after two and three days of treatment (p<0.001) (FIGURE 
25B). The frequencies of NKG2D+ NK cells were higher in LAQ-treated animals than those 
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observed in control animals after two days (p<0.01) and after three days of treatment (p<0.05) 
(FIGURE 25F). TABLE 23 provides sample sizes, mean percentages of CD69+, TACTILE+ and 
NKG2D+ NK cells with corresponding SEM and p-values. 
 
 
TABLE 23: LAQ leads to upregulation of the activation-associated molecules CD69, TACTILE and NKG2D on 
NK cells after one to two days of treatment  
 
 Percentage of CD69+ NK cells  





1 10.6% ± 1.6% 12.8% ± 2.0% >0.05 
2 9.6% ± 0.8% 17.8% ± 1.0% <0.001 
3 10.6% ± 0.9% 28.5% ± 2.3% <0.001 
    
 Percentage of TACTILE+ NK cells  





1 76.8% ± 1.3% 85.6% ± 0.4% <0.01 
2 80.5% ± 0.9% 88.6% ± 0.7% <0.01 
3 79.5% ± 1.7% 86.9% ± 2.9% 0.096 
    
 Percentage of NKG2D+ NK cells  





1 93.6% ± 0.3% 95.3% ± 1.3% >0.05 
2 87.7% ± 1.2% 94.4% ± 0.6% <0.01 
3 91.7% ± 0.3% 95.0% ± 1.0% <0.05 
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FIGURE 25: LAQ alters surface marker expression on NK cells after one to two days of treatment 
Time course experiments were performed to study the kinetics of LAQ-mediated changes in NK cells. 
Splenocytes were isolated from animals immunized with MOG35-55 and pre-treated with LAQ (25 mg/kg) 
(blue) or vehicle (gray) for one, two or three days in vivo. The proportions of CD69+ (A, B), TACTILE+ (C, D) 
and NKG2D+ cells (E, F) among all NK1.1+ NK cells were analyzed using flow cytometry. LAQ treatment 
induces an up-regulation of CD69+ NK cells (n=6 per group, *** p<0.001, unpaired t-test) (B) and NKG2D+ 
NK cells (n=3 per group, ** p<0.01, unpaired t-test) (F) after two days of treatment. The proportion of 
TACTILE+ NK cells is already significantly increased after one single dose of LAQ (n=3 per group, ** p<0.01, 
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In this work, eleven days of LAQ treatment markedly reduced the frequency of total 
splenic dendritic cells in immunized animals (compare 3.2.1 and FIGURE 8). Furthermore, a 
published study reported early effects of LAQ on the expression of the co-stimulatory molecule 
CD86 on dendritic cells (Jolivel et al., 2013). Thus, the kinetics of LAQ-induced changes in dendritic 
cells were evaluated by investigating the total frequency of dendritic cells in the spleen (FIGURE 
26A) and the proportions of MHCII+ CD11chigh cells expressing the co-stimulatory molecules CD80 
(FIGURE 26C) or CD86 (FIGURE 26E).  
As for NK cells, LAQ-mediated effects on dendritic cells occurred within the first days of 
treatment. LAQ led to a significant decrease in the mean frequency of dendritic cells in the spleen 
after three days of treatment (p<0.01) (FIGURE 26B). The percentage of CD80+ dendritic cells was 
considerably higher in LAQ-treated animals compared to controls after two days (p<0.05) and 
three days of therapy (p<0.01) (FIGURE 26D). The proportion of CD86+ dendritic cells was slightly 
increased after two days (p>0.05) and significantly increased after three days of LAQ treatment 
(p<0.05) compared to controls (FIGURE 26F). TABLE 24 summarizes sample sizes, mean 
frequencies of total splenic dendritic cells as well as mean proportions of CD80+ and CD86+ 
dendritic cells with corresponding SEM and p-values.  
 
Previously published data pointed towards an indirect interference of LAQ with T cells, 
mediated by a direct modulation of antigen-presenting cells, which could suggest delayed effects 
of LAQ on T cells compared to dendritic cells. Thus, a treatment interval of four days was chosen 
to analyze early effects of LAQ on T cells in this study. Since LAQ-mediated alterations of naïve 
and effector memory T cells (see 3.1.2 and FIGURE 3) as well as pro-inflammatory Th1 and Th17 
cells (see 3.1.3 and FIGURES 4 and 5) were observed after eleven days of treatment in this work, 
the frequencies of naïve T cells (FIGURE 27A), effector memory T cells (FIGURE 27A), IL-17+ 
(FIGURE 27D) and IFNγ+ (FIGURE 27F) CD4+ T cells were used as readouts for effective LAQ 
treatment after four days. 
The effects of LAQ on T cells were indeed delayed compared to NK cells and dendritic 
cells. After four days of LAQ treatment no considerable changes were observed in any of the 
parameters assessed. The mean frequencies of CD62L+ CD44low naïve T cells were similar in LAQ-
treated animals (mean 68.8% ± 2.6%) and controls (mean 74.6% ± 1.2%, p>0.05) (FIGURE 27B). 
Further, four days of LAQ treatment did not induce a decrease of CD62L- CD44high effector 
memory T cells (Ctrl: mean 13.1% ± 0.9%; LAQ: mean 17.6% ± 2.6%; p>0.05) (FIGURE 27C), as 
observed after eleven days of treatment (compare 3.1.2 and FIGURE 3C). Th17 cells were barely 
detectable at day four after immunization and LAQ treatment and their frequency did not 
significantly differ between the LAQ (mean 0.04% ± 0.03% ) and control group (mean 0.05% ± 
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0.01%, p>0.05) (FIGURE 27E). The frequencies of Th1 cells were also very low after four days of 
LAQ treatment and similar in LAQ-treated (mean 0.3% ± 0.04%) and control mice (mean 0.2% ± 
0.05%) (FIGURE 27G). 
 
 
TABLE 24: In vivo LAQ treatment reduces the total frequency of splenic dendritic cells within three days 
and upregulates the co-stimulatory molecules CD80 and CD86 within two to three days 
 
 Percentage of total splenic dendritic cells  





1 1.7% ± 0.2% 1.9% ± 0.3% >0.05 
2 1.0% ± 0.1% 1.0% ± 0.1% >0.05 
3 0.7% ± 0.05% 0.5% ± 0.05% <0.01 
    
 Percentage of CD80+ dendritic cells  





1 33.5% ± 1.7% 35.9% ± 1.8% >0.05 
2 19.9% ± 0.9% 34.2% ± 3.2% <0.05 
3 21.6% ± 1.0% 36.4% ± 1.5% <0.01 
    
 Percentage CD86+ dendritic cells  





1 17.8% ± 1.8% 18.0% ± 2.1% >0.05 
2 14.6% ± 0.3% 18.9% ± 1.8% >0.05 
3 13.5% ± 1.1% 23.0% ± 2.1% <0.05 
 
Data are presented as mean ± SEM. 
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FIGURE 26: LAQ reduces total dendritic cells and leads to upregulation of the co-stimulatory molecules 
CD80 and CD86 after two to three days of treatment 
Time course experiments were performed to study the kinetics of LAQ-effects on dendritic cells. 
Splenocytes were isolated from animals immunized with MOG35-55 and pre-treated with LAQ (25 mg/kg) 
(blue) or vehicle (gray) for one, two or three days in vivo. Flow cytometry was used to analyze the frequency 
of splenic dendritic cells (A, B), as well as the proportions of CD80+ (C, D) and CD86+ (E, F) dendritic cells. 
Two days treatment with LAQ are sufficient to significantly increase the proportion of CD80+ dendritic cells 
compared to controls (n=3 per group, * p<0.05, ** p<0.01, unpaired t-test, one representative experiment) 
(D). Three days of LAQ treatment are necessary to significantly augment the proportion of CD86+ dendritic 
cells (n=3 per group, * p<0.05, unpaired t-test, one representative experiment) (F) and to reduce the 
frequency of total splenic dendritic cells (n=6 per group, ** p<0.01, Mann-Whitney U test) (B). Data are 
presented as mean ± SEM. 
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FIGURE 27: No effects of LAQ on T cells after four days of treatment 
To study early effects of LAQ on T cells, splenocytes were isolated from MOG35-55-immunized animals which 
had received treatment with 25 mg/kg LAQ (blue) or vehicle (gray) for four days in vivo. The frequencies of 
CD62L+ CD44low naïve T cells (A, B), CD62L- CD44high effector memory T cells (A, C), Th17 cells (D, E) and Th1 
cells (F, G) were evaluated by flow cytometry. Four days of LAQ treatment are not sufficient to induce any 
significant changes in T cells. The proportions of naïve T cells (n=3 per group, p>0.05, unpaired t-test) (B) 
and effector memory T cells (n=3 per group, p>0.05, unpaired t-test) (C) do not significantly differ between 
LAQ- and vehicle-treated animals. The frequencies of Th17 cells (n=3 per group, p>0.05, unpaired t-test) (E) 
and Th1 cells (p>0.05, unpaired t-test) (G) are equally low in LAQ-treated and control samples. Data are 
presented as mean ± SEM. 
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3.5.2 The effect of LAQ on NK cells was independent of T and B cells in vivo 
LAQ induced changes in NK cells as well as T cells after eleven days of treatment (compare 
3.1 and 3.3). As mentioned in the previous chapter time course experiments revealed an earlier 
onset of effects of LAQ in NK cells compared to T cells (compare 3.5.1 and FIGURES 25 and 27). To 
confirm that LAQ-mediated effects on NK cells were independent of T and B cells in vivo, the next 
set of experiments investigated naïve Rag1-deficient mice, which are devoid of T and B cells 
(Mombaerts et al., 1992). As previously shown in this work, the response of NK cells to LAQ 
therapy was similar in naïve and immunized mice, indicated by a comparable shift towards more 
CD27+ NK cells (compare 3.3.2.1 and FIGURE 11) and increased expression of the activation 
marker CD69 (compare 3.3.2.2.1 and FIGURE 12). Thus, naïve Rag1-deficient mice are a suitable 
model to study the role of T and B cells for the effects of LAQ on NK cells. Rag1-deficient mice 
were treated with either 25 mg/kg LAQ or vehicle for 20 days. Changes in subpopulations and the 
activation of NK cells were evaluated, whereby the surface markers CD27, CD11b (FIGURE 28A) 
and CD69 (FIGURE 28D) were assessed on NK1.1+ CD3- cells by flow cytometry.  
The effect of LAQ on NK cells was independent of T and B cells in vivo. LAQ-induced 
changes in NK cells of Rag1-/- mice were comparable to those observed in immunized wild type 
mice (compare 3.3.2.1 and FIGURE 11B). 
LAQ treatment induced a shift in NK cell subpopulations towards more CD27+ and fewer 
CD11b+ NK cells in Rag1-/- mice. LAQ significantly increased the mean frequency of CD27+ NK cells 
from 11.2% ± 3.1% in controls to 35.8% ± 2.0% in treated animals (p<0.01) (FIGURE 28B), which 
corresponds to a three-fold increase. The mean frequency of CD11b+ NK cells was nearly halved 
in LAQ-treated animals (mean 28.5% ± 3.8%) compared to controls (mean 52.4% ± 6.7%, p<0.05) 
(FIGURE 28C). 
LAQ therapy significantly augmented the mean frequency of CD69+ NK cells from 33.7% ± 
5.2% in controls to 71.8% ± 8.8% in treated Rag1-/- animals (p<0.01) (FIGURE 28E). 
 
3.5.3 NK cell depletion did not affect the dendritic cell phenotype after LAQ treatment 
in vivo 
The kinetic of LAQ-induced changes was similar for NK cells and dendritic cells (compare 
3.5.1 and FIGURES 25 and 26). Additional experiments investigated whether the effects of LAQ on 
NK cells and dendritic cells were independent. As previously described in this work, LAQ 
treatment reduced the frequencies of total splenic dendritic cells and myeloid dendritic cells 
(compare 3.2 and FIGURES 8 and 9). The next set of experiments assessed these two parameters 
in NK cell-competent and NK cell-depleted animals. 
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FIGURE 28: T and B cells are dispensable for the LAQ effect on NK cells 
To confirm that the effects of LAQ are independent of T and B cells, NK cell changes under LAQ were 
investigated in Rag1-/- mice. Splenocytes were isolated from Rag1-/- mice pre-treated with 25 mg/kg LAQ 
(blue) or vehicle (gray) for 20 days in vivo. The effect of LAQ on NK cell subpopulations (A, B, C) and 
activation (D, E) were analyzed by flow cytometry, measuring the surface expression of CD27, CD11b and 
CD69 on NK1.1+ NK cells. LAQ treatment significantly increases the proportion of CD27+ NK cells  
(*** p<0.001, unpaired t-test) (B) and reciprocally decreases the proportion of CD11b+ NK cells (* p<0.05, 
unpaired t-test) (C) in Rag1-/- mice (Ctrl: n=3, LAQ: n=4). The frequency of CD69+ NK cells is approximately 
doubled in LAQ-treated Rag1-/- (n=4) mice compared to controls (n=3, ** p<0.01, unpaired t-test) (E). Data 
are presented as mean ± SEM. 
    
 
NK cells were depleted in C57Bl/6J mice by intraperitoneal administration of 300 µg anti-
NK1.1 antibody (clone PK-136) per animal at the two days prior to immunization and then every 
other day until splenocytes were harvested. NK cell-competent animals received identical 
treatment with the isotype control antibody C1.18.4. Successful NK cell depletion was controlled 
in the peripheral blood before immunization by flow cytometry, which revealed highly efficient 
depletion of NK cells (above 99%) in all PK-136-treated animals. Daily administration of either 25 
mg/kg LAQ or vehicle to NK cell-competent and NK cell-depleted mice was started at the day of 
immunization with MOG35-55. After eleven days of LAQ treatment, splenic dendritic cells were 
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isolated and effects of LAQ were evaluated by flow cytometry. Data were analyzed as total 
frequency of MHCII+ CD11chigh cells (FIGURE 29A) and as frequency of CD11b+ cells among the 
MHCII+ CD11chigh cells (FIGURE 29C).  
LAQ affected dendritic cells independently of NK cells in vivo. The total frequency of 
splenic dendritic cells was significantly reduced in LAQ-treated NK cell-competent mice (mean 
0.6% ± 0.1%) compared to their controls (NK cell-competent mice without LAQ: mean 1.6% ± 
0.2%, p<0.01). A similar reduction was observed in NK cell-depleted mice treated with LAQ (mean 
0.7% ± 0.1%) compared to these controls (mean 1.5% ± 0.2%, p<0.05) (FIGURE 29B).  
The mean frequencies of CD11b+ myeloid dendritic cells were also decreased upon LAQ 
treatment irrespective of a prior NK cell depletion. In NK cell-competent mice, LAQ therapy 
reduced the mean frequency of CD11b+ myeloid dendritic cells from 72.1% ± 1.5% in controls to 
52.3% ± 0.2% in treated animals (p<0.001). An analogous effect was observed in NK cell-depleted 
animals, where LAQ induced a drop in the mean frequency of CD11b+ myeloid dendritic cells from 
71.2% ± 1.5% in controls to 50.2% ± 1.1% in treated animals (p<0.001) (FIGURE 29D). 
  
3.5.4 LAQ directly activated NK cells in vitro 
LAQ treatment influenced dendritic cells independently of NK cells in vivo (compare 
3.5.3). To elucidate whether the LAQ-mediated changes in NK cells were also independent of 
dendritic cells, NK cells were isolated from naïve mice and treated with 0 or 10 µM LAQ in vitro. 
The frequency of CD69+ NK cells in samples with and without LAQ was analyzed by flow 
cytometry (FIGURE 30A). 
LAQ directly increased the frequency of CD69+ NK cells in vitro. CD69+ NK cells were 
augmented from 64.8% ± 0.9% in control samples to 72% ± 1.1% in LAQ-treated samples (p<0.05) 
(FIGURE 30B).  
To investigate whether bone marrow-derived dendritic cells, pre-treated with LAQ, could 
mimic direct effects of LAQ on the activation of NK cells, NK cells were either cultured alone or co-
cultured with bone marrow-derived dendritic cells, pre-treated with 0 or 10 µM LAQ. 
No significant increase of CD69+ NK cells was observed upon co-culture of NK cells with 
bone marrow-derived dendritic cells, irrespective of LAQ pre-treatment. The mean frequencies of 
CD69+ NK cells were similar when NK cells were cultured alone (mean 67.3% ± 1.0%), co-cultured 
with naïve bone marrow-derived dendritic cells (mean 59.9% ± 2.5%) or co-cultured with pre-
treated bone marrow-derived dendritic cells (mean 67.7% ± 3.1%) (FIGURE 30C). 
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FIGURE 29: The effects of LAQ on dendritic cells are not mediated by NK cells 
To analyze whether LAQ-induced changes of dendritic cells are dependent on the presence of NK cells, NK 
cells were depleted prior to immunization using an anti-NK1.1 antibody. After successful NK cell depletion, 
mice were immunized with MOG35-55 and treated with 25 mg/kg LAQ (blue) or vehicle (gray) for eleven 
days in vivo. LAQ-induced changes in splenic dendritic cell frequencies (A, B) and the proportion of myeloid 
dendritic cells (C, D) were analyzed by flow cytometry. LAQ alters dendritic cells directly without NK cell 
involvement. LAQ reduces the frequency of splenic dendritic cells in NK cell-depleted mice to a similar 
extent as in NK cell-competent mice. The LAQ-dependent reduction is statistically significant in both 
experimental groups (n=3 per group, * p<0.05, ** p<0.01, one way ANOVA with Bonferroni post test) (B). 
The LAQ-induced decrease of myeloid dendritic cells is comparable in NK cell-depleted and NK cell-
competent mice and the effect is statistically significant in both groups (n=3 per group, *** p<0.001, one 
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FIGURE 30: LAQ directly modu-
lates NK cells in vitro 
 To assess direct effects of LAQ on 
NK cells in vitro, NK cells were 
purified from naïve mice. In vitro, 
NK cells were either treated 
directly with 0 or 10 µM LAQ or 
co-cultured with bone marrow-
derived dendritic cells pre-treated 
with 0 or 10 µM LAQ. To assess 
the effects of LAQ the increase of 
CD69+ NK cells was measured by 
flow cytometry (A). Direct treat-
ment with 10 µM LAQ in vitro 
significantly raises the expression 
of CD69 on NK cells (n=4 per 
group, * p<0.05, Mann-Whitney 
test, one representative experi-
ment) (B). Co-culture with pre-
treated bone marrow-derived dendritic cells does not mimic direct LAQ treatment. The frequencies of 
CD69+ NK cells are similar in samples without dendritic cells and in samples incubated with dendritic cells 
with and without LAQ pre-treatment (n=10 per group, p>0.05, Kruskal-Wallis test with Dunn’s post test) 
(C). Data are presented as mean ± SEM.  
 
 
In summary, the presented experiments revealed effects of LAQ on NK cells and dendritic 
cells within the first three days of treatment, whereas T cells had not yet responded to LAQ after 
four days of therapy. The effects of LAQ on dendritic cells were independent of NK cells, as 
evidenced by a similar reduction of dendritic cells in NK cell-competent and NK cell-depleted mice 
after LAQ administration. In turn, NK cells were directly activated by LAQ in vitro in the absence of 
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3.6 NK cell depletion reduced the therapeutic efficiency of LAQ in EAE 
Preventive LAQ treatment completely inhibited EAE induction in C57Bl/6J mice (compare 
3.1.1) and directly modified NK cell properties (compare 3.3, 3.4.1.1 and 3.5.4). Therefore, the 
final set of experiments investigated the impact of NK cells on the therapeutic efficiency of LAQ in 
EAE. 
These experiments were performed using Th/+ mice, which possess MOG-specific B cells 
and pathogenic antibodies (Litzenburger et al., 1998). After immunization with MOG35-55, EAE is 
very efficiently induced in Th/+ mice without therapeutic intervention. The experimental setup is 
summarized in FIGURE 31. Briefly, NK cells were initially depleted in Th/+ mice by the 
administration of 300 µg anti-NK1.1 antibody PK-136 per animal at day one and two before 
immunization. To sustain NK cell depletion, anti-NK1.1 antibody was then applied every other day 
until the end of the experiment (day 28 p.i.). NK cell-competent Th/+ mice received the 
corresponding treatment with the isotype control antibody C1.18.4. At the day of immunization 
with MOG35-55 NK cell-competent and NK cell-depleted Th/+ mice were randomized into the 
different treatment groups, which received either 25 mg/kg LAQ or vehicle. Daily treatment with 
LAQ or vehicle was started at the day of immunization and carried out until the end of the 
experiment. The disease scores were assessed daily in each animal from the day of immunization 
until day 28 after immunization. Finally, this experimental setup compared four different groups: 
1. Th/+ mice treated with vehicle and isotype control antibody: “control” 
2. Th/+ mice treated with vehicle and anti-NK1.1 antibody:  “controlNK cell-depleted” 
3. Th/+ mice treated with LAQ and isotype control antibody:  “LAQ” 
4. Th/+ mice treated with LAQ and anti-NK1.1 antibody:   “LAQNK cell-depleted” 
Disease severity and mortality were compared between these different experimental 
groups to assess the importance of NK cells for the therapeutic effect of LAQ in EAE.  
  
 
 Results 101 
 
 
FIGURE 31: Experimental setup for NK cell depletion and LAQ treatment in immunized Th/+ mice 
The aim of this experimental setup is to investigate the impact of NK cells on the therapeutic efficiency of 
LAQ in EAE. Therefore, NK cells are initially depleted in naïve Th/+ mice at day two and one before 
immunization by intraperitoneal injection of the anti-NK1.1 antibody PK-136 (dashed lines). Subsequent 
administration of the anti-NK1.1 antibody every other day until day 28 p.i. inhibits the recovery of NK cells. 
NK cell-competent Th/+ mice receive identical treatment with the isotype control antibody C1.18.4 (solid 
lines). At the day of immunization with MOG35-55, NK cell-competent and NK cell-depleted animals are 
subjected to different treatment groups, receiving either 25 mg/kg LAQ (blue) or vehicle (gray). LAQ and 
vehicle are administered daily and orally from the day of immunization until the end of the experiment at 
day 28 after immunization. According to the administration of NK cell-depleting antibody or isotype control 
and the therapy with LAQ or vehicle, this experimental setup generates four different experimental 
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3.6.1 NK cell depletion was efficient in Th/+ mice 
The efficiency of the NK cell depletion was controlled in each animal directly before 
immunization and at day 28 after immunization, by analyzing the presence of NK1.1+ NKp46+ 
cells in the blood by flow cytometry (FIGURE 32). NK cells were present in animals treated with 
the isotype control antibody and absent in all animals treated with the NK cell depleting antibody 




FIGURE 32: NK cell depletion is efficient 
NK cells were initially depleted by intraperitoneal administration of 
an anti-NK1.1 antibody one and two days prior to immunization and 
NK cell depletion was sustained by subsequent application of the 
antibody every other day until the end of the experiment. The 
efficiency of NK cell depletion was assessed directly before 
immunization and at day 28 after immunization. The presence or 
absence of NK1.1+ NKp46+ NK cells in peripheral blood was 
analyzed by flow cytometry. NK cells are absent in all depleted 




3.6.2 NK cell depletion exacerbated EAE symptoms in LAQ-treated animals 
To investigate the importance of NK cells for the therapeutic efficiency of LAQ in EAE, the 
disease severity was assessed in the four experimental groups (control, controlNK cell-depleted, LAQ 
and LAQNK cell-depleted) by surveying clinical scores every day from day 1 until day 28 after 
immunization.  
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The overall comparison of all four experimental groups revealed a marked reduction of 
clinical severity after LAQ treatment in NK cell-competent animals (FIGURE 33). This beneficial 
effect of LAQ treatment was markedly attenuated upon NK cell depletion. This group showed a 
temporal delay of the peak of disease in comparison to vehicle-treated control groups and a 
similar disease severity at the end of the experiment (FIGURE 33). NK cell depletion had no 
obvious effect on EAE severity in the vehicle-treated groups, as demonstrated by comparable EAE 




FIGURE 33: LAQ-mediated reduction of EAE severity is dependent on NK cells 
To study the importance of NK cells for the therapeutic efficiency of LAQ in 
EAE, NK cell-competent (filled symbols) and NK cell-depleted (empty symbols) 
Th/+ mice were immunized with MOG35-55 and treated with 25 mg/kg LAQ 
(blue) or vehicle (gray) from day 0 until day 28 after immunization. Clinical 
scores were assessed daily. The overall comparison of all four experimental 
groups reveals a considerable amelioration of EAE severity upon LAQ 
treatment in NK cell-competent mice (n=14) compared to controls (n=13). NK 
cell depletion attenuates the therapeutic LAQ effect, as animals in the 
 LAQNK cell-depleted group (n=14) display similar disease severity as animals in the 
control groups. In contrast, NK cell depletion does not alter EAE severity in the 
vehicle-treated animals, since the EAE courses of control and  
controlNK cell-depleted (n=14) are similar. Data are presented as mean ± SEM.  
 
 
To address the crucial question, whether NK cells were essential for the therapeutic 
efficiency of LAQ in EAE, disease scores from the LAQ group and the LAQNK cell-depleted group were 
directly compared in a subanalysis. This subanalysis revealed a pivotal role of NK cells for LAQ 
efficiency in EAE. NK cell depletion significantly exacerbated the EAE course in LAQ-treated 
animals (p<0.001) (FIGURE 34). The dependence of the LAQ efficiency on the presence of NK cells 
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in EAE was further indicated by increased mean maximal scores in the LAQNK cell-depleted group 
(mean 3.5 ± 0.1) compared to the LAQ group (mean 2.9 ± 0.2) and considerably higher mean 
cumulative scores in the LAQNK cell-depleted group (mean 45 ± 3.4) compared to the LAQ group (mean 
34 ± 4.2). The detrimental effect of NK cell depletion on LAQ efficiency was less obvious during 
the early phase of EAE induction, since disease onset was similar in both LAQ-treated groups, but 
it became evident shortly before the peak of disease and lasted until the end of the experiment 
(FIGURE 34).    
   
 
 
FIGURE 34: NK cell depletion attenuates the therapeutic LAQ effect in EAE 
The aim of this experimental part was to study the impact of NK cells on the 
therapeutic efficiency of LAQ in EAE. Therefore, this subanalysis compared the 
clinical scores of NK cell-competent (filled symbols) and NK cell-depleted 
(empty symbols) Th/+ mice immunized with MOG35-55 and treated with 25 
mg/kg LAQ (blue) from day 0 until day 28 after immunization. This direct 
comparison shows that NK cells are crucial for the effect of LAQ in this animal 
model. NK cell depletion significantly exacerbates EAE symptoms in LAQ-
treated animals (n=14 per group, *** p<0.001). The deleterious effect of NK 
cell depletion on the therapeutic efficiency of LAQ in EAE becomes evident 
shortly before peak of disease and this difference remains until the end of the 
experiment. Data are presented as mean ± SEM. All the statistical analyses of 
this experiment were performed by Mr. Markus Harden (Department for 
Medical Statistics, University Medical Center Goettingen) using non-
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Further subanalyses of the NK cell depletion experiment were performed to assess the 
differences between the remaining groups. Similar to the previously described findings in wild 
type mice (compare 3.1.1) LAQ treatment was also effective in Th/+ mice. The pairwise 
comparison revealed a significant reduction of disease severity in the LAQ group compared to the 
control group (p<0.001) (FIGURE 35A).  
To examine whether LAQ treatment was still partially effective after NK cell depletion, the 
EAE scores of the groups controlNK cell-depleted and LAQNK cell-depleted were directly compared in a 
subanalysis. Indeed, NK cell depletion did not completely abolish LAQ efficiency. A comparison 
over the whole experimental time interval of 28 days indicated a significant benefit of LAQ 
treatment (p<0.001), which was mainly due to a delayed and attenuated onset of disease (FIGURE 
35B). However, the long lasting LAQ effect, which was observed in NK cell-competent animals 
(FIGURE 35A) was not maintained after NK cell depletion. At later time points of the experiment, 
NK cell-depleted animals treated with LAQ displayed similar disease scores as the corresponding 
control group (day 18 – 28 p.i.) (FIGURE 35B). 
The subanalysis of the EAE scores from the two control groups (control and controlNK cell-
depleted) revealed that NK cell depletion had no significant effect on EAE severity in these groups 
(FIGURE 35C). 
 
Taken together, the presence of NK cells appears to be essential for full and long lasting 
protective effects of LAQ in EAE. 
 
3.6.3 NK cell depletion reduced the survival of LAQ-treated animals 
The impact of NK cells on the LAQ efficiency was further investigated by comparing the 
survival of the four experimental groups (control, controlNK cell-depleted, LAQ and LAQNK cell-depleted) 
during the complete course of the experiment. Animals were classified as dead if they either died 
of EAE (score 5) or had to be sacrificed due to ethical reasons (score 4). The Kaplan-Meier curve 
for all four groups is shown in FIGURE 36. 
LAQ treatment efficiently increased the survival of Th/+ mice with EAE. LAQ therapy was 
fully protective in NK cell-competent animals, mirrored by a survival rate of 100% at day 28 after 
immunization. NK cell depletion partially abrogated this beneficial effect, reducing the survival 
rate to 71.4% in the LAQNK cell-depleted group. Still, NK cell-depleted animals were partly protected, 
since LAQ treatment halved the risk to die compared to the control groups (hazard ration 
[controlNK cell-depleted versus LAQNK cell-depleted]=2.2). The relationship between NK cell depletion and 
reduced survival rates was specific for LAQ therapy, since NK cell depletion did not alter the 
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survival rates in the control groups. At day 28 p.i. the control group and the controlNK cell-depleted 




FIGURE 35: LAQ treatment is efficient in Th/+ mice and NK cell depletion does not alter EAE severity in 
controls 
To study the importance of NK cells for the therapeutic efficiency of LAQ in EAE, NK cell-competent (filled 
symbols) and NK cell-depleted (empty symbols) Th/+ mice were immunized with MOG35-55 and treated with 
25 mg/kg LAQ (blue) or vehicle (gray) from day 0 until day 28 after immunization. Clinical scores were 
assessed daily. This figure provides different subanalyses of the overall experiment.  
LAQ treatment is efficient in NK cell-competent Th/+ mice. The subanalysis of NK cell-competent animals, 
treated with LAQ or vehicle, reveals significant amelioration of the disease course by LAQ (Ctrl: n=13, LAQ: 
n=14, *** p<0.001) (A). Furthermore, LAQ treatment is still partially effective in NK cell-depleted Th/+ mice 
(*** p<0.001). The subanalysis of the groups controlNK cell-depleted (n=14) and LAQNK cell-depleted (n=14) shows 
delayed and attenuated onset of EAE, but the therapeutic effect is only transient. NK cell-depleted animals 
reach a similar peak of disease irrespective of LAQ treatment (B). Finally, pairwise comparison of the two 
control groups reveals that NK cell depletion does not alter EAE severity per se in Th/+ mice (control: n=13, 
controlNK cell-depleted n=14, p>0.05) (C). Data are presented as mean ± SEM. All the statistical analyses of this 
experiment were performed by Mr. Markus Harden (Department for Medical Statistics, University Medical 
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FIGURE 36: NK cell depletion reduces the survival of LAQ-treated mice 
The survival during the EAE experiment was assessed using a Kaplan-
Meier curve. LAQ treatment is beneficial in terms of survival. LAQ 
completely protects NK cell-competent animals from death. This 
protective effect is partially reduced by the depletion of NK cells, but 
still the risk to die is halved by LAQ in NK cell-depleted animals 
compared to depleted controls (hazard ration [controlNK cell-depleted 
versus LAQNK cell-depleted]=2.2, log-rank test). This effect of NK cell 
depletion is specific for LAQ, since NK cell depletion does not directly 
reduce the survival in the control group.  
 
In conclusion, the depletion of NK cells attenuated the protective effect of LAQ in EAE, 
regarding EAE severity and survival. Previous chapters showed that LAQ treatment was associated 
with a shift in NK cell subpopulations and an increased activation of NK cells, phenotypically as 
well as functionally. Taken together, LAQ-mediated changes on NK cells seem to be crucial for its 
mechanism of action and its therapeutic efficiency in EAE. 
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4. Discussion 
The present study investigated effects of the new immunomodulatory drug LAQ on cells 
of the innate and adaptive immune system in mice with EAE. 
First, this study aimed to analyze the impact of preventive LAQ treatment on EAE 
induction and pro- and anti-inflammatory T cell subsets. In C57Bl/6J mice, LAQ treatment 
completely suppressed EAE symptoms and shifted the balance from pro-inflammatory Th1 and 
Th17 cells to regulatory FoxP3+ T cells in vivo (FIGURE 37). In contrast, in vitro therapy of 
splenocytes with LAQ did not show any direct effects on IL-17 and IFNγ production in T cells. 
Further, this work intended to analyze the effect of preventive LAQ treatment on antigen 
presenting cells by investigating dendritic cells. Data analysis revealed lower frequencies of total 
dendritic cells and myeloid dendritic cells in the spleen of LAQ-treated animals and LAQ increased 
the expression of co-stimulatory molecules within the first days of treatment (FIGURE 37).  
To characterize additional treatment effects on innate immune cells, LAQ-mediated 
alterations were studied in NK cells. In the spleen, LAQ reduced total cell numbers as well as 
absolute NK cell numbers, but NK cell frequencies remained unaltered. NK cell subpopulations 
were shifted towards more CD27+ and fewer CD11b+ NK cells. Furthermore, LAQ increased NK 
cell activation by upregulating CD69 and several activating NK cell receptors and by 
downregulating inhibitory NK cell receptors. Functionally, ex vivo purified NK cells from LAQ-
treated animals killed tumor cells more efficiently and produced more IFNγ than NK cells from 
vehicle-treated controls (FIGURE 37). In addition, NK cells from LAQ-treated mice led to a more 
pronounced contact-dependent reduction of T cell proliferation in a co-culture system with T cells 
and dendritic cells than NK cells from controls.  
The work additionally aimed to evaluate direct effects of LAQ on NK cells. The LAQ-
induced changes in NK cells occurred quickly and independently of T cells in vivo. Notably, LAQ 
directly activated NK cells in vitro in the absence of any other cell type, whereas co-culture of NK 
cells with pre-treated bone marrow-derived dendritic cells could not mimic this effect. 
The final aim of this thesis was to determine, whether NK cells were essential for the 
therapeutic efficiency of LAQ in EAE. Experiments in Th/+ mice revealed a central relevance of NK 
cells for LAQ treatment. LAQ considerably ameliorated EAE symptoms in NK cell-competent mice, 
but this beneficial effect was profoundly reduced upon NK cell depletion. Survival analysis yielded 
similar results, whereby all NK cell-competent mice survived under LAQ, but NK cell depletion 
clearly decreased survival in the LAQ-treated group.  
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FIGURE 37: Summary of the effects of LAQ treatment on NK cells, dendritic cells and T cells in vivo 
LAQ exerts effects on different cells of the innate and the adaptive immune system in vivo. The present 
work has identified NK cells as new target of LAQ within innate immunity. In vivo LAQ treatment markedly 
shifts NK cell subpopulations towards more CD27+ and fewer CD11b+ NK cells. Moreover, LAQ increases 
the activation of NK cells, indicated by the upregulation of the activation marker CD69 and several 
activating NK cell receptors (TACTILE, DNAM-1, NKG2D) and the reciprocal downregulation of inhibitory NK 
cell receptors (TIGIT, Ly49C/I/F/H). Functionally, LAQ-treated NK cells display a higher killing efficiency 
towards tumor cells in vitro and produce more IFNγ upon stimulation ex vivo. Regarding effects of LAQ on 
antigen-presenting cells, this thesis reveals a pronounced LAQ-mediated reduction of total dendritic cell 
and myeloid dendritic cell frequencies in the spleen. With regard to T cells, this work demonstrates a 
significant increase of naïve T cells and a corresponding decrease of effector memory T cells upon LAQ 
treatment. Furthermore, LAQ markedly shifts the balance from pro-inflammatory Th1 and Th17 cells 
towards anti-inflammatory regulatory T cells (Tregs). FIGURE 37 was designed by Mr. Stephan Ott. 
  
 
4.1  Preventive LAQ treatment inhibited EAE and reduced dendritic cells 
and pro-inflammatory T cells in vivo 
EAE is the most commonly used animal model for MS, in which potential 
immunomodulatory drugs for the treatment of MS are initially tested. First experiments evaluated 
the efficiency of LAQ on EAE in C57Bl/6J mice immunized with MOG35-55. Preventive treatment 
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with 25 mg/kg LAQ completely abolished EAE incidence, whereas vehicle-treated animals 
developed clinical EAE symptoms. These data are in line with several published studies. 
Preventive LAQ treatment has been shown to inhibit EAE induction in a dose dependent manner 
in mice (Runström et al., 2006, Wegner et al., 2010, Moore et al., 2013, Ruffini et al., 2013) and 
rats (Yang et al., 2004) previously and was most effective at 25 mg/kg in mice (Runström et al., 
2006, Wegner et al., 2010, Aharoni et al., 2012, Mishra et al., 2012, Schulze-Topphoff et al., 2012, 
Thöne et al., 2012, Jolivel et al., 2013, Moore et al., 2013).  
Recent reports suggest that LAQ might exert its immunomodulatory effects in EAE mainly 
by decreasing antigen presentation, which impairs the generation of pro-inflammatory myelin 
protein specific T cells upon immunization and thereby attenuates EAE.  
The present work described a LAQ-mediated shift from pro-inflammatory to regulatory  
T cells. LAQ treatment decreased the frequency of pro-inflammatory Th1 and Th17 cells in the 
spleen, which was paralleled by reduced secretion of the corresponding cytokines IFNγ and IL-17. 
Regulatory FoxP3+ T cells were in turn increased in the spleen upon LAQ administration. 
Published studies report analogous LAQ-mediated alterations of T cell subpopulations and pro-
inflammatory cytokines (Wegner et al., 2010, Schulze-Topphoff et al., 2012, Jolivel et al., 2013). 
These studies further indicate that the observed effects on T cell differentiation appear to be 
secondary to the LAQ-dependent reduction and modulation of antigen-presentation.  
Several additional observations support the notion of an indirect action of LAQ on T cells. 
LAQ-treated mice display lower frequencies of splenic CD4+ CD11b+ dendritic cells (Schulze-
Topphoff et al., 2012). In RRMS, LAQ treatment induces a similar reduction of CD1c+ conventional 
dendritic cells and CD303+ plasmacytoid dendritic cells in the peripheral blood (Jolivel et al., 
2013). The reduced frequencies of antigen-presenting cells could decrease T cell priming per se 
and LAQ-treated dendritic cells additionally display an anti-inflammatory type II phenotype 
(Schulze-Topphoff et al., 2012, Thöne et al., 2012). Moreover, the co-stimulatory molecule CD86 is 
associated with the differentiation of Th2 cells (Kuchroo et al., 1995, Ranger et al., 1996) and has 
been shown to be upregulated by LAQ (Thöne et al., 2012, Jolivel et al., 2013). In contrast, IL-12, a 
pivotal cytokine for the differentiation of Th1 cells, is downregulated in LAQ-treated antigen-
presenting cells (Schulze-Topphoff et al., 2012). Functionally, LAQ-treated antigen-presenting cells 
reduce Th1 and Th17 differentiation and antigen-dependent T cell proliferation in vitro, whereas 
in vivo LAQ treatment of T cells fails to inhibit T cell differentiation in vitro (Schulze-Topphoff et al., 
2012, Jolivel et al., 2013). In line with these reports, the present work revealed a pronounced drop 
of total dendritic cells as well as CD11b+ myeloid dendritic cells in the spleen after LAQ therapy. 
Temporally, the effects of LAQ on dendritic cells were detected within the first days of treatment 
in vivo, whereas T cells responded to LAQ therapy with a considerable delay. In vitro treatment of 
 
 Discussion 111 
 
splenocytes with LAQ failed to reduce IFNγ and IL-17 secretion, which further supports the 
concept of an indirect action of LAQ on T cells in vivo.  
This body of evidence illustrates that LAQ modulates antigen-presenting cells in vivo and 
indirectly reduces pro-inflammatory T cell differentiation. Th1 as well as Th17 cells play pivotal 
roles in the pathogenesis of EAE (Steinman, 2007, Stromnes et al., 2008). Therefore, the shift from 
pro-inflammatory to regulatory T cell subsets could be a crucial part of the mechanism of action 
of LAQ in EAE and MS.    
 
4.2  Preventive LAQ treatment induced NK cell activation in vivo 
4.2.1 LAQ did not alter splenic NK cell frequencies 
LAQ was shown to reduce the frequency of different dendritic cell subsets, revealing an 
effect of LAQ treatment on innate immune cells. As additional players of innate immunity, NK cells 
were examined in animals treated with LAQ or vehicle. First, absolute numbers and the frequency 
of splenic NK cells were determined. Assessment of total splenocytes revealed a 50% reduction in 
LAQ-treated compared to vehicle-treated animals. Absolute NK cell numbers were diminished to a 
similar extent upon LAQ treatment, whereas NK cell frequency remained unaltered. 
These data suggest that LAQ inhibits the expansion of splenocytes in MOG35-55-immunized 
animals. A likely mechanism for this effect is the reduced frequency of CD11chigh MHC-II+ dendritic 
cells in LAQ-treated animals (Schulze-Topphoff et al., 2012, Jolivel et al., 2013), which impairs the 
induction of a primary immune response to MOG. However, other possible mechanisms, like 
drug-induced apoptosis for instance, cannot be ruled out completely.  
Absolute NK cell numbers showed a similar LAQ-mediated decrease as total splenocytes 
and NK cell frequencies remained stable. Hence, LAQ does not selectively impede NK cell 
proliferation or induce NK cell apoptosis, but exerts an overall effect on immune cell expansion 
after immunization.   
 
4.2.2 LAQ treatment led to a relative expansion of the CD27+ NK cell subset 
To assess LAQ-mediated alterations in different subpopulations of NK cells, splenic NK 
cells from LAQ- and vehicle-treated animals were phenotyped.  
For this purpose, this study evaluated the expression of the surface molecules CD27 and 
CD11b on NK cells. Subpopulations were classified as follows: CD27+ CD11b- (referred to as 
CD27+), CD27+ CD11b+ and CD27- CD11b+ (referred to as CD11b+) (Chiossone et al., 2009). These 
three subpopulations differ with regard to their proliferative potential and their expression 
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pattern of chemokine and inhibitory receptors (Kim et al., 2002, Hayakawa et al., 2006, Chiossone 
et al., 2009). For human NK cells, CD27+ cells were shown to be better cytokine producers in 
response to soluble factors and less cytotoxic against tumor cells than CD11b+ NK cells (Fu et al., 
2011). Predominant effector functions of individual subsets of murine NK cells are still more 
controversial (Takeda et al., 2000, Kim et al., 2002, Hayakawa et al., 2006, Vahlne et al., 2008, 
Chiossone et al., 2009). LAQ treatment markedly altered the relative frequency of NK cell 
subpopulations, increasing CD27+ and reciprocally decreasing CD11b+ NK cells, whereas CD27+ 
CD11b+ NK cells remained unaffected. This LAQ-induced shift in NK cell subpopulations was 
observed in immunized as well as naïve animals, suggesting a mechanism which is independent of 
immunological activation.  
CD27+ NK cells were shown to further differentiate into CD11b+ NK cells in vivo 
(Chiossone et al., 2009). As splenic NK cell frequencies were relatively stable under LAQ treatment 
(as discussed in 4.2.1), the drug-related shift towards more CD27+ NK cells is more likely to be 
related to a block of NK cell differentiation than to a specific induction of proliferation in this 
subpopulation.   
  
4.2.3 LAQ activated NK cells 
Next, the present work investigated the activation state of NK cells after in vivo LAQ 
treatment on different NK cell subsets.  
Ex vivo flow cytometry revealed a considerable activation of NK cells upon LAQ treatment, 
evidenced by the increased expression of the activation marker CD69. This effect was 
independent of prior immunization and not restricted to a specific subset of NK cells, since the 
frequency of CD69+ NK cells was markedly higher among total NK cells as well as among CD27+ 
and CD11b+ NK cells in response to LAQ treatment.  
The LAQ-induced activation of NK cells was accompanied by the specific up- and 
downregulation of activating and inhibitory receptors, respectively. With regard to activating 
receptors, LAQ significantly increased the frequencies of TACTILE+, DNAM-1+ and NKG2D+ NK 
cells. In contrast, the proportions of NK cells expressing the inhibitory receptors TIGIT and 
Ly49C/I/F/H were reduced upon LAQ treatment. The frequencies of NK cells expressing the 
activating receptors Ly49D, CD244.2 and LFA-1 and the inhibitory receptors Ly49A and Ly49G2 
were similar in LAQ- and vehicle-treated animals. In these experiments only one single activating 
receptor, CD2, was found to be decreased upon LAQ exposure and there was not any inhibitory 
receptor increased, among all the investigated receptors. 
Taken together, LAQ treatment altered the balance of activating and inhibitory NK cell 
receptors in a way which should lower the threshold for NK cell activation.  
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NK cells express pairwise receptor families, consisting of activating and inhibitory 
receptors which recognize the same ligands on target cells, to assure precise regulation of NK cell 
effector functions (Stanietsky et al., 2009, Stanietsky et al., 2013). The activating receptors  
DNAM-1 and TACTILE together with the inhibitory receptor TIGIT represent such a family of 
pairwise receptors in humans and mice and interact with the ligands CD155 and CD112 (Bottino et 
al., 2003, Fuchs et al., 2004, Tahara-Hanaoka et al., 2004, Seth et al., 2007, Stanietsky et al., 2009, 
Stanietsky et al., 2013). Remarkably, LAQ differentially regulated the expression of these 
receptors by increasing the frequencies of DNAM-1+ and TACTILE+ NK cells and by simultaneously 
decreasing the frequency of TIGIT+ NK cells.  
The ligand CD155, a member of the nectin-like protein family, is expressed on a variety of 
cells including endothelial cells, diverse tumor cells (Bottino et al., 2003, Tahara-Hanaoka et al., 
2004, Lakshmikanth et al., 2009) as well as different immune cells such as T cells, NK cells, NKT 
cells, B cells, monocytes and dendritic cells (Maier et al., 2007).  
Binding of the activating receptor DNAM-1 to its ligand increases the cytotoxic activity of 
NK cells towards the respective target cell (Bottino et al., 2003, Tahara-Hanaoka et al., 2004). 
DNAM-1 plays an important role in NK cell-mediated tumor surveillance (Lakshmikanth et al., 
2009) and the regulation of immune cells (Pende et al., 2006, Ardolino et al., 2011). A single 
nucleotide polymorphism in the gene of DNAM-1, leading to the amino acid substitution glycine 
to serine at position 307, is associated with an increased risk to develop multiple autoimmune 
diseases, including diabetes type I, rheumatoid arthritis and MS (Hafler et al., 2009, Wieczorek et 
al., 2009, Qiu et al., 2013). The mutation at position 307 is located within the intracellular domain 
of the protein, which is important for DNAM-1 signaling. The functional impact of this mutation 
has not yet been characterized and it is thus unknown if and - if so - how it alters DNAM-1 
signaling. Still, these studies point towards a major impact of DNAM-1 on the pathogenesis of 
autoimmunity (de Andrade et al., 2013). In vitro studies indicate a regulatory role of DNAM-1+ NK 
cells, by limiting T cell activation. CD155 expression was upregulated on activated T cells upon 
stimulation by superantigen and on dendritic cells during the maturation, which rendered both 
cell types susceptible to lysis by DNAM-1+ NK cells (Pende et al., 2006, Ardolino et al., 2011). Both, 
direct lysis of activated T cells and killing of antigen-presenting cells could contribute to NK cell-
mediated inhibition of T cell activation.  
TACTILE, the second activating receptor of this pairwise receptor family was first cloned in 
1992 and is expressed on T cells and NK cells (Wang et al., 1992). Despite this early discovery, the 
function of TACTILE is less well characterized. TACTILE binds to CD155, which confers stable 
adhesion of NK cells to the target cells and enhances their cytotoxic effector functions (Fuchs et 
al., 2004, Seth et al., 2007).  
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TIGIT is the inhibitory receptor belonging to this pairwise receptor family. Antagonistic to 
DNAM-1 and TACTILE, binding of TIGIT to CD155 inhibits NK cell cytotoxicity and reduces IFNγ 
secretion (Stanietsky et al., 2009, Stanietsky et al., 2013). Recently, a mechanism for this 
inhibitory effect has been proposed by Liu and colleagues, who reported a disruption of granule 
polarization within the NK cell upon TIGIT engagement, which led to subsequent reduction of 
cytotoxic activity (Liu et al., 2013).  
Different studies provide evidence that DNAM-1, TACTILE and TIGIT compete for the 
binding of CD155 (Stanietsky et al., 2009, Yu et al., 2009, Levin et al., 2011, Stanietsky et al., 2013). 
Interestingly the inhibitory receptor TIGIT displays the highest affinity for CD155 (Yu et al., 2009, 
Stanietsky et al., 2013). Functionally, this translates into a dominant inhibition of TIGIT over the 
activating effect of DNAM-1 (Stanietsky et al., 2009, Stanietsky et al., 2013). The data provided in 
this thesis indicate that LAQ considerably shifts the balance within this pairwise receptor family 
towards higher NK cell activity, by increasing the activating signals (DNAM-1 and TACTILE) and 
decreasing the corresponding inhibitory signal (TIGIT).  
 
Additionally, LAQ treatment slightly but significantly enhanced the frequency of NKG2D+ 
NK cells. NKG2D is an activating receptor expressed on NK cells and T cells (Bauer et al., 1999), 
which binds to members of the retinoic acid early-inducible protein family (RAE) and H-60 in mice 
(Diefenbach et al., 2000, Lodoen et al., 2003) and to MHC class I polypeptide-related sequence A 
and B (MICA and MICB) and UL-16 binding proteins (ULBPs) in humans (Bauer et al., 1999, 
Cosman et al., 2001, Raulet, 2003). The interaction of NKG2D with its ligands promotes NK cell-
mediated cytokine secretion and cytotoxicity (Diefenbach et al., 2000, Lodoen et al., 2003). The 
role of NKG2D in the pathogenesis of MS and EAE is still unclear. In vitro experiments revealed 
NKG2D-dependent killing of oligodendrocytes, suggesting that NKG2D+ NK cells could be harmful 
within the CNS (Saikali et al., 2007). On the other hand, antigen-dependent stimulation of T cell 
proliferation led to an increased expression of NKG2D ligands on activated T cells and rendered 
them susceptible to NK cell-mediated lysis, favoring a beneficial role of NKG2D+ NK cells in the 
periphery (Rabinovich et al., 2003, Cerboni et al., 2007). Interestingly, a human study provided 
evidence for increased serum titers of the NKG2D ligand MICB in MS patients. MICB was 
especially elevated during the relapse phase, indicating that high serum levels of soluble MICB 
might be associated with disease activity (Fernandez-Morera et al., 2008). In tumor patients, 
stimulation of NKG2D+ NK cells with soluble ligands induces the internalization and degradation 
of NKG2D, which in turn impairs the responsiveness of these effector cells towards tumor cells 
and thus reduces tumor cell clearance (Groh et al., 2002). These findings suggest an inhibitory role 
of soluble NKG2D ligands on the activity of NK cells, which could potentially contribute to relapse 
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rates in MS patients. In this setting, the LAQ-dependent increase of NKG2D+ NK cells could 
possibly compensate for a downregulation of NKG2D, which might be mediated by the presence 
of soluble MICB in MS patients. 
  
One important feature of the regulation of NK cell activity is the discrimination between 
“self” and “non-self”. For this purpose, NK cells express a variety of receptors that interact with 
MHC class I molecules. In mice, these receptors belong to the family of L49 receptors, which 
comprises inhibitory as well as activating receptors (Ortaldo et al., 2000, Natarajan et al., 2002). 
In the present study, the effect of LAQ on NK cells expressing the receptors Ly49C, I, F and H were 
investigated by using the monoclonal antibody 14B11, which detects all these receptors 
simultaneously (Corral et al., 1999). Ly49C, I and F are inhibitory receptors (Coles et al., 2000, 
Benoit et al., 2005, Orr et al., 2010), whereas Ly49H is an activating receptor which recognizes the 
glycoprotein m157 of the mouse cytomegalovirus (Corral et al., 1999, Ortaldo et al., 2000, Orr et 
al., 2009). LAQ treatment decreased the frequency of Ly49C/I/F/H+ NK cells. Since the antibody 
mainly detects inhibitory receptors this effect was interpreted as treatment-related reduction of 
inhibitory NK cell receptors. Beside the receptors from the Ly49 family, LAQ also diminished the 
frequency of the inhibitory receptor TIGIT, as discussed above. EAE severity in C57Bl/6 mice is 
reduced by a decrease of inhibitory NK cell signals, as shown after blocking of the interaction 
between the inhibitory receptor NKG2A and its ligand and the subsequently enhanced NK cell 
activity (Lu et al., 2007, Leavenworth et al., 2010).  
  
Next, this work investigated whether receptors which are shared by other immune cells 
are specifically regulated on NK cells. Therefore, effects of LAQ on the expression of DNAM-1, 
TACTILE and TIGIT were assessed on T cells. Interestingly, the pattern of LAQ-mediated regulation 
differed between NK cells and T cells. The investigation of effects of LAQ on DNAM-1, TACTILE and 
TIGIT on T cells, revealed no alteration of TACTILE+ and TIGIT+ T cells, but a decreased frequency 
of DNAM-1+ T cells upon LAQ treatment. 
Regarding T cells, the activating receptor DNAM-1 is associated with proliferation and 
differentiation (Shibuya et al., 2003). DNAM-1 is upregulated during Th1 differentiation and 
downregulated during Th2 differentiation (Dardalhon et al., 2005) and is highly expressed on Th1 
and Th17 cells (Lozano et al., 2013). Antibody-mediated blocking of DNAM-1 inhibits T cell 
activation and proliferation and reduces the production of the pro-inflammatory cytokines IL-17 
and IFNγ (Lozano et al., 2013). Reduced frequencies of DNAM-1+ T cells after LAQ treatment are 
thus in line with the observed inhibition of pro-inflammatory T cell subsets upon treatment which 
were discussed before (see 4.1).  
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In contrast to DNAM-1, the inhibitory receptor TIGIT is a negative regulator of T cell 
activation. Binding of TIGIT to its ligands reduces Th1 and Th17 differentiation (Lozano et al., 
2012, Lozano et al., 2013) and TIGIT is associated with an anti-inflammatory T cell phenotype 
(Joller et al., 2011, Lozano et al., 2012). LAQ did not decrease the frequency of TIGIT+ T cells in 
contrast to its action on NK cells.  
   
Taken together, these data indicate that LAQ treatment selectively increases the 
activation of NK cells, which potentially contributes to its mechanism of action in MS and EAE.       
 
4.2.4 LAQ enhanced NK cell effector functions 
Next, this work evaluated the functional impact of the LAQ-induced upregulation of 
activation markers on NK cells. Therefore, NK cell effector functions were investigated in vitro by 
sorting out NK cells from LAQ- or vehicle-treated animals. In line with previous studies on human 
NK cells (Fu et al., 2011), CD27+ NK cells killed less efficiently B16F10 melanoma cells than 
CD11b+ NK cells. In vivo LAQ treatment resulted in higher killing efficiencies of CD27+ as well as 
CD11b+ NK cells. Furthermore, IFNγ production upon ex vivo stimulation was measured in NK cells 
derived from LAQ- and vehicle-treated animals. NK cells, pre-treated with LAQ in vivo, were 
characterized by an elevated frequency of IFNγ+ cells and higher IFNγ concentrations in the 
supernatant. In summary, LAQ markedly affected the main effector functions of NK cells 
evidenced by increased NK cell cytotoxicity and IFNγ production. 
The increased killing efficiency of CD27+ as well as CD11b+ NK cells upon LAQ treatment 
points towards a general LAQ effect on NK cells irrespective of the subpopulation. This is in line 
with the LAQ-mediated upregulation of the activation marker CD69 on the surface of both, CD27+ 
and CD11b+ NK cells, reported in this work. The enhancement of NK cell-mediated killing of 
B16F10 melanoma cells could be explained by the increased expression of DNAM-1 on LAQ-
treated NK cells (compare 3.3.2). The DNAM-1 ligand CD155 is expressed on B16F10 melanoma 
cells (Lakshmikanth et al., 2009) and DNAM-1 is thought to be one crucial NK cell surface receptor 
for the recognition of these cells. Genetic depletion of DNAM-1 renders NK cells irresponsive to 
the challenge with B16F10 cells in vivo and in vitro (Gilfillan et al., 2008). 
The promoting effect of LAQ on NK cell effector functions is substantiated by comparable 
observations published for its precursor substance roquinimex. In vivo treatment with roquinimex 
increases NK cell mediated lysis of tumor cells in vitro in mice (Kalland et al., 1985, Karussis et al., 
1993) and humans (Bengtsson et al., 1992). Further, roquinimex boosts the rejection of B16F10 
cells in mice in vivo and blocks the development of metastases (Kalland, 1986). Due to the 
different methodologies used to isolate NK cells in the 1980s and early 1990s in contrast to the 
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present study, comparisons have to be drawn with caution. Still, the data provided on effects of 
roquinimex on NK cell cytotoxicity resemble those observed for LAQ in the present work. LAQ also 
increased the cytokine secretion of NK cells in addition to the higher cytotoxicity. None of the 
studies on roquinimex assessed its effects on the cytokine production by NK cells. 
 
In summary, LAQ treatment markedly shifted NK cell subsets towards more CD27+ NK 
cells, led to the upregulation of activating NK cell receptors and increased NK cell effector 
functions in mice. 
 
4.2.5 Human NK cells in MS – a potential target for LAQ treatment? 
Human NK cells are classically divided into two distinct subpopulation according to their 
expression of the surface markers CD56 and CD16: CD56bright CD16- regulatory NK cells and 
CD56dim CD16+ cytotoxic NK cells (Lanier et al., 1986). Alterations in these NK cell subpopulations 
could have an impact on the pathogenesis of MS, since a recently published report evidenced 
significantly increased frequencies of CD56dim perforin+ NK cells among peripheral blood 
mononuclear cells (PBMCs) of patients with progressive MS compared to healthy controls 
(Plantone et al., 2013). Furthermore, the concept that increased numbers of CD56bright NK cells 
could be beneficial in MS is supported by studies which reveal a differential upregulation of the 
CD56bright subset in peripheral blood from MS patients in response to treatment with IFNβ (Saraste 
et al., 2007, Vandenbark et al., 2009, Martinez-Rodriguez et al., 2010) and daclizumab (Bielekova 
et al., 2006). For daclizumab the elevation of CD56bright NK cells was directly correlated with a 
positive treatment response (Bielekova et al., 2006). CD56 is not expressed on murine NK cells, 
but recently CD27 and CD11b were reported to be mainly expressed by human CD56bright and 
CD56dim NK cells, respectively (Fu et al., 2011), facilitating the comparison of human and murine 
data. Therefore, the LAQ-mediated increase of CD27+ or CD56bright NK cells could be potentially 
beneficial for the treatment of MS, as previously described for other MS therapies. 
Different activating and inhibitory receptors appear to be implicated in the pathogenesis 
of MS. The study of Martinez-Rodriguez and colleagues revealed an increased expression of the 
inhibitory receptors LILRB1 and NKG2A on NK cells from patients with progressive MS compared 
to healthy controls. Treatment with IFNβ also decreased the expression of LILRB1 on NK cells 
efficiently (Martinez-Rodriguez et al., 2010, Martinez-Rodriguez et al., 2011). Moreover, a recent 
report describes a negative association between the activating NK cell receptor gene KIR2DS1 and 
MS (Bettencourt et al., 2014). Considering the LAQ-mediated shift in the receptor profile of 
murine NK cells, LAQ therapy could also be beneficial for MS patients with increased expression of 
inhibitory NK cell receptors. 
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Furthermore, MS is thought to be associated with defects in NK cell effector functions. 
Several studies show reduced in vitro killing efficiency of NK cells isolated from the peripheral 
blood of MS patients compared to healthy controls (Benczur et al., 1980, Hauser et al., 1981, 
Neighbour et al., 1982, Kastrukoff et al., 1998). The development of relapses and new MRI lesions 
seems to be associated with preceding phases of low NK cell activity (Kastrukoff et al., 2003). A 
few studies also reported no alteration in NK cell function of MS patients (Vervliet et al., 1983, 
Satoh et al., 1990). These diverging observations could be due to differences in the study 
populations, as NK cell activity is heterogeneous within MS patients as well as healthy controls 
(Kastrukoff et al., 2003). The study design could also profoundly influence the outcome, since an 
intra-individual oscillation of NK cell activity was observed in longitudinal studies (Kastrukoff et al., 
1998, Kastrukoff et al., 2003). Given a defective phenotype of NK cells in MS with reduced effector 
functions, LAQ could potentially compensate for this defect by activating NK cells and by restoring 
their effector functions. 
 
4.3 LAQ-treated NK cells inhibited antigen-specific T cell proliferation in 
a contact-dependent manner 
The analysis of the NK cell phenotype and effector functions in LAQ-treated animals 
revealed a considerable activation of NK cells upon treatment, as discussed before (compare 4.2). 
In vivo, NK cells are part of a functional network and can regulate the process of immune 
activation by interacting with dendritic cells and T cells. Triple co-culture experiments of NK cells 
with dendritic cells and T cells were used to evaluate the effect of NK cells, pre-treated with LAQ 
or vehicle in vivo, on MOG35-55-induced T cell proliferation. The addition of LAQ-treated NK cells 
markedly reduced antigen-dependent T cell proliferation, evidenced by an increased frequency of 
non-proliferating T cells. Vehicle-treated NK cells also inhibited T cell proliferation to a certain 
extent, but less efficiently than LAQ-treated NK cells. Further, the NK cell-mediated reduction of 
MOG35-55-stimulated T cell proliferation was dependent on direct cell contact, as separation of NK 
cells from T cells and dendritic cells in a transwell plate completely abolished the inhibitory effect. 
Taken together, LAQ-treated NK cells inhibited antigen-dependent T cell proliferation more 
efficiently than control NK cells and this inhibition was mediated by direct cell contact. 
The observed inhibitory effect of NK cells on antigen-dependent T cell proliferation is in 
line with previously published studies. Murine, rat and human NK cells have been shown to 
reduce antigen-triggered T cell proliferation in a cell contact-dependent manner in vitro (Zhang et 
al., 1997, Smeltz et al., 1999, Wolf and Swanborg, 2001, Takao et al., 2010).  
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In the applied triple co-culture system, NK cells could reduce T cell proliferation either 
directly by interacting with the activated T cells or indirectly by interacting with the antigen-
presenting dendritic cells. Regarding the mechanism, direct killing of activated T cells or dendritic 
cells could be one way how NK cells reduce T cell proliferation. The clear dependency on direct 
cell contact could argue for this hypothesis, as NK cells mediate their cytotoxicity towards target 
cells via contact dependent pathways involving granule exocytosis (perforin, granzyme), Fas-Fas-
ligand engagement and TRAIL-TRAIL-ligand interaction (Segal, 2007). Further, several cell culture 
experiments demonstrate that NK cells efficiently induce cell death of immature dendritic cells 
(Carbone et al., 1999, Wilson et al., 1999, Ferlazzo et al., 2001, Ferlazzo et al., 2002, Piccioli et al., 
2002, Della Chiesa et al., 2003, Ferlazzo et al., 2003, Hayakawa et al., 2004, Pende et al., 2006, 
Alter et al., 2010) and activated T cells (Smeltz et al., 1999, Rabinovich et al., 2003, Xu et al., 2005, 
Bielekova et al., 2006, Takao et al., 2010, Ardolino et al., 2011, Nielsen et al., 2012) by direct 
interaction of activating NK cell receptors with their cognate ligands on the target cells.  
Therefore, this thesis investigated whether the LAQ-specific reduction in T cell 
proliferation was due to NK cell-mediated killing of activated T cells and/or dendritic cells in the 
triple co-culture. The presence of apoptotic T cells and dendritic cells was evaluated by Annexin V 
and 7-AAD staining. Indeed, the addition of NK cells to the co-culture led to a considerable 
increase of late apoptotic/dead T cells and dendritic cells. However, the degree of NK cell-
mediated cell death did not differ between NK cells derived from LAQ- and vehicle-treated 
animals.  
Considering these data, the LAQ-specific inhibition of T cell proliferation can probably not 
be attributed to increased killing of T cells and dendritic cells. Still, these observations do not 
completely exclude a contribution of NK cell-mediated killing to the LAQ-specific reduction of  
T cell proliferation. Significant differences in the killing efficiency of tumor cells were only 
observed at an effector/target ratio of 5:1 (compare 3.3.3.1) between LAQ-treated and control NK 
cells. The effector/target ratios used in the triple co-culture system were 1:1 for NK cells versus 
dendritic cells and 0.5:1 for NK cells versus T cells. Possibly, these effector/target ratios were too 
low to detect marked differences between LAQ- and vehicle-treated NK cells. 
To further dissect the effects of LAQ-treated NK cells on activated T cells and bone 
marrow-derived dendritic cells, NK cells were co-cultured with each cell type separately.  
Simple co-culture experiments of NK cells with bone marrow-derived dendritic cells were 
performed to evaluate NK cell-mediated killing of dendritic cells in the absence of activated  
T cells. These experiments did not reveal any NK cell-mediated lysis of bone marrow-derived 
dendritic cells in culture, irrespective of LAQ treatment. These findings strengthen the hypothesis 
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that killing of dendritic cells is not of central importance for LAQ-treated NK cells to reduce 
antigen-dependent T cell proliferation. 
However, these results appear to be in contrast with several published studies describing 
efficient NK cell-mediated lysis of dendritic cells in vitro. One reason for the conflictive results 
could be the pre-treatment of NK cells with IL-2, applied in most published studies (Chambers et 
al., 1996, Carbone et al., 1999, Wilson et al., 1999, Ferlazzo et al., 2001, Spaggiari et al., 2001, 
Ferlazzo et al., 2002, Della Chiesa et al., 2003, Pende et al., 2006, Alter et al., 2010). In vitro-
activated NK cells might have been more cytotoxic than ex vivo-derived NK cells in this thesis. 
Further, differences in the NK cell to dendritic cell ratios could contribute to the discrepancy, since 
this parameter seems to have a marked impact on the killing efficiency of NK cells (Piccioli et al., 
2002).  
Additionally, the lack of NK cell-mediated lysis of dendritic cells in the simple co-culture is 
contrary to the NK cell-induced apoptosis of dendritic cells reported in the triple co-culture in the 
present work. One possible explanation for these conflicting results could lie within the 
sensitivities of the different methods used to analyze cell death, as the crystal violet assay is 
certainly less sensitive than the Annexin V and 7-AAD staining. Further, NK cells are potentially 
more activated and therefore more cytotoxic in the triple co-culture system, where the 
interaction of CD40 on dendritic cells with CD40L on T cells potentially induces the secretion of 
the cytokine IL-12 by dendritic cells (Ma and Clark, 2009). IL-12 enhances NK cell activation and 
cytotoxicity (Nielsen et al., 2012) and could increase the NK cell-mediated killing of dendritic cells 
in triple co-cultures compared to single co-cultures. 
In an additional set of experiments, LAQ- and vehicle-treated NK cells were co-cultured 
with CD4+ T cells and proliferation was induced in an antigen-independent manner by agonistic 
anti-CD3 and anti-CD28 antibodies. This experimental setup did not reveal any inhibitory effect of 
NK cells on antigen-independent T cell proliferation. Neither LAQ-treated, nor control NK cells 
reduced T cell proliferation in this setting. 
The minor effect of NK cells on T cell proliferation upon antigen-independent stimulation 
potentially indicates that T cells are not the direct target of NK cells in the triple co-culture and 
that the presence of dendritic cells is mandatory for the NK cell-mediated inhibition of T cell 
proliferation. However, a direct interaction of NK cells and activated T cells cannot be ruled out, 
since the strong stimulus of anti-CD3 and anti-CD28 antibodies in the applied concentrations 
possibly overrides the regulatory effect of NK cells. 
Assuming an indirect effect on T cell proliferation via the interaction of NK cells with 
dendritic cells, different mechanisms can be discussed. Nakayama and colleagues have proposed 
that the presentation of dendritic cell MHC class II molecules on the surface of NK cells could 
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account for the inhibition of T cell proliferation. This mechanism is based on direct cell contact 
between NK cells and dendritic cells, which enables the transfer of MHC class II molecules from 
dendritic cells to NK cells by trogocytosis. MHCII-dressed NK cells subsequently compete with 
dendritic cells for the binding of antigen-specific T cells. Since NK cells lack the co-stimulatory 
molecules CD80 and CD86, the interaction of T cells with MHCII-dressed NK cells does not induce 
T cell proliferation and the competition with the potent antigen-presenting dendritic cells leads to 
a reduction of T cell proliferation (Nakayama et al., 2011). 
Contact-dependent cytokine secretion is another possible mechanism by which NK cells 
could indirectly control T cell proliferation. It has been shown that the engagement of different 
activating receptor combinations on human NK cells in vitro potently induced the secretion of 
specific pro-inflammatory cytokines (Fauriat et al., 2010). Beside pro-inflammatory cytokines, NK 
cells also secrete anti-inflammatory cytokines like IL-10 and NK cell-derived IL-10 has been shown 
to reduce antigen-dependent T cell proliferation in vitro (Deniz et al., 2008). Thus, possibly the 
specific engagement of a panel of receptors on LAQ-treated NK cells via direct cell contact with 
dendritic cells could trigger an anti-proliferative cytokine secretion by these NK cells. 
 
In brief, LAQ-treated NK cells specifically reduced antigen-dependent T cell proliferation in 
the presence of dendritic cells, but did not alter antigen-independent T cell proliferation in the 
absence of dendritic cells. Furthermore, NK cell-mediated apoptosis was not enhanced by LAQ 
treatment. On the basis of these results and previously published data the following hypothesis 
could be made: NK cells may directly interact with dendritic cells in the triple co-culture, which 
may impair dendritic cell-mediated T cell activation, potentially by reducing the expression of co-
stimulatory molecules and MHC class II or by altering the cytokine profile of dendritic cells. 
Alternatively, the engagement of specific NK cell receptors by molecules on the surface of 
dendritic cells may trigger the contact-mediated secretion of anti-inflammatory cytokines from NK 
cells. Both mechanisms could subsequently contribute to reduced T cell proliferation. The 
specificity of LAQ-treated NK cells for reducing the antigen-dependent T cell proliferation may 
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4.4 LAQ exerted independent effects on NK cells and dendritic cells 
4.4.1 LAQ-mediated changes displayed a similar kinetic in NK cells and dendritic cells 
and were delayed in T cells 
This study provided evidence for in vivo effects of LAQ on T cells, dendritic cells and NK 
cells. It was further investigated whether these effects represent parallel or sequential 
mechanisms of action. First, time course experiments were performed to elucidate the kinetics of 
LAQ-induced changes. NK cells responded promptly to LAQ treatment, indicated by the 
upregulation of TACTILE, CD69 and NKG2D after one or two days of LAQ therapy, respectively. 
Dendritic cells displayed similar kinetics, with increased frequencies of CD80+ and CD86+ dendritic 
cells after two or three days of LAQ treatment. Total dendritic cells were considerably decreased 
after three days, which corresponds to the half life of dendritic cells in the murine spleen (Kamath 
et al., 2000). In contrast, the onset of treatment effects was delayed in T cells. Analysis of naïve  
T cells, effector memory T cells, Th1 and Th17 cells revealed no drug-related alterations after four 
days of LAQ therapy.  
These results are in line with previous reports. Decreased differentiation of transferred 
2D2 T cells into Th1 and Th17 cells was observed after six days of LAQ therapy (Jolivel et al., 2013) 
and LAQ reduced VLA-4-dependent T cell adhesion after seven days of treatment (Wegner et al., 
2010). 
The temporal analysis provided in this work, revealed fast kinetics of LAQ-induced 
changes in NK cells and dendritic cells, preceding those observed for T cells, which points towards 
a sequential mechanism of action. In this concept, LAQ would exert early and direct effects on 
innate immune cells, which in turn modulate subsequent T cell responses.  
Data presented in this work, support this hypothesis. First, LAQ-induced changes in NK cell 
subpopulations and CD69 regulation were independent of T and B cells, since LAQ exerted 
comparable effects in wild type and Rag1-deficient animals. Further, NK cells, pre-treated with 
LAQ in vivo, shaped the T cell response to antigenic stimulation in vitro by inhibiting T cell 
proliferation (see 4.3). Finally, in vitro LAQ treatment failed to directly inhibit pro-inflammatory 
cytokine production in T cells, as discussed before (see 4.1). 
The effect of LAQ on antigen-presenting cells has been extensively studied by other 
groups and the results further underline the before mentioned hypothesis. The study of Jolivel 
and colleagues also revealed very fast kinetics of LAQ-mediated alterations in dendritic cells, with 
the first changes in CD86 expression after one single dose of LAQ. Generally, LAQ treatment 
decreased the frequency of antigen-presenting cells and induced a more regulatory phenotype 
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(Schulze-Topphoff et al., 2012, Thöne et al., 2012, Jolivel et al., 2013). These changes potentially 
interfere with T cell priming and differentiation as discussed before (see 4.1).  
Taken together, these data support the concept of an early and direct effect of LAQ on 
innate immune cells with a subsequent indirect modulation of the priming and the differentiation 
of T cells.  
    
4.4.2 The effects of LAQ on dendritic cells were independent of NK cells in vivo 
Time course experiments revealed similar kinetics for LAQ-induced changes in NK cells 
and dendritic cells. To further dissect an interrelation of drug effects on these two cell types, NK 
cells were depleted prior to treatment and effects of LAQ on dendritic cells were evaluated. The 
reduction of total splenic dendritic cells and myeloid dendritic cells was comparable in NK cell-
competent and NK cell-depleted mice treated with LAQ. Thus, NK cells seem to be dispensable for 
the action of LAQ on dendritic cells.  
These results are in line with previously published data, reporting a direct effect of LAQ on 
dendritic cells in vitro. LAQ-treatment during the generation of human monocyte-derived and 
murine bone marrow-derived dendritic cells in vitro decreases the ability of these cells to produce 
pro-inflammatory cytokines and chemokines upon stimulation. Further, human monocyte-derived 
dendritic cells, pre-treated with LAQ in vitro, are less efficient in stimulating the proliferation of 
allogeneic T cells in vitro (Jolivel et al., 2013). 
Consequently, LAQ seems to act directly on dendritic cells and NK cells do not interfere 
with this regulation in vivo. 
   
4.4.3 LAQ treatment directly induced NK cell activation  
The effects of LAQ on dendritic cells were independent of NK cells in vivo, as discussed 
before. Similarly, NK cells were found to be a direct target of LAQ in vitro. Culture of naïve NK cells 
with LAQ revealed a direct in vitro activation of NK cells by the compound in the absence of any 
other cell type. Co-culture of NK cells with bone marrow-derived dendritic cells, pre-treated with 
LAQ, could not mimic this effect.   
The idea of NK cells as direct target of LAQ treatment is supported by a published study 
investigating its precursor substance roquinimex. In this work, human adherent lymphokine 
activated killer cells displayed increased cytotoxicity against NK cell-sensitive K562 tumor cells 
upon in vitro treatment with roquinimex (Vaz et al., 1995). 
In general, LAQ seems to directly target different innate immune cells and CNS-resident 
cells to exert its full immunomodulatory mechanism of action. Concerning innate immunity, in 
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vitro effects of LAQ have been previously described for monocytes (Mishra et al., 2012) and 
dendritic cells (Jolivel et al., 2013). Regarding CNS-resident cells, LAQ interfered with astrocytes 
(Brück et al., 2012) and microglia (Mishra et al., 2013) in vitro. 
In consequence, the presented in vitro data identify NK cells as a novel direct target of 
LAQ. 
 
4.4.4 LAQ interferes with different signaling pathways depending on the target cell 
LAQ treatment in vivo and in vitro inhibits different pro-inflammatory signaling pathways 
depending on the target cell investigated. Most evidence is available for effects of LAQ on the  
NF-κB pathway. Inhibitory effects on this signaling pathway have been directly shown in human 
monocytes (Mishra et al., 2012), human monocyte-derived dendritic cells, murine bone marrow-
derived dendritic cells (Jolivel et al., 2013) and murine and human astrocytes (Brück et al., 2012). 
In human microglia LAQ reduced the activation of AKT (protein kinase B), an activator of the  
NF-κB pathway (Dan et al., 2008) and thereby indirectly reduced NF-κB signaling (Mishra et al., 
2013). In murine monocytes, LAQ inhibits the Janus kinase (JAK) and Signal Transducer and 
Activator of Transcription (STAT) pathway, indicated by reduced phosphorylation of STAT1 
(Schulze-Topphoff et al., 2012). It is controversial whether mitogen-activated protein (MAP) kinase 
activities are also altered by LAQ treatment (Mishra et al., 2012, Schulze-Topphoff et al., 2012). 
The described interference of LAQ with NF-κB and JAK-STAT signaling leads to a reduction 
of pro-inflammatory responses in cells, which is potentially beneficial for the treatment of MS and 
EAE. In contrast to monocytes and dendritic cells, LAQ rather activated than attenuated NK cells, 
as reported in this work.  
NF-κB and JAK-STAT signaling play important roles in the activation of NK cell functions. 
Hyperactivation of NF-κB signaling blocks the maturation of NK cells and increases the expression 
of CD69 (Samson et al., 2004). Further, reduced NF-κB activity in NK cells results in a decreased 
expression of perforin (Zhou et al., 2002) and impaired cytotoxicity towards tumor cells in vitro 
(Orange et al., 2002).  
STAT1 becomes phosphorylated and thereby activated upon cytokine signaling (Rawlings 
et al., 2004). The stimulation of NK cells by type I interferons activates STAT1 and leads to 
increased cytotoxicity (Nguyen et al., 2002). STAT1-deficient NK cells are characterized by 
impaired cytotoxicity towards tumor cells in vitro and reduced IFNγ secretion upon stimulation 
(Lee et al., 2000, Fortin et al., 2013). In contrast, one recent report described an opposite function 
of STAT1 phosphorylation on NK cell activation. A point mutation at serine727, which blocked 
cyclin-dependent kinase 8-mediated phosphorylation of STAT1, induced activation and 
cytotoxicity of NK cells (Putz et al., 2013).     
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In conclusion, further studies are required to elucidate the exact mechanism by which 
LAQ increases the activation of NK cells.  
 
4.5  NK cell depletion decreased the therapeutic efficiency of LAQ in EAE 
In this study, NK cells were identified as a promising target for LAQ. The significance of NK 
cells within the mechanism of LAQ action remained to be investigated. For this purpose, the 
therapeutic efficiency of LAQ in EAE was evaluated in NK cell-competent and NK cell-depleted 
Th/+ mice. The effects of LAQ were clearly dependent on the presence of NK cells. LAQ 
treatment markedly reduced EAE symptoms in NK cell-competent animals, whereas NK cell-
depleted animals showed a markedly weaker response to LAQ therapy and displayed only a 
transient drug-related amelioration of disease. In the vehicle-treated group, NK cell depletion did 
not alter EAE severity per se. In terms of mortality, LAQ treatment conferred total protection 
from death to NK cell-competent animals, which was partly abrogated by NK cell depletion. 
Survival rates of approximately 50% were observed in the control groups irrespective of NK cell 
depletion. Thus, NK cells seem to play a major role for the protective effect of LAQ in EAE.  
LAQ markedly reduced EAE severity in NK cell-competent Th/+ mice. Still, the therapeutic 
effect in Th/+ mice was lower compared to wild type mice, where preventive treatment at a dose 
of 25 mg/kg was fully protective in this study. This discrepancy is likely to be related to the fact 
that Th/+ mice develop an accelerated and exacerbated EAE course compared to wild type 
animals upon challenge with encephalitogenic antigens (Litzenburger et al., 1998). The described 
aggravation of disease was also paralleled by the relatively high mortality rate (approximately 
50%) observed for vehicle-treated Th/+ mice in this work. Parallel assessment of the effects of 
LAQ on the survival rate of wild type animals could not be determined in this study, since death 
of wild type mice was an exceptional event in these experiments. However, the beneficial effect 
of LAQ on the survival of Th/+ mice is in line with previously published data, which demonstrate 
an improved survival upon LAQ treatment in wild type mice (Aharoni et al., 2012).  
Th/+ mice were chosen to investigate the impact of NK cells on the efficiency of LAQ in 
EAE for two distinct reasons: First, the incidence of EAE upon immunization is very high in this 
animal model (Litzenburger et al., 1998). This aspect was important, since the animals in this 
experimental setting were exposed to high stress levels due to frequent intraperitoneal 
treatment with either antibody or PTX in addition to the daily oral gavage of LAQ or vehicle. 
Second, naïve Th/+ mice display high serum titers of pathogenic antibodies (Litzenburger et al., 
1998), which could bind to CNS intrinsic structures upon opening of the blood-brain barrier. 
These high levels of pathogenic antibodies might be crucial since antibody-dependent cell-
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mediated cytotoxicity (ADCC) is one important effector function of NK cells (Seidel et al., 2013). 
The physiological role of ADCC is to recognize and kill antibody-coated infected cells, which 
contributes to the clearance of infection. In the case of antibody-mediated autoimmunity, NK 
cells could potentially cause CNS injury by killing antibody-coated CNS cells. Therefore, it was of 
particular importance to test for protective or potentially detrimental effects of LAQ-mediated 
NK cell activation in the presence of pathogenic antibodies. 
There is a controversial discussion on the role of NK cells in the pathogenesis of EAE. NK 
cell depletion with anti-NK1.1 antibody before immunization has been shown to exacerbate EAE 
in C57Bl/6 mice (Zhang et al., 1997, Huang et al., 2006) and SJL/J mice (Xu et al., 2005), which 
suggests a regulatory role of NK cells. Furthermore, deletion of the chemokine receptor CX3CR1 
resulted in a selective block of NK cell migration into the inflamed CNS and was associated with 
increased EAE-mediated mortality (Huang et al., 2006). A regulatory role of NK cells is 
additionally supported by the observation of BDNF-producing NK cells within the CNS of EAE 
mice (Hammarberg et al., 2000). In contrast, other studies provide evidence for an amelioration 
of EAE symptoms after depleting NK cells with anti-NK1.1 antibody prior to immunization, 
favoring a pro-inflammatory role of NK cells (Shi et al., 2000, Winkler-Pickett et al., 2008). It is 
difficult to explain these controversial findings, since all the cited studies used an anti-NK1.1 
antibody to deplete NK cells prior to immunization and effective depletion was controlled before 
EAE induction. Potentially, the different results could be partly explained by the fact that all 
experiments were carried out at different institutions and animal facilities. Each animal facility 
displays its typical pattern of commensal microbiota, which has been demonstrated to influence 
the development of EAE (Ochoa-Reparaz et al., 2009, Ochoa-Reparaz et al., 2010, Ochoa-Reparaz 
et al., 2010, Berer et al., 2011). Further, commensal microbiota are necessary for the efficient 
priming of NK cells by dendritic cells and monocytes. Different patterns of bacteria within the gut 
flora exert immunomodulatory properties by altering the crosstalk between dendritic cells and 
NK cells, which modulates NK cell priming (Rizzello et al., 2011, Ganal et al., 2012). These factors 
are likely to contribute to the different outcomes observed after NK cell depletion in EAE.  
In conclusion, NK cell depletion profoundly reduced the therapeutic efficiency of LAQ in 
Th/+ mice with EAE, arguing for a major contribution of NK cells within the mechanism of action 
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4.6 Outlook 
The present work has identified NK cells as a new target of LAQ therapy and provided 
evidence for a central role of the drug-related NK cell activation within the protective mechanism 
of action of LAQ in EAE. Further research is required to fully understand the effect of LAQ on NK 
cells and the functional consequences in MS and EAE. 
First, LAQ differentially regulated the expression of the NK cell receptors DNAM-1, 
TACTILE and TIGIT, all belonging to the same pairwise receptor family. It would be intriguing to 
investigate the functional impact of this altered receptor profile in vivo and in vitro, using specific 
receptor-deficient mice or blocking antibodies. 
Second, NK cell depletion markedly reduced the protective effect of LAQ in EAE. However, 
it is necessary to exclude a significant contribution of NKT cells in order to substantiate a central 
role of NK cells only for the therapeutic efficiency of LAQ in EAE. This could be achieved by 
assessing the effects of LAQ treatment on adoptive transfer EAE in Rag1-/- in comparison to Rag1-/- 
gamma (c)-/- mice, the former lacking B, T and NKT cells and the latter being deficient for B, T, NKT 
and NK cells.   
Third, LAQ has been shown to interfere with different pro-inflammatory signaling 
pathways in immune cells and CNS-resident cells. The effect of LAQ on signaling pathways within 
NK cells has not been assessed in the present study. Evaluating specific LAQ-induced alterations of 
signaling cascades in NK cells could be of central importance to obtain a deeper understanding 
why LAQ enhances the activity of NK cells, whereas it rather attenuates other immune cells.  
Fourth, the present work mainly focused on potential consequences of LAQ treatment on 
the regulatory role of NK cells during the activation of T cell responses. However, NK cells can be 
found in the inflamed CNS of EAE animals and also exert beneficial effects by producing BDNF 
(Hammarberg et al., 2000). Therefore, it would be important to analyze effects of LAQ on the 
capacity of NK cells to migrate into the CNS and to produce BDNF in order to investigate potential 
neuroprotective properties of LAQ-treated NK cells.  
Finally, it will be crucial to test whether LAQ treatment exerts similar effects on human NK 
cells. It is of central relevance to validate the experimental data in MS patients and healthy 
controls and to evaluate the significance of LAQ-mediated alterations of NK cells for the therapy 
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5. Summary and conclusions 
 The new immunomodulatory substance LAQ is currently under investigation for the 
treatment of relapsing remitting multiple sclerosis. Phase III clinical trials indicate beneficial 
effects of LAQ treatment on relapse rate, brain atrophy and disability progression in RRMS 
patients. In EAE studies, LAQ efficiently inhibited disease induction and development, which was 
attributed to its ability to reduce antigen presentation and the subsequent suppression of pro-
inflammatory T cell differentiation. The present study aimed to investigate effects of the 
immunomodulator LAQ on innate and adaptive immune cells in mice with EAE, with a special 
focus on NK cells.  
 
 First, this work aimed to analyze the effects of preventive LAQ treatment on EAE severity 
and different T cell subpopulations. Preventive treatment with 25 mg/kg LAQ completely inhibited 
EAE induction in C57Bl/6J mice and shifted the balance from pro-inflammatory Th1 and Th17 cells 
to anti-inflammatory regulatory T cells in vivo. The lack of in vitro effects of LAQ treatment on pro-
inflammatory cytokine secretion, together with the delayed onset of LAQ-mediated alterations in 
T cells, indicate an indirect action of LAQ on T cells, which is in line with recently published data. 
Altogether, the LAQ-mediated shift from pro- to anti-inflammatory T cell subpopulations appears 
to be one central aspect of its mechanism of action in EAE.  
 
 Moreover, the present study evaluated the effects of preventive LAQ treatment on 
antigen presenting cells, by investigating dendritic cells. LAQ therapy drastically reduced the 
frequencies of total splenic dendritic cells and myeloid dendritic cells and led to the upregulation 
of the co-stimulatory molecules CD80 and CD86 within the first days of treatment. Considering 
these results and previously published data, LAQ appears to reduce and to alter antigen 
presentation, which in combination results in a decreased pro-inflammatory T cell response and 
thereby attenuates EAE severity. 
 
 The central aim of this study was to investigate the effects of preventive LAQ treatment 
on NK cells and to evaluate the impact of NK cells on the therapeutic efficiency of LAQ in EAE.  
In vivo, the administration of LAQ induced a considerable shift in NK cell subpopulations 
towards more CD27+ and fewer CD11b+ NK cells, whereas total splenic NK cell frequencies 
remained unaltered. Additionally, LAQ treatment markedly increased the activation of NK cells. 
This was evidenced by the pronounced upregulation of the activation marker CD69 and the 
altered balance of activating and inhibitory receptors on the surface of NK cells in favor of more 
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activating signals upon LAQ therapy. Notably, LAQ treatment specifically interfered with one 
pairwise receptor family consisting of DNAM-1, TACTILE and TIGIT, enhancing the activating 
signals and attenuating the corresponding inhibitory signal. Most interestingly, this regulation was 
specific for NK cells, since LAQ led to different regulatory effects on T cells with regard to  
DNAM-1, TACTILE and TIGIT, matching the more anti-inflammatory T cell phenotype in LAQ-
treated animals.  
Functionally, in vivo LAQ treatment boosted NK cell effector functions. LAQ significantly 
enhanced the cytotoxicity of CD27+ and CD11b+ NK cells towards B16F10 melanoma cells in vitro 
and increased the frequency of IFNγ+ NK cells as well as the secretion of IFNγ by NK cells. 
Moreover, NK cells purified from LAQ-treated animals efficiently inhibited antigen-dependent  
T cell proliferation in vitro.   
Additional experiments analyzed whether NK cells represent a novel direct target of LAQ. 
NK cells responded very quickly to LAQ treatment in vivo and the effects of LAQ on NK cells were 
independent of B and T cells. In vitro therapy experiments revealed a direct effect of LAQ on NK 
cell activation in the absence of any other cell type, whereas co-culture with dendritic cells, pre-
treated with LAQ, could not mimic this effect. 
Having identified NK cells as a new direct target of LAQ treatment, it was crucial to 
investigate the impact of NK cells on the therapeutic efficiency of LAQ in EAE. Experiments using 
Th/+ mice revealed a central role for NK cells within the mechanism of action of LAQ in EAE. LAQ 
treatment markedly reduced EAE severity in NK cell-competent animals, whereas NK cell 
depletion considerably attenuated this beneficial effect, since NK cell-depleted animals displayed 
only a transient drug-related amelioration of disease. Regarding mortality, LAQ treatment 
conferred complete protection from death to NK cell-competent mice, which was markedly 
diminished upon NK cell depletion. 
Taken together, the present work identified NK cells as a novel target for LAQ. 
Remarkably, the LAQ-mediated activation of NK cells appears to be crucial for the therapeutic 
efficiency of the substance in EAE. A large body of evidence indicates that MS is associated with 
reduced NK cell activity and that enhancing NK cell functions by different treatments is beneficial 
for MS patients. Considering these published data and the results provided in this work, LAQ 
treatment could potentially restore the functional defects of NK cells in MS patients and this could 
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